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Oral and oropharyngeal cancer (commonly referred to collectively as oral cancer, or OC) is 
the sixth most common cancer. Cancer Registry records show that the incidence of OC in 
New Zealand (NZ) has increased over the last 50 years, and distinct incidence patterns persist 
by gender, age, ethnicity and anatomical site. Despite advances in treatment, a poor prognosis 
persists for those diagnosed. Improving survival rates will need better rates of early diagnosis. 
Little is known about the factors leading to delays in OC diagnosis in NZ or whether 
clinicians’ deficiencies in knowledge contribute to delays in diagnosis. International studies 
have observed regular dental care to be associated with an earlier stage of OC diagnosis, but 
whether this holds in NZ is not known.  
This study explored factors which may contribute to the stage of diagnosis of OC in NZ. It 
had two main aims: to assess the OC knowledge, beliefs and practices of NZ dentists and 
clinical dental technicians (CDTs); and to determine whether regular dental care affects the 
stage of OC diagnosis in the Canterbury region. 
Methods 
A self-administered questionnaire was developed and sent to all general dentists and CDTs 
registered with the Dental Council of NZ. The questionnaire data were compared with those 
from the NZ Cancer Registry (cases diagnosed with OC from 1 January 2012 until 31 
December 2013), to determine whether clinicians have adequate knowledge to enable early 
detection of suspicious oral lesions. Data from the OC cases from the Canterbury District 
Health Board (CDHB) were analysed for associations of tumour extent by regular dental 
attendance.  
Results 
Dental clinicians were found to be knowledgeable about many aspects of OC, but differences 
in knowledge exist among clinicians, suggesting that some are more able to detect early OCs 
than others. Time from graduation, the type of clinician and the graduation country may 
influence some beliefs and practices about OC, thereby affecting clinicians’ ability to detect 
malignant lesions. Most clinicians reported providing OC screening (OCS) examinations for 
all patients, but one-third identified barriers to doing so. Consequently, it is likely that a 
proportion of dentists and CDTs do not provide routine OCS examinations. 
 iii 
Non-smokers and those of higher socio-economic status were more likely than others to be 
routine users of dental care. However, there was a lack of data on the dental history of cases, 
and so, whether differential access to dental care impacts on stage of diagnosis of OC could 
not be explored in this study. It was noteworthy that general medical practitioners (GMPs) 
continue to detect most of the OC in NZ, but their knowledge, beliefs and practices in respect 
of OC have yet to be explored. 
Conclusion 
Missed opportunities for early diagnosis of OC may result from identified deficiencies in 
dental clinicians’ knowledge of OC, their failure to provide an OCS examination for all 
patients, and high-risk patients not seeking regular dental care. A better understanding of 
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Oral and oropharyngeal cancer (commonly referred to as mouth cancer) is the sixth most 
common cancer worldwide, with an estimated annual incidence of over 442,000 cases (Ferlay 
et al., 2015). Distinct geographic incidence patterns exist, reflecting the prevalence patterns of 
known risk factors for oral cancer (OC) and oropharyngeal cancer (OPC) (Sankaranarayanan 
et al., 2015). Historically, high incidence rates of OC and OPC have been reported in South 
and South-East Asia, and in parts of Central Europe and South America (Chaturvedi et al., 
2013).  
Review of the New Zealand Cancer Registry has shown the incidence of OC and OPC has 
increased over the last fifty years (Cox et al., 1996; Elwood et al., 2014). It is noteworthy that 
the incidence of OPC in males has increased rapidly since 2005 (Chelimo and Elwood, 2015). 
Distinct patterns of OC and OPC in New Zealand have been demonstrated with respect to age, 
gender, ethnicity, anatomical site and social deprivation (Chelimo and Elwood, 2015; Cox et 
al., 1996). Overall, incidence rates are highest among older, New Zealand European men but 
rates are increasing for both genders in deprived areas (Chelimo and Elwood, 2015).  
Despite major advances in the treatment of OC and OPC and some improvement in quality of 
life for those affected, the overall 5-year survival rate has not significantly improved (Rapidis 
et al., 2009). Worldwide, there are an estimated 242,000 deaths annually from OC and OPC 
(Ferlay et al., 2015). Substantial ethnic and socioeconomic inequalities in OC and OPC 
survival are known to exist in New Zealand (Soeberg et al., 2012). The factors contributing to 
disparity in survival rates have not been fully explained, but have been, at least partly, 
attributed to a later stage of diagnosis for Māori and those of lower socioeconomic status 
(Robson et al., 2010; Soeberg et al., 2012). It is widely accepted that the key to improving 
survival rates lies in improving the rates of early diagnosis of oral malignant and potentially 
malignant disorders (van der Schroeff and Baatenburg de Jong, 2009).  
Delays in the diagnosis of OC and OPC have been largely attributed to late-stage presentation 
(Goy et al., 2009). The factors contributing to diagnostic delay are multifactorial and related 
to patient, provider and healthcare system factors (Gómez et al., 2010). Whether New Zealand 
patients delay seeking medical care prior to diagnosis of OC and OPC (and how this may 
impact on stage of diagnosis) has not been reported to date.  
It is generally accepted that whole-population screening for OC and OPC is unlikely to be 
cost-effective in low prevalence populations, however there is evidence that screening of 
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high-risk individuals can improve survival rates (Brocklehurst et al., 2013). The Ministry of 
Health’s New Zealand Cancer Plan: Better, faster cancer care 2015–2018 identifies primary 
healthcare workers as crucial to enable an improvement in early cancer detection rates in New 
Zealand (Ministry of Health, 2014). However, primary care clinicians’ current understanding 
of OC and OPC has not been reported. International studies have reported differences in 
primary healthcare clinicians’ knowledge regarding OC and that gaps in clinicians’ 
knowledge can contribute to delays in the diagnosis and treatment (Horowitz et al.,2000; 
Carter and Ogden, 2007; Brocklehurst et al., 2010; Allen and Farah, 2015;). Whether New 
Zealand’s primary care practitioners have a similar range of understanding of OC is unclear. 
Therefore, their ability to detect OC and OPC in early stages of presentation is unknown.  
International studies have observed regular dental care to be associated with an earlier stage 
of diagnosis for OC and OPC (Watson et al., 2009; Frydrych and Slack-Smith, 2011;). 
However, concern has been expressed that at-risk individuals may be less likely to regularly 
attend the dentist and are therefore less likely to be diagnosed in early stages of disease 
(Frydrych and Slack-Smith, 2011). The New Zealand Oral Health Survey (2009) reported 
poorer access to dental care for Māori, Pacific people and those of lower socioeconomic status 
(Ministry of Health, 2010). Whether irregular dental attendance impacts on the stage of 
diagnosis in New Zealand is not known. Other factors (such as tobacco use and cancer site) 
have been associated with the stage of diagnosis internationally (das Neves et al., 2015). 
However, whether factors such as smoking and cancer site are associated with the stage of 




2 Literature review 
The published literature on oral and oropharyngeal cancer (commonly referred to as mouth 
cancer) was reviewed prior to exploring the patterns of diagnosed OC and OPC, in New 
Zealand, and whether tumour stage at diagnosis may be associated with dental attendance, and 
affected by the knowledge, beliefs and practices of general dentists and clinical dental 
technicians. The domains reviewed included the definition of OC and OPC, clinical features, 
epidemiology, aetiology and the role of primary healthcare clinicians in the diagnosis of OC 
and OPC. This chapter describes the definition of OC and OPC, incorporating the clinical 
description and classification of the disease. Epidemiological aspects will be discussed 
including, incidence rates and risk factors for OC and OPC. Finally, the diagnosis of OC and 
OPC will be discussed. This will include the internationally accepted standards for diagnosis, 
the role of primary healthcare providers in diagnosis, and the reasons behind delays in 
diagnosis that lead to poorer outcomes for people diagnosed with advanced OC and OPC. 
2.1 Introduction 
The term “oral and oropharyngeal cancer” describes malignant lesions arising from the 
mucosal surfaces of the oral cavity and/or the oropharynx (Sankaranarayanan et al., 2015). 
Oral cancer may occur in the following anatomical subsites: the lip, the anterior two-thirds of 
the tongue, the salivary glands, the buccal mucosa, the gingiva, the floor of mouth, the hard 
palate, or other unspecified parts of the mouth (Barnes et al., 2005). Lesions of the 
oropharynx are those that occur within the part of the pharynx bounded superiorly by the soft 
palate and inferiorly by a hypothetical horizontal line level with the tip of the epiglottis 
(Barnes et al., 2005). Anatomical subsites within the oropharynx include the posterior third of 
the tongue, the soft palate, the palatopharyngeal arches and the tonsils, and are distinguished 
from the nasopharynx, the hypopharynx and the laryngeal pharynx. Collectively, OC and 
OPC is the sixth most common cancer worldwide, with an annual incidence estimated at 
442,000 cases (Warnakulasuriya, 2009; Ferlay et al., 2015).  
A cell may undergo malignant transformation leading to a primary malignancy in any of the 
oral and oropharyngeal tissues. Less commonly, an oral malignancy will occur due to spread 
from an adjacent local site (such as the maxillary sinus) or a distant site (such as the liver). 
Primary tumours may arise from epithelial, mesenchymal or haematological tissue (Barnes et 
al., 2005). Globally, at least ninety percent of all OCs and OPCs arise from oral epithelial 
cells (Barnes et al., 2005) and these are referred to as oral squamous cell carcinomas (OSCC). 
Other malignant tumours in the oral cavity and the oropharynx include sarcomas (such as 
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osteosarcomas and fibrosarcomas), some salivary gland tumours (such as mucoepidermoid 
carcinoma and adenoid cystic carcinomas) and melanomas. Increasingly, primary oral 
lymphomas are being diagnosed. The World Health Organization’s (WHO) classification of 
malignant tumours of the oral cavity and the oropharynx, according to the tissue of origin, is 
presented in Table 2.1.  
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Table 2.1 WHO’s classification of malignant tumours of the oral cavity and oropharynx 
 Morphology code
a 
Malignant epithelial tumours   
Squamous cell carcinoma  8070/3 
Verrucous carcinoma 8051/3 
Basaloid squamous cell carcinoma  8083/3 
Papillary squamous cell carcinoma  8052/3 
Spindle cell carcinoma  8074/3 
Acantholytic squamous cell carcinoma  8075/3 
Adenosquamous carcinoma  8560/3 
Carcinoma cuniculatum  8051/3 
Lymphoepithelial carcinoma  8082/3 
  
Salivary gland carcinomas   
Acinic cell carcinoma  8550/3 
Mucoepidermoid carcinoma  8430/3 
Adenoid cystic carcinoma  8200/3 
Polymorphous low-grade adenocarcinoma 8525/3 
Basal cell adenocarcinoma  8147/3 
Epithelial-myoepithelial carcinoma 8562/3 
Clear cell carcinoma, not otherwise specified 8310/3 
Cystadenocarcinoma  8450/3 
Mucinous adenocarcinoma  8480/3 
Oncocytic carcinoma  8290/3 
Salivary duct carcinoma 8500/3 
Myoepithelial carcinoma  8982/3 
Carcinoma ex pleomorphic adenoma 8941/3 
  
Soft tissue tumours   
Kaposi sarcoma  8982/3 
  
Haematolymphoid tumours   
Diffuse large B-cell lymphoma (DLBCL)  9680/3 
Mantle cell lymphoma  9673/3 
Follicular lymphoma  9690/3 
Extranodal marginal zone B-cell lymphoma of MALT type  9699/3 
Burkitt lymphoma  9687/3 
T-cell lymphoma (including anaplastic large cell lymphoma  9714/3 
Extramedullary plasmacytoma  9751/1 
Extramedullary myeloid sarcoma  9930/3 
Follicular dendritic cell sarcoma / tumour  9758/3 
  
Mucosal malignant melanoma  8720/3 
a
Morphology code of the International Classification of Diseases for Oncology (ICD-O) and the Systematized 
Nomenclature of Medicine (http://snomed.org). Behaviour is coded /3 for malignant tumours, and /1 for 
borderline or uncertain behaviour, as cited in Barnes et al., 2005. 
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Metastatic OCs and OPCs arise from the haematogenous spread of malignant cells from 
distant sites such as the breast, the liver, the lungs, the prostate glands and the kidneys 
(Hirshberg and Buchner, 1995; Hirshberg et al., 2008). Metastatic tumours are rare in the oral 
cavity and are usually evidence of more widespread disease (Hirshberg et al., 2008). Overall, 
metastatic spread is more common in bony tissues (the mandible and the maxilla), than in the 
soft tissues of the mouth (Lim et al., 2006; Hirshberg et al., 2008). For example, oral tumours 
arising from prostate cancer are ten times more likely to occur in the mandible or the maxilla 
than in the soft tissues (Hirshberg et al., 2008).  
2.2 Classification of oral and oropharyngeal carcinomas 
The International Classification of Diseases (ICD) is the standard diagnostic tool for 
epidemiology and health services research. It is used internationally to monitor the incidence 
and prevalence of diseases. The ICD-10 is the most recent version of the ICD. The codes for 
OC and OPC are those from C00 through to C14. The codes refer to the following anatomical 
sites: the lip and intraoral sites (C00 ̶ C06), the minor and major salivary glands (C07 ̶ 08), the 
oropharyngeal sites (C09 ̶ 10) and other ill-defined sites within the oral cavity or the 
oropharynx (C14). Neoplasms of the nasopharynx (C11), the piriform sinus (C12) and the 
hypopharynx (C13) are considered separately from OC and OPC so are not included in Table 





Table 2.2 ICD Codes for malignancies of the oral cavity, salivary glands and the oropharynx 
Site description ICD codesa
 
External lip C00—02 
  
Oral cavity carcinomas  
Internal lip C003—005 
Lip unspecified C006—009 
Tongue C020—23, C028, C029 
Floor of mouth C040—049 
Gum and cheek C030—039, C060-062 
Hard and soft palate C050—C059 
Other parts of mouth C068 
  
Oropharyngeal carcinomas  
Base of tongue, lingual tonsil C01, C024 
Tonsil C090—C099, C142 
Oropharynx C100—109 
Overlapping or unspecified lesion of oropharynx C140 and C148 
  
Salivary glands carcinomas  
Minor salivary gland C069 
Major salivary gland C070—C089 
a
 ICD-10 Codes for malignant neoplasms of the oral cavity, salivary glands and the oropharynx, available from 
http://apps.who.int/classifications/icd10/browse/2016/en#/II 
 
2.3 Risk factors for oral and oropharyngeal cancer 
In epidemiology, the term ‘risk factor’ has been used to describe an environmental, 
behavioural or biologic factor that, if present, directly increases the probability of a disease 
occurring (Beck, 1998). Likewise, if the factor is absent or removed, the probability of the 
disease occurring is lower. The risk factors for OC and OPC that have been reviewed in the 
published literature are discussed in the following section. In particular the role of; oral 
potentially malignant disorders (OPMD), lifestyle risk factors (such as the use of tobacco, 
alcohol and betel quid
1
) and oral infections, in the development of OC and OPC, will be 
discussed. 
                                                 
1
 Betel quid is the term used to describe the combination of the areca nut with various ingredients including 
tobacco, lime and P. betle leaf (World Health Organization, 2012). 
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2.3.1  Oral potentially malignant disorders 
Although the natural history of OC and OPC is not fully understood (Napier and Speight, 
2008; Scully, 2014), it is widely accepted that many neoplastic lesions are preceded by 
clinically detectable potentially malignant lesions (Napier and Speight, 2008; van der Waal, 
2009; Warnakulasuriya, 2009). Moreover, potentially malignant lesions may not be limited to 
one anatomical site within the mouth. Abnormal epithelium may be present adjacent to an 
OSCC (Walsh et al., 2013) or distant from the primary site (Thomson, 2002; Thomson and 
Hamadah, 2007). The term “OPMD” is now commonly used to describe potentially malignant 
lesions, and this term reflects the risk of malignant transformation of oral mucosa within, 
adjacent to or distant from previously detected lesions (Warnakulasuriya et al., 2007). The 
term “OPMDs” also includes hereditary disorders that have a higher risk of malignant 
transformation. 
The OPMDs identified by the WHO expert working group include: erythroplakia (also known 
as erythroplasia); oral submucous fibrosis (OSF); leukoplakia (particularly nodular, speckled, 
proliferative verrucous, candidal, syphilitic and erythro-leukoplakia); oral lichen planus 
(particularly the non-reticular or erosive type); and actinic cheilitis (mainly on the lower lip). 
Other rare conditions (such as dyskeratosis congenita, discoid lupus erythematosus, Paterson-
Kelly syndrome and Fanconi syndrome), may be associated with a higher risk of developing 
OPMDs (van der Waal, 2009).  
OPMDs differ in their incidence and their potential for malignant transformation (Mithani et 
al., 2007; Napier and Speight, 2008; Scully, 2014). It is currently not possible to predict 
which individual OPMDs will progress to OSCC if exposure to risk factors is maintained, or 
conversely, which individual lesions will resolve if the exposure is removed (Lee et al., 2000; 
Holmstrup et al., 2007; Scully and Bagan, 2009). Although most OPMDs are chronic 
conditions with a low susceptibility for malignant transformation (generally less than 5%), the 
severity of epithelial dysplasia is recognised as a significant prognostic factor for malignant 
transformation (Warnakulasuriya et al., 2015). In addition, malignant transformation is more 
likely to occur within the first five years of lesion development (Walsh et al., 2013). 
2.3.1.1 Erythroplakia 
Erythroplakia has been described as a clinically detected red patch on the oral mucosa that 
cannot be accounted for by any specific disease entity (Pinborg et al., 1997). Clinically, 
erythroplakia may present as a flat lesion with a smooth or a granular surface, although it 
more commonly presents as a mixed red and white lesion, termed “erythro-leukoplakia” 
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(Warnakulasuriya, 2009). Erythroplakia has been reported predominantly in older age groups 
(Shafer and Waldron, 1975; Feller et al., 1991; Hashibe, Altini and Slabbert, 2003). However, 
the global prevalence of erythroplakia is not well reported and the data are limited to studies 
from South and Southeast Asia. The reported prevalence in these populations ranges between 
0.02% and 0.83% (Reichart and Philipsen, 2005).   
The highest malignant transformation rate (MTR) for OPMDs is reported for erythroplakia 
and erythro-leukoplakia, with reported rates ranging from 14.3% to 50.0% (Reichart and 
Philipsen, 2005). However, it has been suggested that most erythroplakias will undergo 
malignant transformation (van der Waal, 2009). An early study by Mashberg and Feldman 
(1988) reported that erythroplakia was evident in 64% of the 263 invasive OCs and OPCs 
reviewed. While the evidence suggests that the presence of erythroplakia is associated with a 
higher risk of malignant transformation than other lesions, this is not necessarily a linear 
process, and lesions may undergo episodes of regression and progression over time (Macey et 
al., 2015). It is not possible to determine which individual erythroplakia or erythro-
leukoplakia lesions will progress to carcinoma but due to the known risk, these lesions should 
be carefully monitored by a specialist experienced in their management and excised if 
possible.  
2.3.1.2 Oral submucous fibrosis 
Oral submucous fibrosis (OSF) is a chronic disorder of the mucosa that causes epithelial 
atrophy and leads to fibrosis and hyalinization of the underlying lamina propria (van der 
Waal, 2009; Warnakulasuriya, 2009). It has been proposed that atrophic epithelium increases 
the exposure to carcinogens, and this in turn, predisposes tissue to malignant transformation 
(van der Waal, 2009). The prevalence of OSF shows marked geographic variation, with the 
distribution mainly concentrated in Southeast Asia, Melanesia and Micronesia, consistent 
with the prevalence of betel (areca) nut chewing. Early studies have reported a MTR for OSF 
of between 0.5% and 7.6% (Pindborg et al., 1984; Sinor et al., 1990; Murti et al., 1995). 
Cessation of the betel quid chewing habit has been reported to limit the progression of OSF 
lesions and reduce the MTR of existing lesions (Barnes et al., 2005; Gupta et al., 1995). 
2.3.1.3 Oral leukoplakia 
The most prevalent OPMD is leukoplakia, with a global prevalence estimated at between 
0.5% and 2% (Petti, 2003; van der Waal, 2009). The reported MTR for oral leukoplakia 
differs considerably according to the anatomical subsite, leukoplakia type and the populations 
studied, with annual rates ranging from 0.3% to 1.4% reported (Gupta et al., 1980; Petti, 
2003). Proliferative verrucous leukoplakia (PVL), which may begin as a homogeneous 
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leukoplakia and non-homogeneous leukoplakias have greater malignant potential (Holmstrup 
et al., 2007). Moreover, hospital-based studies report higher MTRs for leukoplakia than 
community-based studies (Macey et al., 2015). This is as expected since hospital-based 
studies would contain more individuals deemed to be at higher risk of developing OC. 
Although Petti (2003) reported an MTR of 1.4% for oral leukoplakia from global pooled 
prevalence data, this rate did not match the predicted development of OC in the study 
populations and greatly exceeded the known incidence of OC. Thereby suggesting the overall 
MTR for leukoplakia lesions is significantly lower than 1.4%, or conversely, that globally the 
level of OC is underreported.  
2.3.1.4 Oral lichen planus 
Oral lichen planus (OLP) is a chronic mucocutaneous inflammatory condition with a reported 
population prevalence of between 0.1% and 4.0% (Mollaoglu, 2000). OLP is an 
immunologically mediated condition, although the factors which initiate it are not fully 
understood (Pol et al., 2015). The malignant potential of OLP lesions has been debated over 
many years. Whether OLP is potentially malignant or whether OLP-like dysplastic lesions 
undergo malignant transformation is uncertain (Patil et al., 2015). Pol et al. (2015) have 
proposed that HPV infections play a role in the pathogenesis of OLP, and they may also 
contribute to the malignant potential of OLP lesions. OLP has a reported annual malignant 
transformation rate of less than 1% (van der Waal, 2009). 
2.3.1.5 Actinic cheilitis 
The association between actinic cheilitis (also reported as solar cheilitis) and squamous cell 
carcinoma of the lip has been reported for many years International Agency for Research on 
Cancer, 1992; International Agency for Research on Cancer, 2012a). Actinic cheilitis is a 
condition which occurs in individuals with a history of chronic exposure to ultraviolet (UV) 
radiation (de Souza Lucena et al., 2012). Clinically, actinic cheilitis may present as erythema, 
atrophy, erosion or keratotic plaques and fissures on the epithelium of the external lip. 
Predominantly, actinic cheilitis occurs on the lower lip, because this is a site with high sun 
exposure (Pukkala et al., 2009). Infiltration of the lesion across the vermilion border is 
suggestive of malignant transformation (Nico, Rivitti, and Laurenco, 2007). 
The reported prevalence rates of actinic cheilitis range from 0.5% to 2.4%, with middle-aged 
and light-skinned men whose occupations involve chronic sun exposure having higher rates. 
Studies based solely in high risk populations have reported prevalence rates as high as 43.2% 
(da Silva et al., 2006). Whether actinic cheilitis lesions are exacerbated by other known risk 
factors (such as tobacco use and alcohol consumption) is unclear (Campisi and Margiotta 
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2001; de Souza Lucena et al., 2012). The rate of malignant transformation of untreated actinic 
cheilitis has not been reported (van der Waal, 2009). 
2.3.2 Tobacco consumption 
Tobacco smoking has long been reported as a risk factor for OPMDs as well as OC and OPC 
(International Agency for Research on Cancer, 2004a; International Agency for Research on 
Cancer, 2012b). More recently, other forms of tobacco use, such as snuff (ground tobacco 
leaves inhaled into the nostrils) and chewing tobacco, have also been identified as being 
carcinogenic to the oral and oropharyngeal tissues (International Agency for Research on 
Cancer, 2007a; International Agency for Research on Cancer, 2012b). Detailed evaluation of 
the role and mechanism of tobacco in the development of OC and OPC is contained within 
the International Agency for Research on Cancer Monographs (International Agency for 
Research on Cancer, 2004a; International Agency for Research on Cancer, 2007a; 
International Agency for Research on Cancer, 2012b). The Monographs review evidence 
from different populations in differing geographical regions, thereby reinforcing the 
importance of tobacco as a risk factor for OC and OPC. In addition, tobacco is a dose-
dependent risk factor with higher exposure conferring greater risk. Risk among current 
smokers is consistently greater than among former smokers, with risk reducing as the number 
of years since quitting increases (International Agency for Research on Cancer, 2004a).  
Historically, in industrialised populations, at least 75% of OSCCs and OPSCCs were 
attributed to alcohol and tobacco use (Hashibe et al., 2007). Since tobacco and alcohol habits 
frequently co-exist, separating the role of alcohol consumption and tobacco use in the 
aetiology of OSCC and OPSCC has been challenging. Hashibe et al. (2007) calculated the 
odds ratio for developing head and neck cancer among users of tobacco who did not drink 
alcohol. An odds ratio of 2.13 (95% CI 1.52, 2.98) for ‘ever smokers’ was reported. There 
were clear dose–response relationships for the frequency and the duration of cigarette 
smoking. The study also concluded that 24% (95% CI 16%, 31%) of head and neck cancers 
among non-drinkers could have been prevented if those individuals had not smoked 
cigarettes. In addition, distinct geographical variation has been reported in the population 
attributable risk (PAR) for developing head and neck cancer among smokers who do not use 
alcohol. Studies from Europe and Latin America reported greater risk (PAR of 84% and 83%, 
respectively) than those from North America (PAR 51%) (Hashibe et al., 2009). Whether this 
variation reflects regional differences in the contents of cigarettes (in particular, variations in 
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the levels of nitrosamines, polycyclic aromatic hydrocarbons and other tobacco carcinogens), 
the patterns of smoking, or other risk factors remains unclear.  
Extensive research conducted into the joint effects of consumption of tobacco products and 
alcoholic beverages on OC and OPC concluded that tobacco works both individually and 
synergistically with alcohol to multiply the risk (International Agency for Research on 
Cancer, 2004a; International Agency for Research on Cancer, 2007a; International Agency for 
Research on Cancer, 2012b). The PAR for tobacco or alcohol was calculated by Hashibe et al. 
(2009) as 72% (95% CI 61%, 79%) for head and neck cancer (33% due to tobacco alone and 
35% due to tobacco and alcohol combined). The reported total PAR also differed by 
anatomical subsite, (64% and 72% for OCC and pharyngeal cancer, respectively), by sex 
(74% and 57% for males and females, respectively) and by age (33% for those aged less than 
45 years; 73% for those aged more than 60 years). The greatest risk was attributable to male 
smokers and drinkers over the age of 60 years. 
In view of the strong evidence for the role of tobacco in the development of OC and OPC, it 
had been expected that the decline in tobacco consumption in many industrialised countries 
over the last 30 years would be accompanied by a decline in the incidence of these cancers. 
However, this expected decline has not been observed. Instead, many countries have recorded 
an increase in registered OC and OPC cases. Therefore, the role of additional risk factors in 
the development of OC and OPC is important and continues to be explored.   
2.3.2.1 Patterns of tobacco use in New Zealand 
Findings from the 2014/2015 New Zealand Health Survey show that the prevalence of 
tobacco smoking continues to decline, with 16.6% of the population aged over 15 years being 
current smokers, down from 25.0% in 1996/1997 (Ministry of Health, 2015). However, much 
higher rates of tobacco smoking are reported in Māori (38.1%) and Pacific peoples (24.8%). 
Moreover, those living in the most deprived areas were 3.1 times more likely to smoke than 
those living in less deprived areas, after adjusting for age, sex and ethnicity (Ministry of 
Health, 2015). Tobacco smoking remains slightly more prevalent in males than females 
(adjusted rate ratio of 1.2 for the former).  
2.3.2.2 Marijuana consumption 
The evidence for marijuana use as a risk factor in the development of OC and OPC remains 
weak (Rosenblatt et al., 2004; Aldington et al., 2008). A review of cases of head and neck 
cancer cases in those aged under 55 years in New Zealand concluded that, while it is 
biologically plausible for cannabis use to be associated with a higher risk of head and neck 
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cancer, it has not yet been demonstrated (Aldington et al., 2008). In addition, marijuana and 
tobacco use habits frequently co-exist, complicating the task of differentiating the risk 
associated with either habit. 
2.3.3 Alcohol consumption 
Alcoholic beverage consumption has long been recognised as playing a key role in oral and 
oropharyngeal carcinogenesis. Evidence has been reported from differing geographical 
regions and populations (International Agency for Research on Cancer, 2010; International 
Agency for Research on Cancer, 2012b). As discussed in Section 2.3.2, extensive research has 
been conducted into the synergistic effects of co-existing tobacco and alcohol habits in the 
development of OC and OPC. Hashibe et al. (2009) reported that a PAR of 4% for developing 
head and neck cancer was due to alcohol use alone. In addition, alcoholic beverage 
consumption has also been reported to be associated with a higher risk of developing a second 
primary OC lesion (Day et al., 1994; Dikshit et al., 2005).  
The exact mechanisms by which alcohol consumption exerts its carcinogenic effects on the 
oral and oropharyngeal tissues are not fully understood. Acetaldehyde, the first metabolite of 
ethanol, is accountable for at least part of the carcinogenicity (Boffetta and Hashibe, 2006). 
Disruption of the oral epithelium may also result from alcohol use, thereby enabling the more 
ready absorption of carcinogens across the epithelium (Howie et al., 2001). Additional 
theories suggest that alcohol-related immunodeficiency and immunosuppression may 
facilitate carcinogenesis (Watson et al., 1994).  
A significant dose-response relationship (for both the frequency and the duration of alcoholic 
beverage consumption) in the development of OPC has been reported (International Agency 
for Research on Cancer, 2010). Heavy drinkers have 5.1 times the risk of non-drinkers or 
occasional drinkers of developing OPC (Bagnardi et al., 2015). Hasibe et al. (2009) reported 
an increasing odds ratio for developing OC with increasing daily alcohol consumption. An 
OR of 1.7 (95% CI 1.2, 2.3) was reported for 1–2 alcoholic drinks per day, 2.3 (95% CI 1.4, 
4.0) for 3–4 alcoholic drinks per day and 5.5 (95% CI 2.3, 13.4) for five or more drinks per 
day.  
Further studies have reported that the risk attributable to alcohol use differs according to 
anatomical subsite. Sigvardsson et al. (1996) reported a 12-fold (95% CI 1.6, 92) higher risk 
of oral cavity cancer, an 8.5-fold (95% CI 2.0, 3.7) higher risk of tongue cancer, and an 11-
fold (95% CI 1.4, 8.5) higher risk of tonsillar cancer associated with alcoholic beverage 
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consumption. In contrast to the studies on quitting tobacco, the relative risk for OC for 
quitters of alcohol is initially higher than current drinkers, and becomes similar to that of non-
drinkers after 10 to 20 years of abstinence (Castellsagué et al., 2004; Hayes et al., 1999).  
2.3.3.1 New Zealand patterns of alcohol use 
Surveys of New Zealand adults suggest that most adults drink alcohol (79.5% of those aged 
over 15 years), and one-third drink regularly (defined as 3-4 times per week) (Ministry of 
Health, 2015). Hazardous
2
 drinking patterns are reported for 17.7% of the population, 
although the proportion of hazardous drinkers is higher in Pacific males (52% of those who 
have consumed alcohol in the past year are hazardous drinkers) and tobacco users (40% of 
tobacco smokers who had consumed alcohol in the past year had a hazardous drinking pattern, 
while it was only 14% in non-smokers) (Ministry of Health, 2013a; Ministry of Health, 2015). 
2.3.4 Areca (betel) nut use 
The use of areca nut has been associated with OC for many years (Orr, 1933; Eisen, 1946, as 
cited in World Health Organization, 21012). However, whether the association was due to the 
areca nut alone or the products used alongside it has been contested. The manner in which 
areca nut is used is culturally determined (World Health Organization, 2012). Frequently, it is 
used alongside tobacco: either both are chewed together as a quid, or a smoking habit co-
exists alongside an areca nut chewing habit (World Health Organization, 2012). Moreover, 
the betel quid may be immersed in alcohol before it is chewed. An extensive review of the 
available literature that has linked OC to the use of betel quid with and without tobacco, and 
OPC to betel quid use with tobacco is available in the IARC Monographs (International 
Agency for Research on Cancer, 2004b; International Agency for Research on Cancer, 
2012b). There is also strong evidence that betel quid use is the main aetiological factor in the 
OPMD, oral submucous fibrosis (International Agency for Research on Cancer, 2004b; 
International Agency for Research on Cancer, 2012b). 
Estimates of the global use of areca nut in some form range from 10 to 20% of the world’s 
population, or at least 600 million people (Gupta and Warnakulasuriya, 2002). However, 
marked geographic variation exists, with high rates of usage among sub-continental Indian, 
South and South-East Asian, Melanesian and Micronesian populations, as well as in migrant 
populations resident in the United Kingdom, South Africa, Australia and the United States 
(World Health Organization, 2012; Petti et al., 2013). In countries where areca nut use is 
                                                 
2
 The NZ MoH defines hazardous drinking as an established drinking pattern that carries a risk of harming 
physical or mental health, or having harmful social effects to the drinker or others. It is measured as a score of 8 
or more on the 10-question Alcohol Use Disorders Identification Test (AUDIT). (Ministry of Health, 2013a) 
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common, up to 50% of reported OC cases in males and up to 90% of OC cases in females 
have been attributed to betel nut use (Balaram et al., 2002).  
2.3.4.1 Use of areca nut in New Zealand 
Despite areca nut being commonly available in Asian and other small grocery stores in New 
Zealand, its use is not a common practice and appears to be limited to a cultural practice 
within sub-continental Indian, South-East Asian and some Western Pacific migrant 
populations (Yoganathan, 2002). However, neither the prevalence of areca nut use nor the 
incidence of OC or OPC which may be attributed to its use, has been reported in New 
Zealand.   
2.3.5 Dietary factors 
Recently, the role of diet and nutrition in the aetiology of OC has been highlighted in the 
literature. Some of the early research stemmed from the observed association of a higher risk 
of OC in women with the iron-deficiency condition Plummer-Vinson syndrome (Larsson et 
al., 1975; Boyle et al., 1990). Recent studies have reported on the salutogenic effects of diets 
high in fruit and vegetables. The International Head and Neck Cancer Epidemiology 
(INHANCE) consortium reported diets high in fruit and vegetables and low in red meat were 
associated with a lower risk of head and neck cancer (per score increment OR 0.90; 95% CI 
0.84, 0.97) (Chuang et al., 2012). Further support for high consumption of fruit and 
vegetables reducing the risk of head and neck cancer comes from the Netherlands Cohort 
Study, which reviewed participants’ consumption of fruit and vegetables prospectively over 
two decades (Maasland et al., 2015). Total fruit and vegetable consumption was found to be 
inversely associated with the risk of head and neck cancer overall, with the strongest risk 
“reduction” for OC (Maasland et al., 2015). 
Pavia et al. (2006) undertook a meta-analysis of the available studies in an attempt to quantify 
the reduction in OC risk per daily serving of fruit and vegetables. Using combined adjusted 
odds ratio estimates, they reported a reduction in OC risk by 49% for each portion of fruit 
(OR 0.51; 95% CI 0.40, 0.65) and 50% for each portion of vegetable (OR 0.50; 95% CI 0.38, 
0.65) consumed per day. However, isolating the effects of dietary factors from other 
behavioural risk factors (such as smoking and alcohol consumption) is difficult. Some studies 
suggest that cigarette smokers are less likely to consume high amounts of fruit and vegetables 
(Dallongeville et al., 1998). It has been proposed that using a “multiple risk factor model” is 
more appropriate for assessing the overall risk of developing OC, rather than attempting to 
isolate the risks pertaining to separate behavioural (lifestyle) factors (Conway et al., 2008).   
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2.3.6 Human papillomavirus  
Infection with certain types of human papillomavirus (HPV) may be sexually transmitted and 
have been linked to the development of cervical cancer and other anogenital cancers (Feller et 
al., 2010; International Agency for Research on Cancer, 2007b). While there are more than 
100 HPV genotypes, the HPV-16 and HPV-18 genotypes are designated as high-risk types 
and have played the major role in the development of HPV-associated cervical cancers (Feller 
et al., 2010). In Australasia, 76.2% of cervical cancer cases have been attributed to these two 
HPV genotypes (World Health Organization, 2010).  
Prevalence rates for HPV infection are commonly available only for women. A recent global 
estimate suggests that 11.4% of women are infected with HPV at any given time (World 
Health Organization/Information Centre on HPV and Cancer, 2010). Reported prevalence 
rates of HPV oral infection in the United States are significantly greater in males (10.1%) than 
females (3.6%) (Gillison et al., 2012). There is no treatment for HPV infection per se and, 
typically, it is cleared by the body’s immune system within two years of infection. However, 
in 10% of cases, infection may persist (Centres for Disease Control and Prevention, 2016). A 
higher frequency of persistent HPV infection has been linked to tobacco smoking and older 
age (D’Souza et al., 2007). It has been proposed that tobacco-mediated and age-related 
genetic and immune factors may increase the tissues’ susceptibility to HPV infection 
(D’Souza et al., 2007).  
More recently oral HPV infection has been linked to OPC (D’Souza et al., 2007, Gillison et 
al., 2012, International Agency for Research on Cancer, 2012a). Oral HPV infection is 
associated with orogenital sex practices, with a greater risk of infection associated with an 
earlier age of sexual initiation and multiple sexual partners (Feller et al., 2010; Osazuwa-
Peters et al., 2015). Other acquired transmission routes have been proposed, including open-
mouth kissing, autoinoculation and vertical birth-transmission (Kreimer et al., 2005; D’Souza 
et al., 2007; Syrjanen, 2007). The majority of HPV-associated OPSCCs (85-90%) arise from 
the HPV-16 genome type (Kreimer et al., 2005; D’Souza, 2007; Marur et al., 2010). Evidence 
for the role of HPV-16 in the pathogenesis of OPSCC arises from three areas: the presence of 
HPV genomic sequences and expression of oncoproteins in the nuclei of malignant tumours 
and their metastases; integration of the HPV DNA in to the cellular genome; and confirmation 
of a higher HPV DNA copy-number within tumours (Feller et al., 2012). However, HPV-16 
seropositivity is not recognised as strongly associated with an increased risk of developing an 
HPV-positive OPSCC. It is unclear whether other proven risk factors (such as alcohol and 
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tobacco) act synergistically with oral HPV infection in the development of OPSCCs (Feller et 
al., 2012).  
Studies report considerable variation in the proportion of HPV-attributable cancers among the 
different sites of the oropharynx and the oral cavity (Kreimer et al., 2005; Parkin and Bray, 
2006; Gillison et al., 2007). The systematic review by Kreimer et al. (2005) calculated the 
average HPV-DNA positivity rate to be 35.6% for OPC and 23.5% for oral OC. However, the 
presence of HPV-DNA in a tumour does not confirm causation, and substantially fewer OC 
and OPC cases have been attributable to HPV than tumours determined to be HPV-DNA 
positive. The multinational study conducted by Parkin and Bray (2006) estimated that only 
12% of OPCs and 3% of OCs were HPV-attributable. However, over the last three decades, 
many studies have reported a two-to three-fold increase in the prevalence of HPV-attributable 
OPSCC. This pattern has been reported particularly in the developed countries of Australia, 
Northern Europe and North America (Hong et al., 2010; Chaturvedi et al., 2011; Brotherton et 
al., 2012; Chenevert and Chiosea, 2012; Garnaes et al., 2015). The incidence of HPV-
attributable OPSCC in New Zealand has also been increasing (Chelimo and Elwood, 2015). 
Gillison et al. (2007) have reported that the percentage of HPV-attributable OPCs may be up 
to 60% in the United States.  
Tonsillar SCC is the condition shown to be most strongly associated with HPV infection 
(Ryerson et al., 2008). However, the exact mechanism for this site predilection remains 
unclear (Pai, 2013). HPV-OPSCC is now recognised as a distinct disease entity (Gillison and 
Lowy, 2004; Fakhry and D’Souza, 2013) with distinct epidemiological features. For example, 
many of those affected are non-smokers, and younger than those with non-HPV OPSCC 
(Anderson et al., 2014). Recognition of the role of HPV in the aetiology of OPSCC has 
significant implications for national OPSCC prevention strategies (Ryerson et al., 2008). 
Many countries have implemented HPV vaccination programmes to reduce the incidence of 
cervical and other anogenital cancers. HPV vaccination programmes available for both boys 
and girls are likely to provide the best opportunity to reduce the incidence of HPV-OPSCC, 
although the efficacy of HPV vaccines in preventing OPSCC has yet to be evaluated (Fakhry 
and D‘Souza, 2103). OPSCC is more prevalent in New Zealand males over forty years of age, 
and therefore the impact of the national HPV vaccination programme (introduced in 2008, 
and Government-funded for girls) on the prevalence of HPV-OPSCC is uncertain. Recent 
proposals suggest the Government-funded vaccination programme will be available for both 
boys and girls from January 2017 (Ministry of Health, 2016).  
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2.3.7 Other infections 
There is evidence that chronic inflammation caused by persistent viral, bacterial and chemical 
agents is a risk factor for many cancers (Porta et al., 2009). Therefore, associations between 
many viral, bacterial and fungal infections and OCs and OPCs have been proposed. 
Association with viral infections such as the human immunodeficiency virus (HIV), the 
herpes simplex virus (HSV) and the Epstein-Barr virus (EBV)
3
 have been investigated 
(Maden et al., 1992; Frisch et al., 2001; Shimakage et al., 2002; Parker et al., 2006). HIV has 
been associated with several malignancies including non-Hodgkin lymphoma (Hicks et al., 
1993) and Kaposi’s sarcoma (Beral et al., 1990). However, there is only limited evidence 
suggesting that HIV and the associated acquired immunodeficiency syndrome (AIDS) are 
associated with OSCC (Flaitz et al., 1995). Kreimer et al. (2005) reported that HIV-
seropositive individuals have a higher prevalence of HPV-16 than HIV-seronegative 
individuals. Furthermore, a large US study that linked AIDS and cancer registries reported a 
higher rate of HPV-associated cancers (including tonsil cancer) in persons with HIV/AIDS 
(Frisch et al., 2001). It is therefore possible that HIV infection confers a greater risk of HPV-
attributable OPC on infected individuals. 
The EBV has been associated with lymphoepithelial carcinoma (LEC), particularly in the 
salivary glands (Barnes et al., 2005). However, marked ethnic variation in EBV-positivity in 
LECs has been reported. LECs are frequently EBV-positive in Chinese populations but 
commonly EBV-negative in Caucasian populations (Barnes et al., 2005).  
Candida albicans causes a range of oral mucosal lesions, including candidiasis. It has been 
speculated that chronic candidiasis poses a significant risk of malignant transformation due to 
C. albicans being more commonly detected in OSCC sites than control sites (Nagy et al., 
1998; Scully, 2002). A case-controlled study by Alnuaimi et al. (2015) reported C. albicans 
was significantly more common in individuals with OCs as well as in individuals who 
consumed alcohol daily. Genotype variation was also present between the study groups, with 
significantly more OC patients having genotype A than the matched controls, who were (in 
turn) more likely to have genotype B. Overall, they concluded that the persistent presence of 
C. albicans should be considered a significant risk marker for OC.  
The possible association between OC and poor tooth brushing, periodontal disease and 
excessive plaque accumulation on dentures has been explored (Tezal et al. 2009; Zeng et al., 
2013; Manoharan et al., 2014; Zeng et al., 2015). However, a causative role for chronic 
                                                 
3
 EBV is also known as the human herpes virus 4 (HHV4). 
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inflammation caused by dental bacterial plaque in the development of oral malignancies is not 
proven (Feller et al., 2013). 
2.4 Epidemiology of oral and oropharyngeal cancer 
2.4.1 Incidence  
Incidence is the number of new cases diagnosed (or deaths) over a defined period and is 
usually expressed as an annual rate per 100,000 persons (International Agency for Research 
on Cancer, 2016). Furthermore, an age-standardised incidence rate (ASR) is the rate of new 
cases that a population would have if it had the standard age structure. Standardisation is 
necessary to enable rate comparisons between populations that have differing age 
distributions. Because age has a strong influence on the risk of developing OC and OPC, 
ASRs are frequently used when comparing incidence rates in different populations. 
Incidence data for OC and OPC are calculated from population-based cancer registries. 
Registries may cover an entire country or be limited to a particular region or treatment 
hospital. Comparing incidence rates of OC and OPC across populations can be challenging 
due to differences in the proportion of the population reported within the Register and the 
quality of the data collected. Furthermore, different Cancer Registries may have different 
category criteria. For example, the lesions of the lip may be separately recorded as the 
external lip (which may be excluded from the Registry) and the internal lip (which may or 
may not be included). Variations also exist in the reporting of cancers of the tongue. For 
example, all malignant lesions of the tongue may be reported as OC, or lesions of the base of 
the tongue may be separately recorded as OPC. In the following discussion on incidence rates, 
the ICD codes, (if known) have been included to aid cross-population comparisons.  
2.4.1.1 Global incidence oral and oropharyngeal cancer 
There are an estimated 300,000 cases of cancer involving the lip and oral cavity (C00-08) and 
142,000 cases of cancer of the pharynx (C09-10, C12-14) worldwide, comprising 2.1% and 
1.0% of all cancers, respectively (Ferlay et al., 2015). However, distinct geographic incidence 
patterns exist, reflecting the prevalence patterns of known risk factors for OC and OPC 
(Sankaranarayanan et al., 2015). Historically, high incidence rates of OC and OPC have been 
reported in South and South-East Asia, and in parts of Central Europe and South America 
(Chaturvedi et al., 2013). India alone accounts for at least one quarter of the total number of 
new cases of OC and OPC globally (Warnakulasuriya, 2009). Overall, the highest incidence 
of OC is reported in Melanesia among both males and females (22.9 ̶ 36.3 per 100,000 and 
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16.0 ̶ 23.6 per 100,000, respectively) (Parkin et al., 2005; Ferlay et al., 2015). Western Europe 
has the highest reported incidence of OPC (7.5 per 100,000 for men and 1.6 per 100,000 for 
women), although OPC incidence rates have been increasing over the last 20 years in many 
regions, including Australasia, North America and parts of East Asia (Chaturvedi et al., 2013; 
Simard et al., 2014).  
Worldwide, there are an estimated 145,000 deaths (1.8% of total cancer deaths) due to OC 
and a further 97,000 deaths (1.2% of total cancer deaths) due to OPC (Ferlay et al., 2015). At 
least three-quarters of the deaths occur in less developed regions. Regions with the highest 
estimated annual number of cancer deaths from OC include Asia (65,000), South-Central Asia 
(46,900), Europe (17,600) and Eastern Asia (12,200). Similarly, the most estimated annual 
deaths from OPC are recorded for Asia (51,100), South-Central Asia (37,200) and Europe 
(15,200) (Ferlay et al., 2015). 
2.4.1.2 Incidence of oral and oropharyngeal cancer in New Zealand 
Cases of OC and OPC have been recorded in the New Zealand Cancer Registry (NZCR) since 
1951. Although the NZCR records show that the incidence of OC and OPC in New Zealand is 
relatively low, it has increased over the last fifty years (Cox et al., 1995; Elwood et al., 2014). 
Distinct patterns of OC and OPC have been demonstrated with respect to gender, age, 
ethnicity and anatomical site.  
2.4.1.3 Gender incidence of oral and oropharyngeal cancer 
Traditionally, OC and OPC are male-dominated diseases with incidence rates at least two 
times higher in men than women (Simard et al., 2014). Almost two-thirds of the 267,000 
cases of the OC cases registered in the year 2000 were men (Parkin et al., 2005). Males also 
accounted for nearly two-thirds of global OC cases in 2012 (199,000 of the 300,000 cases) 
(Ferlay et al., 2015). However, some populations have a more pronounced gender differential. 
The Slovak Republic and Belarus report incidence rates more than 10-fold greater in males 
than females (Simard et al., 2014).  
The OC incidence ratio in New Zealand during the period 1987 ̶ 1991 for males to females 
was 2.6 (95% CI 2.3, 2.9), with all types of OC being more common in males than females 
(Cox et al., 1995). Elwood et al., (2014) reported that the age-standardised rates in New 
Zealand from 1981 ̶ 2010 were nearly two times higher in males (2.68 per 100,000) than 
females (1.46 per 100,000). Australian studies have reported a similar male-to-female OC 
incidence ratio, ranging between 1.3:1 and 2.2:1 (Rich and Radden, 1984; Sugerman and 
Savage, 2002; Hogan et al., 2005; Elwood et al., 2014).  
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Globally, the incidence of OPC is reported as being two to five times higher in males than 
females (Simard et al., 2014). Although some countries have a much greater sex difference, 
with a reported male-to-female OPC incidence ratio of at least 20-fold reported for Belarus 
and the Slovak Republic (Simard et al., 2014). The difference in gender incidence has been 
attributed to males having greater exposure to the known risk factors of alcohol and tobacco 
(Warnakulasuriya, 2009).  
In New Zealand, the incidence of OPC is much also higher in males (ASR of 1.87 and 0.47 
per 100,000 for males and females respectively) (Chelimo and Elwood, 2015). Of note was 
the doubling of the male incidence of OPC cases in New Zealand in the years from 1996-2000 
to 2006-2010, which resulted in an increase in the male-to-female ratio in OPC cases over 
time (male-to-female ratio of 3.8:1 and 4.6:1 during the periods from 1981-1985 and 2006-
2010, respectively).  
2.4.1.4 Age incidence of oral and oropharyngeal cancer 
Oral cancer has typically presented in the fifth or sixth decade of life. Internationally only 
four to six percent of OC cases occur in those under 40 years (Bodner et al. 2014; Llewellyn 
et al., 2001). New Zealand studies also report that age-specific rates (ARs) for OPC and OC 
are higher for older age than younger age groups (Cox et al., 1995; Gavidi et al., 2014; 
Chelimo and Elwood, 2015). Gavidi et al. (2014) reported that for OSCC the ARs were 
highest among males aged 75 ̶ 79 years and females aged 85 years and above. The average 
age at diagnosis during this period was 61 years for males and 67 years for females, with only 
five of the total cases (0.003%) occurring in people aged between 15 and 25 years. However, 
the recent rise in the incidence of OPC in New Zealand has been associated with a decrease in 
average age at diagnosis. The average age at diagnosis decreased from 61.3 years in 1981 ̶ 
1985 to 59.7 years in 2006 ̶ 2010 for males, and from 64.9 years to 60.0 years for females 
over the same period (Chelimo and Elwood, 2015). 
OC among young people has been suggested to be aetiologically different from OC in older 
adults. It is more commonly associated with potentially malignant disorders such as Fanconi’s 
anaemia (Bodner et al., 2014; Llewellyn et al., 2001), rather than exposure to known risk 
factors such as tobacco and alcohol. Moreover, OC in younger people affects males and 
females similarly rather than being the male-dominated disease of older people (Bodner et al., 
2014). 
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2.4.1.5 Ethnic differences in the incidence of oral and oropharyngeal cancer 
The literature has reported on ethnic differences in the incidence of OC (Saman, 2012). These 
have been attributed to differing patterns of lifestyle risk factors such as tobacco smoking, 
alcohol consumption and betel nut chewing (Moore et al., 2000). Other factors, including 
variations in diet and cultural beliefs, may also influence ethnic differences in OC (Goodwin, 
2008). 
Ethnic differences in the incidence of OC have also been reported in New Zealand. When 
reviewing data compiled for the ‘Cancer Incidence in Five Continents’, Moore et al., (2000) 
reported that the OC and OPC incidence rate for Māori males was double that for non-Māori 
males (3.6 per 100,000 and 1.8 per 100,000 per annum respectively) in 1997. However, this 
finding is contrary to those of other studies reporting over longer periods. From 2000 to 2006, 
Māori adults were diagnosed with OC at a similar rate to non-Māori adults (6.1 Māori and 6.0 
non-Māori cases per 100,000) (Robson et al., 2011). Incidence rates were also similar when 
comparing Māori with non-Māori by sex (with a rate ratio of 1.02 for males and 0.98 for 
females).  
More recent studies of incidence rates of OSCC by ethnicity found New Zealand Europeans 
had the highest rates in New Zealand. Chelimo and Elwood (2015) reported that Māori had 
significantly lower rates of OSCC (ASR 1.72) during the period 1981 to 2010, than other 
ethnic groups (ASRs of 3.09, 2.32 and 2.17 for Pacific people, Asian and European/other 
ethnic groups, respectively). Gavidi et al. (2014) also reported that New Zealand Europeans 
had a significantly higher incidence of OSCC during the period of 2000 ̶ 2010 than other 
ethnic groups (ASR of 3.5 per 100,000, compared with 0.2 for Māori, and 0.1 for Asian or 
Pacific peoples). The difference in incidence rates between these two studies may be 
explained by the difference in the observation periods and in the inclusion criteria for the 
cases reported. While both studies included only OSCC cases and excluded salivary gland 
tumours (ICD-10 codes C07-C08), Chelimo and Elwood (2015) also excluded the external lip 
and other unspecified lip cancers (ICD-10 codes C00-02 and C006-009), whereas these were 
included by Gavidi et al. (2014). 
The incidence of OPC is less commonly reported in New Zealand. Chelimo and Elwood 
(2015) reported Māori had the highest ASR for OPC (ASR per 100,000 of 1.83 and 1.41 for 
Māori and European/Other ethnic groups respectively) in the period 1981 to 2010. However, 
when considering OPC and OCC during the period 1984 to 2004, Meredith et al. (2012) 
concluded that Pacific males had higher rates of lip, mouth and pharynx cancer than European 
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and Others (Standardized Relative Risk (SRR) 1.49; CI 1.13, 1.98), which was consistent with 
the pattern of greater tobacco use in this group.  
2.4.1.6 Site incidence of oral and oropharyngeal cancer 
The frequency of OSCC at different sites differs substantially among countries (Moore et al., 
2000). Lip cancers represent 30% of all OSCC (Scully et al., 2005), of which 90% involve the 
lower lip. However, when the external lip is excluded, the percentage of OSCC originating in 
the lips is much lower. For example, Rich and Radden (1984) reported that lip cancer in 
Melbourne comprised 10% of all OCC, excluding skin cancer of the lip.  
In developed countries, the tongue and the floor of the mouth are the most common sites for 
OCs (25% of all OCs and up to 45% of OCs when the external lip is excluded) (Scully et al., 
2005). New Zealand data also support the tongue being a common site for OC. Cox et al. 
(1995) reported an age-standardised incidence of 0.7 per 100,000 in the total population in the 
years 1957 ̶ 1991. A site-related birth-cohort pattern was also reported, with those born from 
1922 onwards having a higher incidence of tongue cancer than in other sites (Cox et al., 
1995). Gavidi et al. (2014) reported that 42.5% of the New Zealand cases of OSCC from 2000 
to 2010 involved the tongue. However, there were variations in site incidence with respect to 
ethnicity, with a higher percentage of the OSCCs occurring in the tongue for Māori, Pacific 
people and Asians (64%, 71% and 51% respectively) than for New Zealand Europeans. 
Moreover, a higher percentage of OSCCs occurred in the buccal mucosa in Asians (24%) than 
in other ethnic groups (9% for New Zealand Europeans and 7% for both Māori and Pacific 
people). Although the reasons behind the differences in OSCC site were not explored as part 
of that study, they may be related to the pattern of risk activities such as betel nut chewing, 
which has previously been associated with higher rates of lesions of the buccal mucosa 
(Endican, 2010 as cited in World Health Organization, 2012; Thomas and MacLennan, 1992).  
2.4.2 Prevalence 
Measures of mortality and morbidity can be used to describe the impact of a disease on a 
population. Mortality is a measure of the number of deaths occurring in a specified population 
within a given period. It may be expressed as an absolute number or as a rate per 100,000 
persons per year (International Agency for Research on Cancer, 2016). The latter is more 
useful, because the former cannot really be interpreted without information on the size of the 
population in which the deaths occur.  
 24 
Prevalence data for cancer cases records the proportion or number of persons within a defined 
population who have been diagnosed with that cancer and remain alive at a specified time 
(Rothman and Greenland, 1998). However, using prevalence rates for cancer can be 
problematic because ‘complete prevalence’ represents all people alive on a certain day who 
have been diagnosed with cancer, and it does not take into account the length of time since 
diagnosis, whether the person remains under treatment, or whether the individual is 
considered ‘cured’ (International Agency for Research on Cancer, 2016). More commonly, 
the population cancer burden is expressed as ‘partial prevalence’ and refers to the number of 
persons alive within a defined period following diagnosis (for example, one year or five 
years) (International Agency for Research on Cancer, 2016).  
2.4.3 Mortality 
Despite major advances in the treatment of OC and OPC and some improvement in quality of 
life for those affected, the global 5-year survival rate has not significantly improved and 
remains at 55 to 60% (Ries et al. 2007; Rapidis et al., 2009; Huang et al., 2015). Several 
patient and tumour factors (including gender, lifestyle-related risk factors, socioeconomic and 
nutritional status, presence of co-morbidities, tumour site, disease stage and expression of key 
biomarkers) have been proposed as prognostic indicators for OC (Warnakulasuriya et al., 
2016). An analysis by Tromp et al. (2005) concluded that the stage of disease was the only 
independent risk factor influencing OC survival. This view was supported by 
Warnakulasuriya et al. (2016), who reviewed multivariate analyses from more recently 
published studies and confirmed that an advanced stage of disease was associated with poor 
prognosis. A recent review of OC cases in Taiwan reported that the five-year overall survival 
rates for Stage IV cancers were less than half that of Stage I (5-year survival rates of 79.0%, 
69.4%, 54.6% and 36.2% for Stages I, II, III and IV respectively) (Huang et al., 2015). Other 
studies report five-year survival rates of between 10 and 28% for patients with OC with 
distant metastases at diagnosis (Sciubba, 2001; Kao et al., 2009; Liao et al., 2011). Large 
tumour volumes (a measure of tumour advancement) have also been associated with lower 
overall survival in tongue cancer (Mücke et al., 2015). It is widely accepted that the key to 
improving survival rates lies in improving the rate of early diagnosis of oral malignant and 
potentially malignant disorders
 
(van der Schroeff and Baatenburg de Jong, 2009). 
When reviewing patterns of OC in New Zealand, Cox et al. (1995) reported mortality rates by 
gender and subsite. In the years 1954 to 1991, the male-to-female mortality rate ratio was 3.1 
(95% CI 2.5, 3.9), with approximately 80 men and 35 women dying each year from OC. The 
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age-standardised mortality per 100,000 from 1987 to 1991 was highest for men with tongue 
(0.79) or mouth cancer (0.77) and lowest for lip cancer (0.09 for men and 0.05 for women). 
Substantial ethnic and socioeconomic inequalities in OC survival are known to exist in New 
Zealand (Robson et al., 2011; Soeberg et al., 2012). A review of cancer mortality rate patterns 
in New Zealand from 1991 to 2004 reported Māori had an excess mortality rate ratio of 1.37 
compared with non-Māori (Soeberg et al., 2012). Those from the lowest income quintile had 
an excess mortality rate ratio of 1.28 over the highest income quintile. A higher mortality rate 
for Māori males than for non-Māori has also been observed for OC (with age-standardised 
mortality rates of 2.7 and 1.8 per 100,000 for Māori and non-Māori, respectively)(Robson et 
al., 2011). The factors contributing to different mortality rates have not been fully explained, 
although part of the difference has been attributed to higher rates of smoking and a later stage 
of diagnosis for Māori (Robson et al., 2011; Soeberg et al., 2012). During the period from 
1996 to 2006, Māori males had the lowest proportion of OCs diagnosed at a localised stage 
(15.6% and 30.5% for Māori and non-Māori respectively) and the greatest proportions of OCs 
diagnosed with both regional (38.3% Māori; 30.3% non-Māori) and distant spread (8.6% 
Māori; 5.2% non-Māori). However, the overall significance of this finding is difficult to 
interpret because over one-third of the cases reviewed did not have their tumour stage 
recorded, and the rates were not adjusted for age. Nevertheless, when controlling for stage and 
age at diagnosis, the relative risk of dying from OC was 66% higher in Māori males than in 
non-Māori males (Robson et al., 2011). Other possible explanations for the disparity in 
mortality rates (such as the role of variation in site incidence or co-morbidities) have yet to be 
explored in New Zealand. 
2.4.3.1 Morbidity 
Various post-diagnosis morbidities may arise from the physical and/or psychosocial effects of 
the tumour, or from the treatment provided. Surgery for tumour removal and the post-
radiation therapy sequelae of OC and OPC (including trismus and dry mouth) have 
detrimental impacts on social functions such as eating, speaking, and swallowing (Rogers 
2009). OC and OPC survivors may continue to suffer from these detrimental effects for many 
years after their treatment is complete. More recently, health-related quality of life (HRQoL) 
measures have been validated as patient-perspective outcome measures following cancer 
treatment (Rogers, 2009). Studies have reported a decline in general and mental health, 
appearance, physical function, employment and social functioning during and immediately 
following treatment for head and neck cancer (Abendstein et al., 2005; Funk et al., 2012). 
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HRQoL tends to be poorer with more advanced stages of disease, with those experiencing 
tumour recurrence having the poorest HRQoL scores (Rana et al., 2015).  
Although many studies have shown that patients with head and neck cancer usually 
experience an improvement in their quality of life in the first two to three years following 
treatment (Morton and Izzard, 2003), others report significantly poorer HRQoL up to ten 
years after diagnosis (Mehana and Morton, 2006; Oskam et al., 2013). Conversely, some 
long-term survivors have reported retaining their quality of life following cancer diagnosis 
and treatment (Goldstein et al., 2007). A recent study of patients treated at the Auckland 
Hospital Head and Neck Cancer Clinic reported that those who were assisted to develop 
general coping skills following diagnosis had improved QoL (Cavell et al., 2015). Greater 
benefit was demonstrated in those with more advanced disease, those of Māori and Pacific 
ethnicity and those with poorer baseline QoL. It was suggested that many head and neck 
cancer patients have substantial unmet needs, and by providing adequate support there is 
potential to improve their quality of life. 
Attempts have been made to quantify the disease burden for a population by combining 
mortality and morbidity data using the Disability-Adjusted Life-Years (DALY) measure. The 
DALY score for a disease is calculated using estimates for the Years of Life Lost (YLL) due 
to premature mortality in the population and the Years Lost due to Disability (YLD) for long-
term survivors (Murray and Lopez, 1996). A DALY score of one may be interpreted as one 
year of "healthy" life lost. Higher DALY scores reflect a higher disease burden for a 
population. DALY scores have been calculated for many cancers including OC and OPC. 
Soerjomataram et al. (2012) used a systematic analysis of Globcan 2008 figures to calculate 
DALY scores for Australasia due to OC (C00-C08) of 43 for men and 18 for women, and for 
OPC (C09-C14, excluding C11) of 29 for men and 6 for women. These figures were similar 
to the DALY scores for North America (for men 33 and 28, for women 14 and 7 for OC and 
OPC respectively). However, these scores are significantly less than those for Oceania 
(excluding Australia and NZ) of 235 for men and 157 for women for OC and 68 for men and 
11 for women for OPC. The difference reflects the high rate of OC in Melanesia. However, 
interpretation of DALY scores can be problematic, because their calculation relies on the 
recording of extensive data. Population data, cancer incidence and mortality data, treatment 
data, standard life expectancy data and disability estimates from disease burden studies are all 
required to calculate accurate DALY scores (Soerjomataram et al., 2012). The collection of 
detailed data in all these fields across differing populations remains challenging. In addition, 
the use of DALY scores remains controversial, as score calculations may include inherent 
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inequities when assessment of disability (as opposed to life years lost) are included (Wald and 
Oppenheimer, 2011).   
2.5 Diagnosis of oral and oropharyngeal cancer 
Accurate diagnosis of OC and OPC first requires a thorough clinical assessment of the oral 
and oropharyngeal tissues. Clinical assessment includes visual inspection of tissues, as well as 
palpation of all mucosal surfaces and bimanual manipulation of the floor of the mouth 
(Barnes et al., 2005). Palpation of the neck is required to assess lymph node involvement. 
Following clinical assessment of suspicious lesions, malignancy is confirmed by a biopsy and 
histological diagnosis. Several other tests have been proposed to aid in the diagnosis of OC. 
These include vital staining (toluidine blue, tolonium chloride), oral cytology (such as brush 
biopsy), light-based detection and oral spectroscopy. However, these methods are not 
currently recognised as a replacement for the internationally accepted standard of biopsy and 
histological diagnosis (Macey et al., 2015) 
A wide variety of anatomical and histological subsites make up the oral cavity and the 
oropharynx. Thus, the clinical manifestations of malignant lesions may differ according to the 
subsite in which they arise. Since the vast majority (at least 90%) of OC and OPC are 
squamous cell carcinomas, only the clinical presentation of oral squamous cell carcinomas 
(OSCC) will be discussed in this section.  
2.5.1 Clinical features of oral and oropharyngeal squamous cell cancer 
Potentially malignant and early malignant lesions may present as red lesions (termed 
‘erythroplasia’ or ‘erythroplakia’), irregular white lesions (termed ‘leukoplakia’) or mixed red 
and white lesions (termed ‘erythro-leukoplakia’) within the epithelial tissue. Clinically, it may 
be difficult to distinguish among non-malignant, potentially malignant and early malignant 
lesions. Although the clinical appearance of malignant lesions will differ according to which 
subsite is affected, certain features suggest OSCC. These features include induration, non-
healing ulcers (particularly those associated with raised or fissured margins), numbness or 
pain, abnormal blood vessels supplying a lump, a non-healing extraction site, an exophytic 
growth, enlarged neck lymph nodes, unexplained tooth mobility, and bony expansion of the 
mandible or the maxilla (Scully and Bagan, 2009). Additional symptoms, such as trismus, or 




For some head and neck sites both intra-oral and extra-oral radiographs such as 
orthopantomography (OPG) are used to assess whether visually identified lesions involve the 
underlying bone. Suspicious lesions may be an incidental finding on radiographs taken for 
other clinical investigations. Three-dimensional imaging, such as computered tomography 
(CT) or magnetic resonance imaging (MRI), may be utilised to provide additional information 
on the localised spread of disease as well as lymph node involvement (Barnes et al., 2005).  
2.5.3 Histological features of oral squamous cell carcinoma 
OSCC occurs following mutations of the DNA of oral keratinocytes; this enables cells to 
proliferate in an abnormal manner (Scully and Bagan, 2009). The accumulation of cellular 
atypia and tissue architectural changes within an epithelium is termed ‘epithelial dysplasia’. A 
definition of epithelial dysplasia and its histological description and grading is available 
elsewhere (Barnes et al., 2005). OSCC is characterised histologically by invasion of the 
dysplastic cells across the basement epithelial membrane leading to local, regional and 
(ultimately) distant spread (Barnes et al., 2005). 
2.6 Staging of oral and oropharyngeal carcinomas 
The extent of a tumour at the time of diagnosis is an important prognostic indicator and a 
crucial factor in determining the appropriate treatment regime (Edge and Compton, 2010). 
The staging of tumours is also an important tool in epidemiology and health services research. 
Two cancer staging systems will be discussed; these are the Tumour Node Metastases (TNM) 
and the Surveillance Epidemiology and End Results (SEER) staging systems. 
2.6.1 Tumour Node Metastases staging of oral and oropharyngeal carcinomas 
The classification of malignant tumours into different stages began in 1905 by Steinthal and 
was developed further by Paterson in 1940 (van der Schroeff and Baatenburg de Jong, 2009). 
The TNM system for recording the extent of malignant disease at the time of diagnosis was 
developed by oncology surgeon Pierre Denoix over a ten-year period from 1943 to 1952 (van 
der Schroeff and Baatenburg de Jong, 2009). The TNM system classifies tumours according 
to the anatomic extent of the primary tumour (T1─4), regional lymph node involvement 
(N0─3) and the absence or presence of distant metastases (M0─1). There are 32 possible 
TNM combinations, which may be further grouped as cTNM (TNM code based on clinical 
examination and radiologic imaging) or pTNM (TNM code based on histolopathological 
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examination of the tumour and/or regional lymph nodes). The TNM system has been used 
internationally in the staging of cancer for treatment and epidemiological purposes since 
1982. The Union for International Cancer Control (UICC) publishes the TNM system 
guidelines which is currently in its sixth edition (Union for International Cancer Control, 
2009).  
TNM staging is specified according to anatomical site (Barnes et al., 2005). Tumours of the 
oral cavity and the oropharynx that have similar TNM combinations are thought to behave 
similarly (van der Schroeff and Baatenburg de Jong, 2009). This allows simplification of the 
possible TNM combinations into grouped stages: Stages I ̶ IV, with Stage I being the least, 
and Stage IV the most advanced. Stage IV tumours are further classified according to 
therapeutic subcategories in the following manner: tumours likely to respond to surgical 
resection (Stage IVa); tumours requiring locoregional control with chemotherapy (Stage IVb); 
or incurable tumours suitable only for palliative treatment (Stage IVc). However, the TNM 
stage alone is not considered sufficient to determine the prognosis and individual risk factors 
and existing co-morbidities play a crucial role in survival (Yung and Piccirillo, 2008).  
Pugliano et al. (1999) recorded cancer symptoms along with TNM stage and patient factors 
(such as age, comorbidities, symptom severity and alcohol use) in a proportional hazards 
model to predict head and neck cancer survival. The severity of cancer-related symptoms 
alongside the TNM code was used as a measure of the aggressiveness of the tumour, whereas 
patient factors reflected the individual’s ability to deal with the tumour. They estimated that 
the 5-year survival rates using TNM stage alone were 72%, 54%, 37% and 29% for stages I, 
II, III and IV respectively. However, when clinical factors were included the estimated 
survival rates for stages I, II and III rose, but halved for Stage IV (survival rates of 77%, 56%; 
42% and 14% for stages I, II, III and IV respectively). 
Similarly, the Washington University Head and Neck Co-morbidity Index (WUHNCI) 
developed by Piccirillo et al. (2004) is a head and neck cancer-specific index that identifies 
seven co-morbidities (such as congestive heart failure and previous cancer history) that 
impact on either the primary tumour or the cancer treatment provided. It is designed to be 
used alongside tumour classification and staging information to improve individual patient 
management. It is also intended for epidemiological use.  
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2.6.2 Surveillance Epidemiology and End Results system 
The primary role of population Cancer Registries is the systematic collection and recording of 
all cancer cases within a defined population. Such a registry includes personal details of the 
cancer patients and the clinical and pathological characteristics of the tumour. The existence 
of a register enables analysis of patterns of incidence over time and of the characteristics of 
specific cancers. Registries are also used to record cancer-related deaths. Registries are crucial 
for epidemiological research to inform population cancer control programmes (Parkin, 2008). 
The SEER system was developed as a staging system for utilisation in databases including 
Cancer Registries. It was developed in the 1970s by the US National Cancer Institute 
(Division of Cancer Control and Population Sciences, United States) from two earlier 
programs (the End Results Program and the Third National Cancer Survey) (Hankey et al., 
1999). The SEER system is frequently used in population studies and contains the clinical 
stages of tumours at diagnosis (tumours are classified as in situ, localised, regional or distant) 
(Carvalho et al., 2005).  
2.6.3 The New Zealand Cancer Registry (NZCR) 
The NZCR is a population-based cancer register administered by the New Zealand Ministry 
of Health. The NZCR became operational in 1951, with some records from as early as 1948. 
The main source of cancer data for the NZCR comes from pathology laboratories, which have 
been by law since 1 July 1994 (as per the Cancer Registry Regulations, 1994) to report any 
new diagnosis of cancer. Cases of carcinoma in situ and non-melanoma skin cancer are not 
recorded routinely in the NZCR.  
The NZCR collects detailed information (including demographic data) on the individual 
diagnosed, as well as descriptive data on the tumour found (including site (ICD-code), 
morphology and extent) to ensure that each new diagnosis is recorded only once. The data 
recorded for all cancers in the NZCR are summarised in Table 2.3. Further information is 
collected for cases of melanoma, as well as breast, cervical and colorectal cancers. The 
incidence counts from the NZCR may be based on either the number of primary tumours 
diagnosed or the individuals diagnosed, and the NZCR does record multiple registrations at 
different sites of different histological types for the same individual according to ICD codes. 
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Table 2.3 Table of available data recorded within the New Zealand Cancer Registry (Ministry of 
Health, 2013b) 
Data items for cancers Notes 
Health care user HCU) 
number 
Unique patient identifier, also known as National Health Index (NHI) number. 
Restricted access. 
Name Restricted access. 
Date of birth Day, month, year 
Date of death Day, month, year 
Address Restricted access. 
Domicile code A code based on Statistics New Zealand Census Area Unit. 
Sex Male, female, indeterminate, unknown 
Ethnicity Ethnicity information is sourced from the NHI, the Mortality Collection and the 
National Minimum Dataset (containing hospitalisations). 
Age Age in years at date of diagnosis. 
Diagnosis date Sourced from pathology reports, hospital admission date (from the National 
Minimum Dataset) and the Mortality Collection. 
Registration source code A code identifying the initial source of the registration.  Introduced in 2001. 
Site code ICD-10-Australian Modification code identifying the site of origin of the tumour. 
Morphology code ICD-O code identifying the histology (cell type) of the tumour.  
Behaviour code A code identifying how the tumour acts within the body: in situ, primary invasive 
or metastatic malignancy. Introduced in September 2008. 
Grade of tumour code A code specifying the differentiation of the tumour: how much or how little it 
resembles the normal tissue from which it arose. Introduced in 1998. 
Basis of diagnosis code A code specifying the source of the diagnosis, e.g. death certificate, clinical 
diagnosis, histology or cytology. 
Extent of disease code  A code describing the stage of development reached by the tumour at diagnosis. 
Laboratory code A code identifying the laboratory diagnosing and reporting the cancer event. 
Facility code A code identifying the healthcare facility where the cancer was diagnosed or 
treated. 
Laterality code This code is only relevant for paired organs. It indicates which side of the body the 
affected organ is located on. Introduced in 1998 for the breast, and in September 
2008 for other paired organs. 
TNM codes TNM codes indicate the presence, or absence, of distant metastases, as classified 
by TNM (a staging system including Tumour size, Nodes, and Metastases which 
are specific to the site). Introduced in 2001. 
Nodal status fields Several fields which together indicate whether lymph nodes were tested and how 
many nodes were found to have metastases.  Introduced in 2001 for colorectal 
cancers and in September 2008 for other cancers. 
Multiple tumours flag A flag indicating cancer events considered mulitple tumours according to the 
WHO recommended classification. 
Clinical notes Text field containing supplementary information about the cancer registration. 
Introduced 2001 
Cancer group code A code identifying the specialty group to which the cancer event belongs. 
Introduced in 2001. 
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2.7 Oral cancer screening 
Screening is defined by the WHO as the application of a test (or tests) to people who appear 
to be free from disease in order to distinguish between those that have the disease from those 
who probably do not (Wilson and Jungner, 1968). Rather than being a diagnostic test, 
screening is performed on individuals perceived to be at risk of a particular disease, in order 
to identify those who would benefit from a diagnostic test for that disease (National Screening 
Unit, 2016). To justify a screening programme, the target disease should be relatively 
common, with high associated preventable morbidity or mortality (Scully and Boyle, 2005). 
In addition, the natural history of the disease should be completely defined, with a recognised 
latent phase (Scully and Boyle, 2005). The criteria used by the National Health Committee of 
New Zealand to assist in the decision to implement a screening programme are based on 
aspects of the condition, the screening technique, treatment for the condition and the 
screening programme itself (Table 2.4). 
Table 2.4 National Health Committee criteria for a screening programme (NHC, 2003) 
 
The condition 
 The condition is suitable for screening 
  
The screening technique 
 There is a suitable test 
 The potential benefit of the test should outweigh potential harm 
  
The treatment for the condition  
 There is an effective and accessible treatment or intervention for the condition 
  
The screening programme 
 There is high-quality evidence that a screening programme is effective in reducing 
death and illness 
 There is consideration of social and ethical issues and of cost-benefit issues 
 The health sector should be capable of supporting diagnosis, follow-up and programme 
evaluation 
 
In addition, the screening technique of choice should have a high degree of sensitivity (the 
effectiveness of a test in detecting disease that will progress in those who have the disease), a 
high degree of specificity (the extent to which a test gives negative results in those that are 
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free of the disease or for those in whom disease would not progress), have a high positive 
predictive value (the extent to which individuals have the disease in those that give a positive 
test result), and a high negative predictive value (the extent to which individuals are free of 
the disease in those with a negative test result) (Hakama et al., 2007). 
OC and OPC continue to have a high mortality rate and significant morbidity for those 
affected. Survivors report significant physical disfigurement and disability, as well as negative 
social and psychological impacts (Rogers, 2009). High rates of depression (ranging from 33 
to 92%) have been reported for those diagnosed and treated with head and neck cancer 
(Cavell et al., 2015). It is widely accepted that OC and OPC is frequently preceded by 
clinically detectable potentially malignant disorders (Napier and Speight, 2008; van der Waal, 
2009; Warnakulasuriya, 2009) which may exhibit various stages of dysplasia (Scully and 
Bagan, 2009). The premise of oral cancer screening (OCS) is to detect OPMDs early and 
provide treatment to resolve the lesion, thereby preventing, or at least reducing, the risk of 
malignant transformation. However, the process of malignant transformation is complex. The 
clinical presentation of lesions does not reliably predict early malignant disease (McGurk and 
Scott, 2005). The risk of malignant transformation may remain even after OPMDs are 
excised, since the clinically evident lesion may not represent the full extent of the potentially 
malignant tissue (Holmstrup et al., 2007; Holmstrup, 2009). Another essential component of 
screening is to identify those individuals with OPMDs who may benefit from risk-reduction 
interventions, (for example, leukoplakia lesions in tobacco users may resolve following 
smoking cessation). 
Screening may be undertaken using three different approaches: a population-based approach 
(screening all those in the identified at-risk population); an opportunistic approach (screening 
those who present for primary care for an unrelated issue); or a targeted approach (screening 
those deemed to be at high risk of the disease). Population screening programmes are 
recognised as important for detecting early lesions in other cancers such as breast and bowel 
cancer (NHC, 2015). However, it is widely accepted that population screening for OC is 
unlikely to be a cost-effective method of detecting early lesions, particularly in populations 
with relatively low incidence rates (Brocklehurst et al., 2013). To date, only one randomised 
control trial of a population-screening programme for OC has been conducted (Brocklehurst 
et al., 2013). The trial was conducted over a 15-year period in a high-risk population in the 
province of Kerala, India. A visual oral examination was performed by non-medical 
university graduates trained to identify oral tissue as normal, a tissue lesion not requiring 
further investigation, or a tissue lesion requiring further investigation. Participants with 
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lesions requiring further investigation were referred to a dentist or physician for definitive 
diagnosis (Sankaranarayanan et al., 2005). The review supported the study’s findings that 
screened individuals with a high-risk profile (users of tobacco or alcohol or both) had a lower 
mortality rate from OC and had fewer cancers diagnosed as late stage disease (Stage III or 
higher). However, the study did not adequately account for possible bias. The review 
concluded that currently there is insufficient evidence to recommend a whole-population 
approach in screening for OC but that there is evidence to suggest a targeted approach could 
reduce mortality and enable earlier diagnosis. Opportunistic visual screening by dentists and 
trained health practitioners is still the recommended approach to enable prompt diagnosis and 
treatment for OC, particularly for those who use tobacco and alcohol (Brocklehurst et al., 
2013).  
A recent systematic review conducted by Walsh et al. (2013) compared screening techniques 
for OC and OPMDs. Conventional oral examination (COE) by a primary healthcare clinician 
were assessed alongside other screening methods, such as the use of toluidine blue rinse, 
mucosal illumination with special lights, and self-examination by the individual. The review 
concluded that COE remains the most valid method of oral screening and enabled detection of 
between 59% and 99% of all OCs. However, some false positives will be produced with a 
COE, and the accuracy differs according to the skill of the primary health care clinician.  
Further studies have utilised a COE by primary healthcare clinicians to investigate the utility 
of invitational and opportunistic screening for OCs and OPDMs (Monteiro et al., 2015; Nagao 
et al., 2000). Nagao et al. (2000) invited all adults aged over 40 years living in Tokoname 
(Japan) to present for a free general health screen. The oral screening component was 
performed by dentists. Oral mucosal lesions were detected in 783 (4.1%) of the 19,056 study 
participants. The detected lesions were further investigated by specialists and the accuracy of 
the original oral screen was evaluated. The sensitivity, specificity, positive predictive values 
(PPV) and negative predictive values (NPV) of the original visual examination were 92%, 
64%, 78% and 86% respectively, suggesting that the Japanese dentists involved in the study 
were satisfactory at performing oral mucosal screening. A higher sensitivity (96%), specificity 
(98%), PPV (96%) and NPV (98%) were reported for the oral screening of those participating 
in an invitational and opportunistic OCS trial in Portugal, with significantly more positive 
cases (3.4%) detected among those aged over 54 years (Monteiro et al., 2015). 
Within the last 25 years, two New Zealand studies have utilised COEs for oral mucosal 
screening in adults. Thomson et al. (1992) screened institutionalised older people and found 
that one-third of paticipants had oral mucosal lesions, however none had malignant lesions. A 
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low incidence of suspected oral malignant lesions (0.3% of those aged over 18 years) was also 
reported in the most recent New Zealand Oral Health Survey (Ministry of Health, 2010). 
However, those aged 65 years or over were significantly more likely to have an oral mucosal 
lesion, although no differences were apparent by ethnic group or level of deprivation. The low 
prevalence of suspicious malignant lesions reported in these studies adds weight to the belief 
that population screening is unlikely to be a cost-effcetive method of screeing for OC in New 
Zealand. 
Speight et al. (2006) used a decision-analytic computer model to demonstrate that OCS 
programmes that target high-risk groups in low-incidence populations can significantly 
increase the QALYs for those individuals identified. Screening was shown to be more cost-
effective within a general dental practice than in a general medical practice. In addition, 
significant cost savings to the health system were identified by enabling treatment at earlier 
disease stages. The positive impacts on broader society associated with earlier-stage diagnosis 
of OCs have been identified by other studies (Jacobson et al., 2012; Short et al., 2011).  
2.8 Delays in the diagnosis of oral and oropharyngeal cancer 
Despite therapeutic advances, a poor prognosis persists for those diagnosed with OC and 
OPC. The global 5-year survival rate has not significantly improved and remains at 55 ̶ 60% 
(Chan et al., 2015; Rapidis et al., 2009). The poor prognosis has largely been attributed to late 
stage diagnosis of OC and OPC (van der Schroeff and Baatenburg de Jong, 2009). The 
literature suggests that both tumour aggressiveness and diagnostic delay can impact on the 
stage at which OC and OPC are diagnosed (Goy et al., 2009). Biologically aggressive 
tumours are likely to progress rapidly and may not be clinically apparent until they are well 
advanced (Scott et al., 2005; Seoane et al., 2010). An exploration of the possible mechanisms 
impacting on tumour aggressiveness is beyond the scope of this study, and so only the role of 
diagnostic delay will be discussed in the following sections. 
2.8.1 Definition of diagnostic delay 
Diagnostic delay has been described as the time elapsing between an individual first noticing 
an abnormal symptom of a condition and the commencement of treatment for that condition 
(Teppo and Alho 2008; Yu et al., 2008). Gomez et al. (2010) represented the total diagnostic 
delay schematically (Figure 2.1) by dividing the time taken into three stages, depending on 
who was chiefly responsible for the delay.  
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Figure 2.1 Types of diagnostic delay in oral cancer (Gómez et al., 2010) 
 
Patient delay is defined as the time from the discovery of a symptom until consultation with a 
primary healthcare clinician. Provider (also known as professional or referral) delay is defined 
as the time taken from consultation with a primary healthcare clinician until the first specialist 
consultation and establishment of a definitive diagnosis. Treatment (or therapy) delay is the 
subsequent time taken from diagnosis to initiation of definitive treatment. Irrespective of the 
subtype, diagnostic delay is common in cases of OC and OPC (Goy et al., 2009). The causes 
of each type of diagnostic delay will be discussed in the following sections.  
2.8.2 Patient delay 
Patient-related delay is common in cases of OC and OPC, with at least half of those who 
experience a potentially malignant oral symptom delaying seeking professional help (Pinholt 
et al., 1997; Scott et al., 2008). Studies suggest that patient-related delay is responsible for the 
greatest proportion of total diagnostic delay (Groome et al., 2011; Onizawa et al., 2003), with 
head and neck cancer patients typically having waited longer to present to medical 
practitioners than those with other cancers (such as lung, colorectal or breast) (Baughan et al., 
2009). Patient delay has been linked to a more advanced disease stage, with patients who seek 
professional help more than one month after noticing an oral symptom being twice as likely to 
present with late-stage disease as those who seek help more promptly (Brouha et al., 2005). 
While the exact measurement of patient delay is problematic (due to recall bias and errors in 
measurement), at least one third of patients will delay seeking medical advice for three 
months or more following the discovery of an oral symptom (Allison et al., 1998; Scott et al., 
2008). In a large German study, Friedrich et al. (2010) reported that 9.3% of those 
subsequently diagnosed with OC waited more than a year before seeking professional advice.  
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The duration of patient delay has not consistently been associated with patient demographic 
characteristics (such as age or sex), lifestyle behaviours (such as smoking tobacco or high 
alcohol consumption), or clinical factors (such as lesion site or type) (Noonan, 2014; Scott et 
al., 2008; Stefanuto et al., 2014). However, living alone has been associated with delay in 
seeking medical care (Brouha et al., 2005; Rozniatowski et al., 2005; Tromp et al., 2005), as 
has the use of allied health practitioners such as community pharmacists and herbalists (Grant 
et al., 2010; Varea-Centelles et al., 2012). A review of the literature conducted by Noonan 
(2014) suggested that the reasons for patient delay are multifactorial and both barriers in 
accessing primary healthcare and a lack of knowledge or awareness of the signs and 
symptoms of OC play a role. Poor accessibility of healthcare has been associated with longer 
patient delays, particularly for groups experiencing higher levels of deprivation (Llewellyn et 
al., 2004; Scott et al., 2006; Scott et al., 2007; Scott et al., 2009; Güneri and Epstein, 2014). 
A lack of public awareness about OC─and the misinterpretation of OC symptoms as minor 
conditions─have been reported as contributing towards patient-related delay (Brouha et al., 
2005; Scott et al., 2006; Scott et al., 2007; Scott et al., 2008; Rogers, 2009; Scott et al., 2009; 
Grant et al., 2010). A study of patients attending the Oral Health Centre of Western Australia 
reported that, while all had heard of lung cancer, only 72% had heard of “mouth or throat 
cancer” (Park et al., 2011). Scott et al. (2007) suggested most patients do not consider 
common OC symptoms to be associated with cancer, and instead attribute them to other 
causes. Grant et al. (2010) also found that while most of Scottish OC patients had symptoms 
which prompted a consultation with a healthcare worker they did not associate them with OC. 
Moreover, early OC and OPC lesions may be asymptomatic or cause only subtle signs (Yu et 
al., 2008), with symptoms developing only when tumours are advanced (Scott et al., 2005). 
Although the mouth is readily accessible, the ability of the general public to perform mouth 
self-examinations (MSE) to detect early OC lesions and thereby, promptly seek treatment has 
been questioned (Elango et al., 2011). 
The public’s knowledge of OC and OPC had been expected to improve following the 
introduction of public awareness campaigns. This, however, has yet to be demonstrated (Scott 
et al., 2006), although, in an Australian study, Kaing et al. (2016) observed the average 
duration of patient delay was less than for an earlier Australian study conducted by 
Dimitroulis et al. (1992) (average patient delay of 1.8 months and 4.5 months, respectively). 
They suggested that the difference may be attributed to greater public awareness of OC. 
While large-scale public OC awareness campaigns have yet to be conducted in Australia, risk-
reduction strategies such as the National Tobacco Campaign may have had some effect. 
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Likewise, New Zealand does not have specific public health OC awareness campaigns, 
although some information is in the public domain (such as the inclusion of photographic 
images and the message “Smoking causes mouth cancer,” which are mandatory on tobacco 
packaging). Studies to determine the level of public awareness of OC and OPC in New 
Zealand have yet to be conducted. 
2.8.3 Provider (professional or referral) delay 
The ability of primary healthcare clinicians to promptly detect and refer suspicious oral 
lesions for definitive diagnosis is crucial to patient outcome (McGurk and Scott, 2010; 
Ministry of Health, 2014). Professional delay in OC diagnosis was associated with advanced 
stage of disease in British and Canadian studies (Pitchers and Martin, 2006; Groome et al., 
2011) and a higher risk of death in a Finnish study (Alho et al., 2006). In particular, the risk of 
dying for those with tongue or glottis tumours was highest for those whose symptoms had 
been disregarded by primary healthcare clinicians (adjusted hazards ratio (HR) 4.3, 95% CI 
1.6, 11.4) (Alho et al., 2006). Studies suggest that some patient groups (including females, 
non-smokers and those from lower socio-economic groups) experience longer provider delays 
(Yu et al., 2008). Clinician factors that contribute to provider delay include the failure to 
recognise the signs and symptoms of oral potentially malignant lesions, a lack of knowledge 
of the risk factors for OC and OPC, and not providing a thorough OCS examination for at-risk 
patients. These will be discussed in the following sections. 
2.8.3.1 Lack of understanding of the signs and symptoms of OC and OPC 
Considerable heterogeneity has been reported among primary healthcare clinicians in 
detecting oral cancerous lesions (Brocklehurst et al., 2013). A Finnish study that reviewed the 
outcomes of the initial primary healthcare consultation for patients subsequently diagnosed 
with OC suggested that over half (53%) of the patients received specialist referrals at their 
first appointment, with a further 24% having a follow-up appointment before referral, and 
20% receiving neither (Alho et al., 2006). These findings were similar to those from a UK 
study that reported that 53% of patients subsequently diagnosed with OC were referred to a 
specialist after their initial consultation, while 22% were referred for special tests, 12% were 
advised their symptom was not serious, and 12% were given treatment for another condition 
(Crossman et al., 2016). The English National Audit of Cancer Diagnosis in Primary Care 
reported that 22% of patients who were subsequently diagnosed with OC or OPC had more 
than three primary care consultations before being referred for specialist care (Lyratzopoulos 
et al., 2013). Morelatto et al. (2007) explored the types of therapies given to patients prior to 
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their diagnosis of OSCC and reported that most (80%) had received some prescription 
medicine prior to diagnosis, with 26% prescribed mouthwashes and 20% prescribed 
antibiotics or anti-inflammatories. Nearly one-third of patients (30%) had been prescribed 
multiple medications.  
Regular professional dental care is associated with an earlier stage of diagnosis for OC 
(Groome et al., 2011; Holmes et al., 2003; Watson et al., 2009; Yu et al., 2008). Holmes et al. 
(2003) reported that cases of OSCC and OPSCC referred by a dental practitioner were at an 
earlier stage than those referred by medical practitioners. However, those with OC and OPC 
are more likely to be referred for specialist care by medical than dental practitioners 
(Crossman et al., 2016; Kaing et al., 2015). Concern has been expressed that at-risk 
individuals have poorer access to dental care and are therefore less likely to be diagnosed in 
the early stages of disease (Frydrych and Slack-Smith, 2011). While OC is more common in 
those aged over 60 years, older adults and edentulous patients are less likely to visit dentists 
(Haughney et al., 1998). A British study reviewing patterns of dental attendance over a ten-
year period reported that males aged over 40 years and tobacco smokers were less likely to be 
regular dental attenders (Yusof et al., 2006). Poorer access to dental care for Māori, Pacific 
people and those of lower socioeconomic status was also observed in the latest New Zealand 
Oral Health Survey (Ministry of Health, 2010). These groups have been identified as more 
likely to present with late-stage OC or OPC (Robson et al., 2011; Soeberg et al., 2011).  
2.8.3.2 Knowledge of the risk factors for OC and OPC 
A number of international studies have reported that primary healthcare clinicians’ lack of 
knowledge of the risk factors for OC and OPC contributes to delays in diagnosis and 
treatment (Allen and Farah, 2015; Brocklehurst et al., 2010; Carter and Ogden, 2007; 
Horowitz et al., 2000). Carter and Ogden (2007) explored general medical and dental 
practitioners’ knowledge about risk factors for OC. While smoking tobacco was identified by 
both practitioner types, dentists were significantly more likely than their medical colleagues to 
identify alcohol consumption as a risk factor (87.2% of dentists and 43.3% of medical 
practitioners). In addition, dentists were more likely than medical practitioners to regularly 
advise patients of the risk factors for OC. Seoane et al. (2006) reported that most (84.4%) of 
Spanish dentists informed patients of the benefits of avoiding excessive alcohol and quitting 
tobacco, yet only half of the Australian dentists surveyed believed they could influence 
patients to reduce or quit smoking or drinking alcohol (Allen and Farah, 2015). Even so, 
dentists may not routinely attempt to do this. A survey of Scottish dentists found that nearly 
half (49%) occasionally asked patients about their smoking habits, but only 19% routinely did 
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so (Macpherson et al., 2003). Very few practitioners (3%) routinely asked about alcohol 
consumption, with discomfort in enquiring about drinking habits cited as the primary reason 
for not doing so. Daley et al. (2011) explored Florida dentists’ and dental hygienists’ 
knowledge of HPV as a risk factor for OC and OPC. They identified a lack of awareness by 
practitioners of the role of HPV in the development of OC and OPC. Practitioners also 
expressed discomfort in discussing HPV as a risk factor for OC and OPC with their patients.  
Several studies have reported on dentists’ awareness of older age being associated with OC. 
Decuseara et al. (2011) found that 55% of Irish dentists identified older age as a risk factor for 
OC. Likewise, Mahalaha et al. (2009) reported that fewer than one-third (30.3%) of the US 
rest home dentists interviewed knew that most OCs were found in persons aged over 60 years, 
and fewer than half (47.1%) knew that older age was associated with a high risk of OC. 
Notably, dentists who had graduated within ten years of the survey had better knowledge 
about OC than older graduates.  
While many studies have highlighted the differences in knowledge among clinicians and have 
identified the need for improved awareness among practitioners in order to enable early 
detection of OC and OPC (Horowitz et al., 2000; Carter and Ogden, 2007; Brocklehurst et al., 
2010), knowledge gaps clearly persist. Maybury et al. (2012) reported that Maryland (US) 
dentists’ knowledge of OC risk factors had remained relatively unchanged over fourteen years 
despite educative efforts. Whether New Zealand dental practitioners have adequate 
knowledge of the risk factors for OC and OPC to enable them to identify patients at higher 
risk of disease has not been explored. 
2.8.3.3 Oral cancer screening practices of primary care practitioners 
The opinions and practices of dental professionals of oral cancer screening (OCS) have been 
reported on internationally. Farrand et al. (2003) found UK dentists generally reported high 
levels of confidence in their clinical ability to detect OC, whereas Macpherson et al. (2003) 
reported that only 37.8% of the Scottish dentists surveyed were either confident or very 
confident. A study of Australian dentists found that most practitioners (93.1%) believed they 
would encounter OC within their practising career, and most (98.6%) had referred patients to 
a specialist for a suspicious oral lesion (Allen and Farrah, 2015). When asked about 
performing OCS examinations, most dentists reported checking all new patients (94.5%) and 
all recall patients (85.7%) for oral mucosal pathology. However, nearly half (49.4%) of the 
dentists who had been practising for more than ten years targeted OCS examinations only to 
individuals deemed to be at high-risk. These findings compared favourably with a study of 
nursing home dentists in the US which found 83.3% of dentists undertake OCS examinations 
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at all initial examinations, with 72.7% doing so at recall examinations (Mahalaha et al., 2009). 
The OCS practices of general medical practitioners (GMPs) is less well reported, although 
Carter and Ogden (2007) found that 65.1% of GMPs were not screening the oral mucosa of 
high-risk patients.  
The barriers to routinely performing OCS examinations for patients (as identified in the 
literature) are summarised in Table 2.5. At least 43% of the dental professionals surveyed 
cited at least one barrier to routinely performing OCS examinations (Macpherson et al., 
2003). General medical practitioners also report a lack of training in OC detection and a lack 
of confidence in performing OCS examinations as significant barriers to routinely conducting 
OCS examinations (Macpherson et al., 2003; Nicotera et al., 2004). 
Table 2.5 Practitioner-identified barriers to performing oral cancer screening examinations  
Barrier to performing oral cancer screening examination Studies 
Inadequate training or confidence to perform OCS exam Laronde et al., 2008 
 Brocklehurst et al., 2010 
 Decuseara et al., 2011 
 Allen and Farah, 2015 
  
Lack of clinical time Macpherson et al., 2003 
 Laronde et al., 2008 
 Saleh et al., 2016  
  
Lack of remuneration Macpherson et al., 2003 
 Mahalaha et al., 2009 
  
Concern about causing patients undue anxiety Macpherson et al., 2003 
 Noonan, 2014 
  
Lack of patient compliance to screening and referral Saleh et al., 2016  
  
Low incidence of detection Brocklehurst et al., 2010 
 
Understanding primary care clinicians’ barriers to performing OCS examinations is crucial to 
developing strategies to improve the rate of screening examinations provided in the primary 
care setting (Ford and Farah, 2013). Dentists’ fears of causing patients undue anxiety by 
performing OCS examinations may be unfounded, with 91.6% of patients in a private practice 
survey wanting their dentist to inform them when they perform an OC check, and only 1% 
reporting being extremely anxious about having this done (Awojobi et al., 2012). A study of 
British Columbian dental professionals found that commonly cited barriers could be 
overcome with improved knowledge about OC (Laronde et al., 2008). Whether dental 
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professionals experience barriers to providing OCS of their patients is yet to be explored in 
New Zealand.  
2.8.4 Treatment Delay 
Treatment delay encompasses the delays which occur within the healthcare care system once 
diagnosis has been confirmed. Groome et al. (2011) reported that treatment delay was less 
common than provider or patient delay for patients diagnosed with OC in Ontario (Canada) 
and was only experienced by 1.6% of the patients reviewed. However, treatment delay is 
largely dependent on the available healthcare resources (both treatment facilities and clinician 
resources), so will vary among countries. As well as being identified as a cause of undue 
psychological stress for patients (Rapport et al., 1993), treatment delay is generally regarded 
as impacting negatively on disease progression. Although a Dutch study reported no adverse 
effects on tumour progression or survival rate with longer wait times for head and neck cancer 
(HNC) (van Harten et al., 2014), other studies have reported poorer survival rates for HNC 
patients who experience longer waiting times for radiotherapy (Chen et al., 2008) or 
combined therapies (van Harten et al., 2015). In studies which did not identify negative 
clinical consequences for treatment delay, the impact of waiting times on survival rates may 
be confounded by the ‘waiting time paradox’, whereby patients with severe symptoms from 
advanced and rapidly progressing tumours are fast-tracked to receive treatment sooner (Neal, 
2009). Thereby, a poorer survival rate may be found in those with the shortest treatment 
waiting time (van Harten et al., 2014). In addition, the role of co-morbidities (which may 
increase treatment delay) on mortality should be considered when interpreting the relationship 
between treatment delay and overall survival rates (van Harten et al., 2015).  
Despite some conflicting reports, it is widely accepted that treatment delay is likely to be a 
significant prognostic factor for OC and OPC, with greater time from diagnosis to treatment 
associated with disease progression, more extensive treatment and poorer survival (van 
Harten et al., 2015). Government-initiated fast-track cancer programs (often dictating a 
specialist appointment within 2 weeks of referral if malignancy is suspected) have been 
introduced in many countries, including New Zealand, to minimize the time from diagnosis to 
treatment and improve patient outcomes (NICE 2004; National Head and Neck Cancer 
Tumour Standards Working Group, 2013; Sorensen et al., 2014). However, to date, the 
impact of fast-track cancer programs on patient outcomes for OC and OPC has yet to be 
established (Langton et al., 2016). 
 43 
2.9 Summary  
Oral and oro-pharyngeal cancer is the sixth most common cancer worldwide, with an 
estimated annual incidence of over 442,000 cases (3.1% of the total cancer cases). Distinct 
geographic patterns exist in incidence, reflecting the prevalence patterns of known risk factors 
for OC and OPC. Review of the NZCR data has shown the incidence of OC and OPC has 
increased over the last fifty years particularly in men. Most notably, the incidence of OPC in 
males has increased rapidly since 2005. Distinct patterns of OC and OPC have been 
demonstrated in New Zealand with respect to age, gender, ethnicity and social deprivation. 
Overall, incidence rates are highest among older men, but rates are increasing for both 
genders in deprived areas. This is consistent with international findings.  
Worldwide, there are an estimated 145,000 deaths (1.8% of total cancer deaths) due to OC 
and a further 97,000 deaths (1.2% of total cancer deaths) due to OPC. Despite significant 
advances in the treatment of OC and OPC, the overall 5-year survival rate has not 
significantly improved. It is widely accepted that the key to improving survival rates lies in 
improving the rates of early diagnosis of oral malignant and potentially malignant disorders. 
Moreover, substantial ethnic and socioeconomic inequalities in OC and OPC survival have 
been recorded internationally. Likewise, ethnic and socioeconomic inequalities in OC and 
OPC survival are known to exist in New Zealand, with poorer survival rates for Māori and 
those of lower socioeconomic status. The factors contributing to these inequalities have not 
been fully explained, but the difference has been, at least partly, attributed to a later stage of 
diagnosis for Māori and those of lower socioeconomic status.  
Late-stage presentation has been attributed to delays in the diagnosis of OC and OPC. Delays 
may occur due to patient, provider and healthcare system factors. Patient-related delay is 
common in cases of OC and OPC. The factors contributing to delays in seeking medical care 
are multifactorial and include both barriers in accessing primary healthcare and a lack of 
knowledge or awareness of the signs and symptoms of OC and OPC. Whether New Zealand 
patients delay seeking medical care prior to diagnosis of OC (and how this may impact on 
stage of diagnosis) has not been reported to date.  
It is generally accepted that whole-population screening for OC and OPC is unlikely to be 
cost-effective in countries such as New Zealand, where incidence is relatively low. However, 
there is evidence that screening of high-risk individuals can improve survival rates. Tobacco 
and excess alcohol use have long been highlighted as important risk factors for OC and OPC. 
More recently, the role of other factors ─ such as infection with high-risk HPV (particularly 
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in relation to oropharyngeal tumours) ─ has been emphasised. International studies have 
found that deficiencies in primary healthcare clinicians’ knowledge can contribute to delays in 
the diagnosis of OC and OPC. Most identified a need for improved awareness among 
practitioners of the risk factors for OC and OPC, and the clinical presentation of OC and OPC 
to enable early detection. The level of understanding of the risk factors for OC and OPC 
among primary care clinicians in New Zealand, (and thus their ability to identify at-risk 
individuals) is not known. This means that the feasibility and utility of routine screening of at-
risk individuals by clinicians is unclear. 
International studies have observed regular dental care to be associated with an earlier stage 
of diagnosis for OC, but there is concern that at-risk individuals may be less likely to 
regularly visit dentists and are therefore less likely to be diagnosed in the early stages of 
disease. The New Zealand Oral Health Survey (2009) reported poorer access to dental care for 
Māori, Pacific people, older adults and those of lower socioeconomic status (Ministry of 
Health, 2010). Whether irregular dental attendance impacts on the stage of diagnosis in New 





3.1 Study Overview 
Quantitative research was undertaken to explore factors which may contribute to the stage of 
diagnosis of OC and OPC in New Zealand. The research objectives were: to assess the 
knowledge, beliefs and practices of New Zealand primary dental care clinicians about OC and 
OPC and whether this impacts on the stage of diagnosis; and to determine whether differential 
access to dental care impacts on the stage of diagnosis of OC and OPC in the CDHB region of 
New Zealand.  
A self-administered questionnaire was developed to gather information from general dentists 
and clinical dental technicians (CDTs). In New Zealand, the provision of full or partial 
dentures may be undertaken by dentists or clinical dental technicians (CDTs). It is possible 
that edentulous people may be more likely to seek such treatment from a CDT than from a 
dentist. Given that edentulism and OC and OPC are more common in older people, CDTs 
were included in this study alongside general dental practitioners as it can expected CDTs 
may encounter OC and OPC during their routine  practice.  
A cross-sectional observational study was undertaken using descriptive data from the NZCR 
of all new cases of OC and OPC registered in New Zealand within the study period. The 
hospital records of those cases diagnosed and/or treated at CDHB were reviewed and data 
collected to assess patterns of dental attendance. 
3.2 Ethical Approval 
Ethical approval for the research was obtained on 2 September 2015 from the Central Health 
and Disability Ethics Committee (HDEC) (Appendix A). The HDECs ensure that health and 
disability research conducted within New Zealand meets ethical standards and that approved 
research has the potential to provide health benefits to the New Zealand population. A post-
approval adjustment to the original application was obtained on 14 December 2015 
(Appendix B) to enable additional information to be sought from the New Zealand Cancer 
Registry (NZCR) on diagnosed OC and OPC cases. Locality approval was obtained from the 
Canterbury District Health Board (CDHB) and the Nelson-Marlborough DHB (NMDHB) to 
enable study data to be collected from the hospital medical and dental files of those identified 
from the NZCR records. Approval was granted from these organisations on 20 March 2016 
and 19 April 2016, respectively. 
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The Ngāi Tahu Research Consultation Committee (Te Komiti Rakahau ki Kai Tahu) at the 
University of Otago was consulted prior to ethical approval being sought. Support for the 
research was received on the 19 May 2015 (Appendix C). Consultation also occurred with 
both Te Komiti Whakarite (CDHB Research Consultation with Māori) and the NMDHB Iwi 
Health Board prior to locality approval being sought for the study within the CDHB and 
NMDHB regions (Appendices D and E).  
3.3 Questionnaire Methods 
Review of the published literature identified studies exploring primary healthcare clinicians’ 
knowledge, beliefs and practices that might impact on the detection and diagnosis of OC and 
OPC (Allen and Farah, 2015; Brocklehurst et al., 2010; Carter and Ogden, 2007; Daley et 
al.2011; Decuseara et al., 2011; Horowitz et al., 2000; Mahalaha et al., 2009; Seoane et al., 
2006; Nicotera et al., 2004; Yellowitz et al., 2000). No previous New Zealand studies were 
identified, and so international studies were used to create a 30-item self-administered 
questionnaire to assess practitioners’ knowledge of the patterns of OC and OPC in New 
Zealand, the clinical presentation and risk factors for mouth cancer, and practitioners’ referral 
practices for suspicious lesions (Appendix F). The questionnaire content was pre-tested by 
experts in oral pathology, and dental and cancer epidemiology.  
The names and contact details of all New Zealand registered general dental practitioners and 
clinical dental technicians (CDTs) were requested from the Dental Council, New Zealand 
(DCNZ). Practitioners for whom neither an email address nor postal address was available 
were excluded from the study, along with all DCNZ registered dental specialists except those 
deemed to still practise general dentistry on adult patients as part of their routine practice. 
Dental specialists in this category were hospital dental specialists and special care dentists. 
Workforce data were also requested from the DCNZ to enable comparison between the 
respondents to the questionnaire and the general dentist and CDT workforce in New Zealand.  
One hundred and thirty-six CDTs and 1,840 general dentists were identified as potential study 
participants. All were sent the 30-item questionnaire and cover letter (Appendix G). 
Practitioners with a unique email address were contacted via an email containing the cover 
letter and a link to directly access the questionnaire online (using Survey Monkey
TM
). 
Practitioners for whom a unique email address was not available were mailed the cover letter, 
a paper-copy questionnaire and a self-addressed stamped envelope for return of the 
questionnaire. Participation was encouraged with two prize draws of Prezzy cards worth $100 
for those who responded prior to 14 December 2015. Respondents were given a unique study 
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code to enable participation in the prize draws, while allowing the questionnaire responses to 
remain anonymous. The unique code also ensured that multiple responses were not included 
from the same respondent. 
Initial email requests were sent to 1,842 practitioners on 9 November 2015. A reminder email 
was sent on 1 December 2015 to 1,534 non-responding practitioners (30 opted out of the 
survey and a further 30 had non-working email addresses). The final reminder email was sent 
on 26 January 2016 to 1,431 practitioners (2 opted out of the survey and a further 5 had non-
working email addresses). The postal questionnaires were sent during the second week of 
November, 2015 to 165 practitioners who did not have a unique email address this included 
30 practitioners for whom an invalid email address was recorded, but a postal address was 
available. A further copy of the questionnaire was sent to the 86 non-responders who had not 
responded to the initial mailed questionnaire (excluding the 18 questionnaires returned 
unopened) during the first week of December 2016. A third wave was not used because the 
expected low return rate would have made it uneconomic. The final sample size of eligible 
practitioners was 1953 (1,817 dentists and 136 CDTs). 
3.3.1 Statistical analysis of questionnaire data 
The responses to the online questionnaires were downloaded from the Survey Monkey
TM
 
program as an Excel spreadsheet. Hard copy responses were coded and transferred to the 
Excel spreadsheet containing the online responses. Quantitative analysis was undertaken to 
describe clinicians’ knowledge of, and referral practices for, mouth cancer using the R 
(GNU 
GPL)
 statistical program. Frequency tests were conducted and differences in proportions were 
tested for statistical significance using Chi square and Fisher’s exact tests (as appropriate). P 
values of less than 0.05 were deemed to represent a statistically significant difference in 
proportions. 
Graduation year was used to allocate respondents to ordinal categories representing 
graduation cohorts (before 1976, 1976-1985, 1986-1995, 1996-2005 and 2006-2015). The 
countries of graduation were clustered into the following three groups: New Zealand, Asian 
(including South East Asian and Sub-continental Indian countries) and Other (all remaining 
countries). The grouping of Asian countries, as distinct from other countries was made to 
explore whether the responses of graduates from countries with a high incidence of OC and 
OPC differed from those of New Zealand graduates or those from other parts of the world. 
The postcode regions of the respondents’ main work location were divided into nine postcode 
regions using the New Zealand Post Regional Postcode Directory (Northland, Auckland, 
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Waikato, Gisborne, Hawke's Bay and Bay of Plenty, Taranaki, Manawatu and Whanganui, 
Wellington and Wairarapa, Nelson, Marlborough and Tasman, Canterbury and West Coast, 
and Otago and Southland). 
3.4 Descriptive study using NZCR data 
3.4.1 Data Sources 
The NZCR collects detailed information (including demographic details) of individuals newly 
diagnosed with cancer, as well as descriptive data on the tumour, including site (ICD-10), 
morphology and extent, to ensure non-duplication of each new diagnosis. Application was 
made to the NZCR to supply information about the diagnosis of all new cases of OC and OPC 
(ICD-0-10 C00-14 codes, excluding codes C11, C12 and C13) registered in New Zealand 
between 1
st
 January 2012 and 31
st
 December 2013 (Appendix H) and mortality data for those 
who had died from OC and OPC (ICD-0-10 C00-14 codes, excluding codes C11, C12 and 
C13) within the same period. Identified cases who were not New Zealand residents were 
excluded from the study. The study was carried out to describe the incidence, extent of 
tumour spread at diagnosis, clinical features and mortality rates of the identified OC and OPC 
cases.  
The variables of interest were age, sex, ethnicity (using priority ethnic group), DHB of 
domicile, year of diagnosis, anatomical site affected, morphological description of the cancer, 
extent of the tumour at diagnosis and mortality data. Population data by DHB from the New 
Zealand Census 2013 were utilized to calculate age-specific incidence and mortality rates of 
OC and OPC (Statistics NZ, 2014). Comparison was made between the World Standard 
Population for 2000 ̶ 2025 (World Health Organization, 2001) and the NZ Census population 
2013 using the age groups utilised by both WHO and the NZ Census. The structure of the 
New Zealand population is older than the World Standard Population (Figure 3.1). Also, the 
New Zealand population had a greater percentage of females (51.3%) than the World 
Standard Population (50.0%). The sex disparity increased in older age groups with 1.1% of 
the NZ population being female aged 85 years and older, but only 0.3% of the World 
Standard Population being in this group. Therefore, it was decided to utilise age-specific 
rather than age-standardisation for the presentation of incidence rates. Mortality rates were 
presented as crude rates. 
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Figure 3.1 Percentage of population by age group 
 
New Zealand Census criteria for ethnicity enables individuals to identify with more than one 
ethnic group. Māori are identified as a priority ethnic group, therefore all individuals 
identifying themselves as Māori are identified as Māori within the NZ Census data, which 
enabled identification of individuals as either Māori or non-Māori, but did not enable Census 
data for other ethnic groups to be compared. The calculation of age-specific and mortality 
rates could therefore only be achieved for Māori and non-Māori ethnic groups. The group 
identified as non-Māori contains the ethnic groups of New Zealand European, Pacific people, 
Asian and ‘Other’, which are identified from the NZCR data.  
3.5 Observational study of medical and dental records 
A retrospective observational study was undertaken using data from patients’ existing hospital 
medical and dental records. Cases identified from the NZCR data that were diagnosed and/or 
treated within the CDHB were selected for further study. Cases treated at CDHB facilities 
included those who resided in the regions of the Canterbury, the Nelson Marlborough, the 
West Coast and the South Canterbury DHBs. The National Health Index (NHIs) of diagnosed 
individuals were used to access their hospital medical and dental files. Information was 
extracted from the hospital files in order to determine whether attending a dental practitioner 
in the years prior to diagnosis was associated with an earlier stage of diagnosis. Information 
collected included age, sex, ethnicity (using priority ethnic group), referring clinician 

























(medical or dental practitioner), presenting signs or symptoms, duration of symptoms or 
signs, tumour type, tumour site, disease stage (based on the NZCR classification), time since 
last dental visit (measured in months) and best available information pertaining to their usual 
pattern of dental attendance. For many, only a general description was available and adjunct 
information about being dentate (according to OPG radiographs) at the time of diagnosis and 
whether teeth were extracted during the cancer treatment was collected to help inform 
assumptions on dental attendance. Additional information on co-morbidities and employment 
status including whether cases had a Community Services Card (CSC)
4
 was also sought. Once 
collected, information was de-identified prior to data analysis. 
3.5.1 Statistical analysis of NZCR diagnosed OC and OPC cases 2012-2013 
Information received from the NZCR was in the form of a Microsoft Excel (2013) 
spreadsheet and converted to an R data-set for analysis. Quantitative analysis was conducted 
using the R 
(GNU GPL)
 statistical program for the OC and OPC cases diagnosed in New Zealand 
residents during the study period. The information collected from the hospital medical and 
dental files for the cases diagnosed or treated within the CDHB was coded and transferred to 
an Excel spreadsheet. The data were then converted to an R data-set for statistical analysis. 
The analyses tested for associations between stage of diagnosis, tumour site, risk factors, 
referring clinician and pattern of previous dental attendance. Frequency tests were conducted 
and differences in proportions were tested for statistical significance using Chi square and 
Fisher’s exact tests (as appropriate). P values of less than 0.05 were deemed to be significant. 
 
  
                                                 
4
 Community services card (CSC) is available to New Zealand citizens and permanent residents who meet low 
income criteria outlined by the government. Those eligible for CSCs are eligible for subsidised services and 
benefits including reduced costs healthcare.  
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4 Results 
4.1 Results from the dental clinician questionnaires 
4.1.1 Response rate 
Two hundred and forty-seven responses to the initial email invitation were received (response 
rate 13.6%), 30 emails bounced back, and a further 30 practitioners opted out of the study. A 
further 108 responses (7.1%) were received from the first reminder email and 92 responses 
(6.4%) from the final email reminder. The total number of respondents to the online 
questionnaire was 447 (24.7%). Sixty-one practitioners responded to the initial postal 
questionnaire (41.5%), and a further 23 (26.7%) responded after the repeat mailing. The total 
number of postal questionnaire responses received was 84 (56.5%). When combined with the 
online questionnaire responses, the total number of responses received that met the inclusion 
criteria was 527 (27.0%). 
4.1.2 Demographic characteristics of respondents 
Participants’ responses to demographic questions including their scope of practice, their sex, 
the country and year of graduation and their work region are listed in Table 4.1. Most 
respondents identified themselves as general dentists or dental specialists who met the study 





Table 4.1 Demographic characteristics of respondents by practitioner type (brackets contain 
column percentages) 
Characteristic CDTs Dentists Both combined 
Sex    
Male 23 (69.7) 272 (55.1) 295 (56.0) 
Female 10 (30.3) 222 (44.9) 232 (44.0) 
    
Graduation year    
Before 1976   3 (9.1)  47 (9.5) 50 (9.5) 
1976-1985   6 (18.2) 117 (23.7) 123 (23.3) 
1986-1995   4 (12.1) 114 (23.1) 118 (22.4) 
1996-2005 13 (39.4) 88 (17.8) 101 (19.2) 
2006-2015   7 (21.2) 128 (25.9) 135 (25.6) 
    
Work region     
Northland 3 (9.1)  18 (3.6) 21 (4.0) 
Auckland 6 (18.2) 118 (23.9) 124 (23.5) 
Waikato 6 (18.2) 61 (12.3) 67 (12.7) 
Gisborne/HBay/BOP 0 (0.0) 20 (4.1) 20 (3.8) 
Taranaki/Manawatu 0 (0.0) 24 (4.9) 24 (4.5) 
Wellington/Wairarapa  7 (21.2) 61 (12.4) 68 (12.9) 
Nelson Marlborough 3 (9.1) 30 (6.1) 33 (6.3) 
Canterbury/West Coast  5 (15.1) 55 (11.1) 60 (11.4) 
Otago-Southland 1 (3.0) 59 (11.9) 60 (11.4) 
No region listed 2 (6.1) 48 (9.7) 50 (9.5) 
    
Graduation country    
New Zealand 27 (81.8) 356 (72.1) 383 (72.7) 
Asian 3 (9.1)  38 (7.7) 41 (7.8) 
Other 3 (9.1) 100 (20.2) 103 (19.5) 





 527 (100.0) 
    
a
Row percentages  
 
More than half of the respondents were male. A greater proportion of CDTs than dentists 
were male. Respondents had graduated over a 90-year span (1925
5
 to 2015). The graduate 
year cohort with the fewest respondents (50) was the earliest one (those graduating before 
1976), while that with the most respondents (135) was the most recent (2006 to 2015). Fewer 
than one in ten respondents chose not to answer the question on work location. Of those who 
                                                 
5
 One response from a CDT stated his graduation year as 1925 but this was considered a mistake.  
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answered, just over one-quarter were from the greater Auckland region. Most respondents 
were New Zealand graduates. Of the 144 graduates from other countries, 40 (7.6%) had 
graduated in the United Kingdom and one-quarter were from India or Pakistan. In total, nearly 
one-fifth of respondents were from ‘Other’ countries and over one in thirteen were from 
Asian countries.  
Data on the sex of respondents by graduation year and country are presented in Table 4.2.  
Table 4.2 Sex of practitioner by graduation year and country (brackets contain row percentages) 
 Sex of Practitioner  
Graduation groups Male Female Total 
Graduation year    




 50  
1976-1985 81 (65.9) 42 (34.1)  123  
1986-1995 64 (54.2) 54 (45.8)  118 
1996-2005 51 (50.5) 50 (49.5)  101 
2006-2015 53 (39.3) 82 (60.7)  135 
    
Graduation country    
New Zealand  214 (56.0) 16 (39.0) 383 
Asian  25 (61.0)  169 (44.1)   41 
Other  56 (54.3) 47 (45.6) 103 
    
Total 295 (56.0)  232 (44.0) 527 (100) 
    
a
P < 0.05 
 
The ratio of male to female respondents varied by practitioner type and graduation year. Only 
8% of those graduating before 1976 were female, whereas more than half of respondents from 
the most recent graduation group (2006-2015) were female. No significant difference in the 
sex ratio of respondents was found by graduation country. The graduation country of 
respondents by graduation year is shown in Table 4.3. 
Table 4.3 Practitioners’ graduation country by graduation year (brackets contain row 
percentages) 
 Graduation Country  
 New Zealand Asian Other Combined 
Graduation year     
Before 1976 42 (84.0)
 
   0 (0.0)
 a
   8 (16.0)   50 
1976-1985 83 (67.5)   7 (5.7) 33 (26.8) 123 
1986-1995 87 (73.7)   6 (5.1) 25 (21.2) 118 
1996-2005 63 (62.4) 18 (17.8) 20 (19.8) 101 
2006-2015  108 (80.0) 10 (7.6) 17 (12.6) 135 
     
Total  383 (72.7)  41 (7.8)  103 (19.5) 527 (100) 
     
a
P < 0.05 
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No graduates from Asian countries had graduated before 1976. No significant differences 
were found for country of graduation or work region by graduation year. 
4.1.3 Practitioners’ impressions of mouth cancer 
Participants were asked about the sex of those commonly diagnosed with mouth cancer in 
New Zealand (Table 4.4). Most respondents identified mouth cancer as more commonly 
found in males than females, but more than one-fifth were unsure whether there was a sex 
difference.  
Table 4.4 Sex identified as more commonly affected by mouth cancer (brackets contain row 
percentages) 
 More common in which sex  
Practitioner 
characteristic 
Females Males Both equally Don’t know 
Practitioner Type    
Dentist  16 (3.2) 304 (61.5) 63 (12.8) 111 (22.5) 
CDT 0 (0.0)  20 (60.6)   7 (21.2)   6 (18.2) 
     
Graduation year     
Before 1976 1 (2.0)  31 (62.0)    8 (16.0) 10 (20.0) 
1976-1985 6 (4.9)  78 (63.4) 12 (9.8) 27 (22.0) 
1986-1995 1 (0.8)  74 (62.7) 13 (11.0) 30 (25.4) 
1996-2005 4 (4.0)  57 (56.4) 16 (15.8) 24 (23.8) 
2006-2015 4 (3.0)  84 (62.2) 21 (15.6) 26 (19.3) 
     
Graduation country     
New Zealand 7 (1.8) 241 (62.9) 53 (13.8) 82 (21.4)
a
 
Asian 4 (9.8) 19 (46.3)   5 (12.2) 13 (31.7) 
Other 5 (4.9) 64 (62.1) 12 (11.7) 22 (21.3
)
 
     
Total  16 (3.0) 324 (61.5) 70 (13.3) 117 (22.2) 
     
a
 P < 0.05  
 
Similar proportions of dentists and CDTs identified males as more commonly affected, but 
fewer Asian graduates did so. Moreover, respondents from Asian countries were likely to be 
more unsure of any sex predilection for mouth cancer than those graduating from either New 
Zealand or ‘Other’ countries.  
Respondents were asked to identify the age groups of those more commonly affected by 





Table 4.5 Age groups (in years) identified as more commonly affected by mouth cancer (brackets contain row percentages
a
)  
   Age group in years    
Practitioner 
characteristic 
Under 30 30-40 40-50 50-60 60-70 Above 70 Don’t know 
Practitioner type        
Dentist 3 (0.6) 12 (2.4)   115 (23.3)  212 (42.9) 172 (34.8)   84 (17.0) 98 (19.8) 
CDT 0 (0.0) 0 (0.0) 6 (18.2) 14 (42.2) 12 (36.4)  9 (27.3) 6 (18.2) 
        
Graduation year        
Before 1976 0 (0.0) 0 (0.0) 6 (12.0) 17 (34.0)
b
 19 (38.0)   8 (16.0) 9 (17.3) 
1976-1985 1 (0.8) 3 (2.4) 24 (19.5) 38 (30.9)
 
 41 (33.3) 24 (19.5) 22 (17.9) 
1986-1995 1 (0.8) 0 (0.0) 25 (21.2) 53 (44.9)
 
 33 (28.0) 15 (12.7) 31 (26.3) 
1996-2005 0 (0.0) 1 (1.0) 28 (27.7) 50 (49.5)
 
 38 (37.6) 21 (20.8) 22 (22.2) 
2006-2015 1 (0.7) 8 (5.9) 38 (28.1) 68 (50.4)
 
 53 (39.3) 25 (18.5) 20 (14.8) 
        
Graduation country        
New Zealand 2 (0.5) 9 (2.3) 87 (22.7)  173 (45.2) 143 (37.3)
b
 75 (19.6) 80 (20.9) 
Asian 1 (2.4) 3 (7.3) 8 (19.5) 12 (29.2) 7 (17.1)   3 (7.3) 10 (24.3) 
Other 0 (0.0) 0 (0.0) 26 (25.2) 41 (39.8) 34 (33.0) 15 (14.6) 14 (13.5) 
        
Sex of practitioner        
Male 2 (0.7) 7 (2.4) 63 (21.4)  110 (37.3) 104 (35.3) 49 (16.6) 60 (20.3) 
Female 1 (0.4) 5 (2.2) 58 (25.0)  116 (50.0) 80 (34.5) 44 (19.0) 44 (19.0) 
        
Total 3 (0.6) 12 (2.2) 121 (22.9)  226 (42.9) 184 (34.9) 93 (17.6)  104 (19.7) 
        
a
Respondents were able to select more than one option, so that percentages do not sum to 100
 
b
 P < 0.05  
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Nearly one in five respondents were unaware of mouth cancer affecting any age groups more 
commonly in New Zealand. Participants were able to select more than one age group and over 
three-quarters (77.5%) identified those aged over 40 years as more commonly affected than 
those younger than 40 years. The age groups 50-60 years, and 60-70 years, were identified by 
more than one-third of respondents as age groups commonly affected by mouth cancer. Very 
few respondents identified the youngest age groups as being commonly affected. There were 
no significant differences in the age groups identified by the type or sex of practitioner. 
However, differences were observed in the ages selected by both graduation year and 
graduation country group. The age group 50-60 years was significantly more likely to be 
identified by more recent graduates than older practitioners. By contrast, fewer Asian 
graduates than either New Zealand or ‘Other’ graduates identified those aged 60-70 years as 
being commonly affected by mouth cancer. One in ten respondents were unable to identify 
either the sex or age group of those most commonly affected by mouth cancer in New 
Zealand. 
The ethnic groups most commonly identified by respondents as being at high risk of mouth 






Table 4.6 Ethnic groups identified by practitioners as at high risk of mouth cancer (brackets contain row percentages
a
) 
 Ethnic group 
Practitioner Sub-continent NZ Fijian South East Papua NZ Don’t 
characteristic Indian Māori Indian Asian New Guinea European know 
Practitioner type        
Dentist 262 (53.0) 87 (17.6) 87 (17.6) 79 (16.0) 60 (12.1) 46 (9.3) 118 (23.9) 
CDT   13 (39.4)   9 (27.3)   7 (21.1)   1 (3.0)   4 (12.1)   6 (18.1)     9 (27.3) 
        
Graduation country        
New Zealand 200 (52.2) 74 (19.3) 73 (19.1) 74 (19.3) 45 (11.7) 36 (9.4)
 b
   93 (24.3) 
Asian 17 (41.5)   7 (17.1)   7 (17.1)   7 (17.1)   3 (7.3) 11 (26.8)
 
   11 (26.8) 
Other 58 (56.3) 15 (14.6) 15 (14.6) 15 (14.6) 16 (15.5)   5 (4.9)
 
   23 (22.3) 
        
Graduation year       
Before 1976 22 (44.0)   9 (18.0)   8 (16.0)   6 (12.0)   8 (16.0)   2 (4.0) 14 (28.0) 
1976-1985 61 (49.6) 16 (13.0) 28 (22.8) 19 (15.4) 14 (11.4) 11 (8.9) 27 (22.0) 
1986-1995 64 (54.2) 20 (16.9) 15 (16.9) 20 (16.9) 18 (15.3)   9 (7.6) 25 (21.2) 
1996-2005 54 (53.5) 17 (16.8) 16 (16.8) 15 (14.9) 12 (11.9) 13 (12.9) 30 (29.7) 
2006-2015 74 (54.8) 34 (25.2) 27 (25.2) 20 (14.8) 12 (8.9) 17 (12.6) 31 (23.0) 
        
Total 275 (52.2) 96 (18.2) 94 (17.8) 80 (15.2) 64 (12.1) 52 (9.9) 127 (24.1) 
        
a
Respondents were able to select more than one option, so that percentages do not sum to 100
 
b
 P < 0.05  
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Over half the respondents identified Subcontinental Indians as having high risk of mouth 
cancer. Other ethnic groups identified at higher risk of mouth cancer were Māori, Fijian 
Indian and South East Asian. Nearly one in ten respondents identified New Zealand 
Europeans as having a high risk of mouth cancer. In particular, Asian graduates were 
significantly more likely to identify this group as having high risk of mouth cancer than 
graduates from New Zealand or Other countries. Nearly one quarter of respondents did not 
know whether particular ethnic groups are at high risk of mouth cancer.  
4.1.4 Commonly affected anatomical sites and OPMLs 
Participants were asked which anatomical sites are more commonly affected by mouth cancer. 
Fifty two (10.5%) respondents did not know which sites were more commonly affected. All 
these respondents were dentists and nearly half (24 respondents) had graduated in the years 
1976-1985 (19.5% of respondents in this graduate group). It was noteworthy that one in thirty 
respondents knew neither the age nor sex of those more commonly affected by mouth cancer, 
nor the sites more commonly affected. The sites identified by more than one in ten are 
presented in Table 4.7. Seven out of ten respondents identified the floor of the mouth and the 
lateral border of the tongue as common sites for mouth cancer, while fewer than half selected 
the base of the tongue. A significantly higher proportion of newer graduates than the oldest 






Table 4.7 Most frequent sites selected by practitioners as affected by mouth cancer (brackets contain row percentages
a
) 
  Anatomical site affected   
Practitioner Floor of Lateral border Tongue Buccal Soft Salivary Hard 
characteristic mouth of tongue base mucosa palate glands (major) palate 
Practitioner type 
b
        
Dentist 355 (71.9) 352 (71.3)   234 (47.4) 146 (29.6) 91 (18.4) 63 (12.8) 51 (10.3) 
CDT 25 (75.8) 25 (75.8)  26 (78.8) 14 (42.4) 11 (33.3)  5 (15.2) 13 (39.4) 
         
Graduation year group      
 Before 1976 29 (58.0)
b
 38 (76.0) 20 (40.0) 23 (46.0) 9 (18.0)  9 (18.0)   6 (12.0) 
1976-1985 80 (65.0) 79 (64.2) 56 (45.5) 34 (27.6) 23 (18.7) 19 (15.4) 14 (11.4) 
1986-1995 83 (70.3) 85 (72.0) 59 (50.0) 38 (32.2) 27 (22.9) 15 (12.7) 16 (13.6) 
1996-2005 82 (81.2)
 
 71 (70.3) 57 (56.4) 31 (30.7) 21 (20.8)    8 (7.9) 14 (13.9) 
2006-2015  106 (78.5) 104 (77.0) 68 (50.4) 34 (25.2) 22 (16.3) 17 (12.6) 14 (10.4) 
        
Graduation country group      
New Zealand  282 (73.6) 271 (70.8)  197 (51.4)
 b
 113 (29.5) 79 (20.6) 44 (11.5) 50 (13.1) 
Asian 29 (70.7) 30 (73.2) 23 (56.1)
 
 17 (41.5) 3 (7.3)  7 (17.1)   6 (14.6) 
Other 69 (67.0) 76 (73.8) 40 (38.8)
 
 30 (29.1) 20 (19.4) 17 (16.5)   8 (7.8) 
        
Total 373 (70.8) 372 (70.6)  256 (48.6) 158 (30.0)  102 (19.4) 66 (12.5) 63 (12.0) 
        
a
Respondents were able to select more than one option, so that percentages do not sum to 100
 
b
 P < 0.05  
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Two sites were selected by fewer than five percent of the respondents; these were the minor 
salivary glands (4.7%) and the epiglottis (4.2%). Significant differences in the selected sites 
were apparent by practitioner type, with CDTs more likely than dentists to identify the 
alveolar bone, the tongue base, the buccal mucosa, the hard and soft palate, the minor salivary 
glands and the tonsils. Moreover, significant differences in the identified sites were recorded 
by graduation country for the base of the tongue and the tonsils. Over half of the graduates 
from New Zealand and Asian countries identified the base of the tongue as a common mouth 
cancer site, whereas it was identified by fewer than two in five ‘Other’ graduates. The tonsils 
were selected by ten percent of New Zealand graduates, but rarely by Asian and not at all by 
‘Other’ graduates. 
The oral lesions considered by at least one in ten respondents to be potentially malignant are 






Table 4.8 Lesions identified by at least ten percent of clinicians to have malignant potential (brackets contain row percentages
a
) 
  Oral potentially malignant lesions   
Practitioner Erythro- Leuko- Erythro- Oral lichen Submucous Candidiasis Don’t 
characteristic leukoplakia plakia plakia planus fibrosis  know 
Practitioner type
b
       
Dentist 361 (73.1) 337 (68.2) 306 (61.9) 256 (51.8) 168 (34.0) 70 (14.2) 38 (7.7) 
CDT 19 (57.6) 20 (60.6) 20 (60.6) 10 (30.3) 13 (39.3)   6 (18.2)   9 (27.2) 
        
Graduation year        




 35 (70.0) 20 (40.0)
c
 21 (42.0) 16 (32.0)   9 (12.0)   9 (18.0)
b
 
 1976-1985 81 (65.9) 86 (70.0) 62 (50.4)
c
 61 (50.0) 33 (26.8) 21 (13.8) 17 (13.8) 
 1986-1995 90 (76.2) 92 (78.0) 80 (67.8)
c
 68 (57.6) 49 (41.5)  14 (8.5)   7 (5.9) 
 1996-2005 74 (73.3) 69 (68.3) 65 (64.4)
c
 52 (51.5) 34 (33.7)  15 (7.9) 11 (11.0) 
 2006-2015  109 (80.7) 75 (55.6) 99 (73.3)
c
 64 (47.4) 49 (36.3)  17 (9.6)   3 (2.2) 
        
Graduation country        
New Zealand  270 (70.5) 253 (66.1) 221 (57.7)
b
 198 (51.7) 114 (29.8)
b
 36 (9.4) 37 (9.7) 
Asian 33 (80.5) 29 (70.7) 31 (75.6)
 
 20 (48.8) 25 (61.0)
 
   4 (9.8)   1 (2.4) 
Other 77 (74.8) 75 (72.8) 74 (71.8)
 
 48 (46.6) 42 (40.8)
 
 14 (13.6)   9 (8.7) 
        
Total 380 (72.1) 357 (67.7) 326 (61.9) 266 (50.5) 181 (34.3) 76 (14.4) 47 (8.9) 
        
a
Respondents were able to select more than one option, so that percentages do not sum to 100 
b
 P < 0.05  
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Most respondents identified erythro-leukoplakia, leukoplakia, erythroplakia and oral lichen 
planus (OLP) as OPMLs, but only one-third identified oral submucous fibrosis (OSF) as an 
OPML. Fewer than one in eleven respondents were unsure about which of the listed oral 
conditions had substantial malignant potential. Significant differences were observed by 
practitioner type. More CDTs than dentists were unsure of which oral conditions are 
considered potentially malignant, and fewer CDTs considered erythro-leukoplakia and OLP to 
be OPMLs. However, more than one-quarter of CDTs identified fibro-epithelial polyps as 
potentially malignant; these lesions were identified as such by only one in twenty dentists.  
Significant differences in the identification of OPMLs were also observed by graduation year 
and graduation country. The most recent graduates had the lowest proportion of ‘Don’t know’ 
responses, while the oldest graduates had the highest proportion. Also, older graduates were 
less likely to identify both erythro-leukoplakia and erythroplakia as OPMLs than younger 
practitioners, but the most recent graduates were less likely to identify leukoplakia as an 
OPML. More than half of the graduates from Asian countries identified OSF as an OPML, 
while OSF was identified by more than one-third of Other and one-quarter of New Zealand 
graduates. While more than half of the respondents identified erythroplakia as an OPML, New 
Zealand graduates were significantly less likely to do so. Only six respondents felt that none 
of the listed oral conditions had significant malignant potential. Of these practitioners, all 
were dentists who had graduated from either New Zealand or Asian countries.  
4.1.5 Practitioner-identified signs and symptoms of mouth cancer  
Participants were asked about the signs commonly associated with mouth cancer. The most 
frequently identified signs are presented in Table 4.9. Most respondents selected ulceration, 
lumps in the mouth, neck swelling, leukoplakia, erythro-leukoplakia and erythroplakia as 
signs associated with mouth cancer. 
Additional signs of mouth cancer identified by at least half of the respondents are presented in 
Table 4.10. Over half of the respondents selected all of the listed signs, as associated with 
mouth cancer. Dentists were more likely than CDTs to identify mouth ulcers, non-healing 
extraction sites, and loose teeth as being associated with mouth cancer, but the difference was 
not significant. However, significant differences were recorded by graduation year cohort, 
with the oldest graduates being less likely than more recent graduates to identify mouth 






Table 4.9 Practitioner-identified signs as commonly associated with mouth cancer (brackets contain row percentages
a
) 
  Signs of mouth cancer   
Practitioner Ulcers Mouth Neck Leukoplakia Erythroleuko Erythroplakia 
characteristic  Lumps Swelling  plakia  
Practitioner type
b
      
Dentist 466 (94.3) 432 (87.4) 413 (83.6) 406 (82.2) 400 (81.0) 393 (79.6) 
CDT 25 (75.8)   29 (87.9)   26 (78.8)   27 (81.8)   25 (75.8)   23 (69.7) 
       
Graduation year       
Before 1976 46 (92.0)   38 (76.0)
b
    38(76.0)   39 (78.0)   29 (58.0) 32 (64.0) 
1976-1985 117 (95.1) 107 (87.0)
 
 102 (82.9) 107 (87.0) 105 (85.4) 97 (78.9) 
1986-1995 112 (94.9) 109 (92.4)
 
 104 (88.1) 100 (84.7) 98 (83.1) 95 (80.5)  
1996-2005   89 (88.1)   84 (83.2)
 
   78 (77.2)   77 (76.2) 79 (78.2) 79 (78.2) 
2006-2015 127 (94.1) 123 (91.1)
 
 117 (86.7) 110 (81.5) 114 (84.4) 113 (83.7) 
       
Total 491 (93.2) 461 (87.5) 439 (83.3) 433 (82.2) 425 (80.6) 416 (78.9) 
       
a
Respondents were able to select more than one option, so that percentages do not sum to 100
 
b






Table 4.10 Further practitioner-identified signs of mouth cancer (brackets contain row percentages
a
) 
  Signs of mouth cancer  
Practitioner Soft tissue Non-healing Loose Mouth Bad 
characteristic necrosis extraction site teeth bleeding breath 
Practitioner type
b
      
Dentist 392 (79.4) 369 (74.7)  338 (68.4)  310 (62.8) 278 (56.3) 
CDT   24 (72.7)   18 (54.5) 15 (45.5)  21 (63.6) 15 (45.5) 
      
Graduation year      
Before 1976   36 (72.0)   36 (72.0) 29 (58.0)
b
  28 (56.0) 24 (48.0)
b
 
1976-1985 102 (82.9) 97 (78.9) 92 (74.8)
 
  88 (71.5) 80 (65.0)
 
 
1986-1995 97 (82.2) 90 (76.3) 87 (73.7)
 
  75 (63.6) 73 (61.9)
 
 
1996-2005 73 (72.3) 63 (62.4) 54 (53.5)
 
  54 (53.5) 47 (46.5)
 
 
2006-2015 108 (80.0) 101 (74.8) 91 (67.4)
 
  86 (63.7) 69 (51.1)
 
 
      
Total 416 (78.9) 387 (73.4)  353 (67.0)  331 (62.8) 293 (55.6) 
      
a
Respondents were able to select more than one option, so that percentages do not sum to 100 
b




The practitioners who had graduated between 1996 and 2005 were significantly less likely to 
identify loose teeth as a sign associated with mouth cancer than other graduates. The six 
respondents who felt none of the listed lesions were OPMLs also did not identify any of the 
listed further signs as associated with mouth cancer. Very few (0.7%) respondents were 
unsure of the signs associated with mouth cancer. No statistically significant patterns in the 
signs of mouth cancer identified by graduation country were apparent. 
The participants’ responses to the question asking for symptoms associated with mouth cancer 






Table 4.11 Practitioner-identified symptoms associated with mouth cancer (brackets contain row percentages
a
) 
 Numbness or Difficulty Mouth Difficulty Difficulty Loss of Bleeding 
 paraesthesia swallowing pain chewing speaking taste  
Practitioner type
b
       
Dentist 462 (93.5) 452 (91.5) 415 (84.0) 411 (83.2) 412 (83.4) 409 (82.8) 393 (79.6) 
CDT   25 (75.8)   27 (81.8)   27 (81.8)   21 (63.6)   20 (60.6)   20 (60.6)   23 (69.7) 
        
Graduation year group       
Before 1976   42 (84.0)   44 (88.0)   36 (72.0)
b
   37 (74.0)   37 (74.0)   37 (74.0)   34 (68.0) 
 1976-1985 115 (93.5) 114 (92.7) 110 (89.4)
 
 104 (84.6) 104 (84.6) 104 (84.6) 106 (86.2) 
 1986-1995 112 (94.9) 112 (94.9) 103 (87.3)
 
 103 (87.3) 105 (89.0) 103 (87.3)   96 (81.4) 
 1996-2005   93 (92.1)   88 (87.1)   81 (80.2)
 
   80 (79.2)   79 (78.2)   80 (79.2)   77 (76.2) 
 2006-2015 125 (92.6) 121 (89.6) 112 (83.0)
 
 108 (80.0) 107 (79.3) 105 (77.8) 103 (76.3) 
        
Total 487 (92.4) 479 (90.9) 442 (83.9) 432 (82.0) 432 (82.0) 429 (81.4) 416 (78.9) 
        
a
Respondents were able to select more than one option, so that percentages do not sum to 100 
b





Most respondents identified numbness or paraesthesia, difficulty swallowing and mouth pain 
as symptoms associated with mouth cancer. More than two-thirds of respondents indicated all 
of the symptoms listed as being associated with mouth cancer. CDTs generally identified 
fewer symptoms of mouth cancer than dentists, with dentists being more likely to identify all 
the listed symptoms. The oldest graduates were significantly less likely than newer graduates 
to identify mouth pain as associated with mouth cancer.  
4.1.6 Identified risk factors for mouth cancer  
Participants were asked to identify the risk factors for mouth cancer. The most frequently 







Table 4.12 Risk factors for mouth cancer identified by practitioners (brackets contain row percentages
a
) 
    Risk factor    













Sun exposure Older age 
characteristic 
Practitioner type        
Dentist 478 (96.8) 481 (97.4)  466 (94.5) 464 (93.9) 405 (82.0) 390 (78.9) 368 (74.5) 336 (68.0) 
CDT 28 (84.8) 31 (93.9)  21 (84.0) 29 (87.9) 27 (81.8) 22 (66.7) 25(75.8) 17 (51.5) 
         
Graduation year         
Before 1976 47 (94.0) 46 (92.0)  46 (92.0) 47 (94.0)
b
 39 (78.0) 36 (72.0) 28 (56.0)  37 (74.0) 
1976-1985 119 (96.7) 120 (97.6) 113 (91.9) 114 (92.7)
 
 97 (78.9) 101 (82.1) 90 (73.2)  86 (69.9) 
1986-1995 115 (97.4) 115 (97.5) 114 (96.6) 116 (98.3)
 
 93 (78.8) 95 (80.5) 92 (78.0)  76 (64.4) 
1996-2005 95 (94.0) 100 (99.0)   94 (93.1) 88 (87.1)
 
 82 (81.2) 77 (76.2) 77 (76.2)  62 (45.9) 
2006-2015 130 (96.3) 131 (97.0) 127 (94.1) 128 (94.8)
 
 121 (89.6)  103 (76.3) 106 (78.5)  92 (68.1) 
         
Graduation country         
New Zealand  368 (96.1) 370 (96.6) 364 (95.0) 364 (95.0)
 b
 312 (81.5) 301 (78.6) 285 (74.4) 267 (69.7) 
Asian  37 (90.2) 39 (95.1) 34 (82.9) 32 (78.1)
 
 32 (78.1) 32 (78.1) 27 (65.9) 21 (51.2) 
Other  101 (98.1) 103 (100) 96 (95.1) 97 (96.0)
 
 88 (87.1) 79 (78.2) 81 (78.6) 65 (63.1) 
         
Total 506 (96.0) 512 (97.1) 494 (93.7) 493 (93.5) 432 (82.0) 412 (78.2) 393 (74.6) 353 (67.0) 
         
a
Respondents were able to select more than one option, so that percentages do not sum to 100 
b
 P < 0.05  
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More than nine out of ten respondents identified chewing tobacco, chewing areca nut, 
smoking tobacco and heavy alcohol use were risk factors for mouth cancer (Tables 4.12 and 
4.13). Most respondents also identified a family history of oral cancer, previous HPV 
infection, sun exposure, older age and smoking marijuana as risk factors for mouth cancer. 
CDTs were less likely than dentists to recognise smoking tobacco or previous HPV infection 
as risk factors for mouth cancer, although the differences were not significant. 
The oldest graduates were significantly less likely than newer graduates to identify sun 
exposure as a risk factor for mouth cancer. Practitioners who had graduated from 1996 to 
2005 were the least likely to identify heavy alcohol use as a risk factor for mouth cancer. 
Asian graduates were also significantly less likely than other graduates to identify heavy 
alcohol use and older age as risk factors for mouth cancer. 
CDTs were more likely than dentists to identify denture stomatitis, recurrent cold sores, poor 
oral hygiene and ill-fitting dentures as risk factors for mouth cancer. On average, respondents 
chose ten risk factors, with over one-quarter selecting all 15 risk factors listed. No differences 
were found by type of practitioner, graduation year or graduation country and mean number 






Table 4.13 Further risk factors for mouth cancer identified by practioners (brackets contain row percentages
a
) 
   Risk factor   
Practitioner Smoking EBV Poor Poor oral Ill-fitting Denture Recurrent 
Characteristics marijuana infection diet hygiene dentures stomatitis cold sores 
Practitioner type       
Dentists 311 (63.0) 256 (51.8) 250 (50.6) 231 (46.8) 201 (40.7) 193 (39.1) 158 (32.0) 
CDTs 22 (66.7) 13 (39.4) 16 (48.5) 21 (63.6) 18 (54.5) 19 (57.6) 14 (42.4) 
        
Graduation year        
Before 1976 29 (58.0) 25 (50.0) 24 (48.0) 26 (52.0) 28 (56.0) 26 (52.0) 18 (36.0) 
1976-1985 77 (62.6) 62 (50.4) 63 (51.2) 69 (56.1) 55 (44.7) 51 (56.1) 39 (31.7) 
1986-1995 77 (65.3) 51 (43.2) 60 (50.8) 53 (44.9) 47 (39.8) 45 (44.9) 37 (31.4) 
1996-2005 63 (62.4) 54 (53.5) 48 (47.5) 46 (45.5) 37 (36.6) 38 (45.5) 36 (35.6) 
2006-2015 87 (64.4) 77 (74.8) 71 (68.9) 58 (43.0) 52 (38.5) 52 (43.0) 42 (31.1) 
        
Graduation country        
New Zealand 247 (64.5) 188 (49.1) 193 (50.4) 182 (49.1) 153 (39.9) 312 (39.2) 127 (33.2) 
Asian 23 (56.1) 27 (65.9) 20 (48.8) 24 (58.5) 24 (58.5) 22 (53.7) 16 (39.0) 
Other 63 (62.4) 54 (52.4) 53 (51.5) 46 (44.7) 42 (40.8) 88 (38.8) 29 (28.2) 
        
Total 333 (63.2) 269 (51.0) 266 (50.5) 252 (47.8) 219 (41.5) 212 (40.3) 172 (32.6) 
        
a 
Respondents were able to select more than one option, so that percentages do not sum to 100 
b




4.1.7 Discussing mouth cancer risk factors with patients 
Participants were asked about whether they discussed the risk factors for mouth cancer with 
their patients (Table 4.14).  















alcohol use characteristic 
Practitioner type     
Dentist 254 (51.4) 402 (81.3) 234 (47.4)  116 (23.4) 66 (13.4) 
CDT   18 (54.5)  22 (66.7)   15 (45.4) 8 (24.2)   6 (18.2) 
      
Sex of practitioner     
Males 154 (52.2) 224 (75.9) 141 (47.8) 70 (23.7) 43 (14.5) 
Females 118 (51.1) 200 (86.2) 108 (46.6) 54 (23.2) 29 (12.5) 
      
Graduation year      
Before 1976 21 (42.0)
b
  27 (54.0)
 b
 19 (38.0)   5 (10.0)
 b
   5 (10.0) 
1976-1985   63 (51.2) 100 (81.3)   59 (48.0) 24 (19.5) 12 (9.8) 
1986-1995 71 (60.2)  99 (83.9)   57 (48.3) 33 (28.0)
 
 19 (16.1) 
1996-2005 56 (55.4)  84 (83.1)   51 (49.5) 23 (22.8) 18 (17.8) 
2006-2015 61 (58.1) 114 (84.4)   63 (46.7) 39 (28.9) 18 (13.3) 
      
Graduation country      
























   93 (90.3)
 







      
Total 272 (51.6) 424 (80.5) 249 (47.2)  124 (23.5) 72 (13.7) 
      
a 
Rows contain responses to different questions, therefore row percentages do not sum to 100 
b
 P < 0.05  
 
More than half of the respondents routinely advised patients about risk factors for mouth 
cancer. However, New Zealand graduates were significantly less likely to advise patients than 
graduates from other countries. Most practitioners routinely asked patients about their current 
tobacco use, whereas fewer than half the practitioners routinely asked about past tobacco use 
and even fewer asked about current or past alcohol use. Those who had graduated prior to 
1976 were significantly less likely than more recent graduates to ask about current tobacco 
and alcohol use. There were also significant differences in responses by graduation country. 
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‘Other’ country graduates were the most likely to ask about current tobacco use and advise 
patients on the risk factors for mouth cancer, but Asian graduates were the most likely to ask 
about previous tobacco use, current alcohol and past alcohol use. 
4.1.8 Detection of oral mucosal lesions  
The responses to the questions relating to the detection of oral mucosal lesions and oral cancer 
screening practices are displayed in Table 4.15. 







an oral lesion 




Screen only high 
risk patients 
Practitioner type     
Dentist 433 (87.7) 173 (35.0) 442 (90.1) 84 (17.1) 
CDT   32 (97.0)  9 (27.2) 30 (89.7) 3 (9.1) 
     
Graduation year     


































 25 (18.5) 
      
Graduation country     
New Zealand 338 (88.3) 132 (34.5)
b
 339 (88.7) 64 (16.7) 
Asian 35 (85.4)  8 (19.5)
 
 39 (95.1) 9 (22.5) 
Other 92 (89.3) 42 (40.1)
 
 94 (91.2) 14 (13.9) 
     
Sex of practitioner    
Male 268 (90.8)  109 (36.9) 268 (91.1) 44 (15.1) 
Female 197 (84.9) 73 (31.5) 204 (87.9) 43 (18.5) 
     
Total 465 (88.2) 182 (34.5) 472 (89.6) 87 (16.5) 
     
a 
Rows contain responses to different questions, therefore row percentages do not sum to 100 
b
 P < 0.05  
 
Most respondents had previously detected a suspicious oral mucosal lesion, but there were 
significant differences by graduation year. Nearly all practitioners who graduated from 1986 
to 1995 had previously detected a suspicious oral lesion, while one in ten of the oldest 
graduates had never done so. Just over one-third of respondents thought patients were able to 
detect lesions themselves, but Asian graduates were significantly less likely to believe that 
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patients could self-detect lesions. Significant differences by graduation year were recorded, 
with a higher proportion of newer graduates believing that patients could detect oral mucosal 
lesions themselves. Most participants (86.7%) responded to the open question asking for 
patient-identified signs or symptoms that would alert practitioners to a suspicious oral lesion. 
Nearly three-quarters of respondents identified non-healing ulceration as a sign of a 
suspicious lesion.  
Most practitioners checked all patients for oral mucosal lesions, with only one in six 
respondents specifically checking those patients deemed to be at high risk of mouth cancer. 
The proportion of practitioners checking all patients and those targeting OCS were similar 
when reviewed by practitioner type, country of graduation and sex of practitioner. However, 
significant differences were found for graduation year, with the oldest practitioners being the 
least likely to screen all patients for oral mucosal lesions, and those who graduated from 1976 
to 1985 being most likely to do so.  
When asked about their level of confidence in detecting potentially malignant oral lesions 
(Table 4.16), over two-thirds of respondents were confident or very confident about detecting 
OPMLs. No significant patterns in the level of confidence in detecting OPMLs by practitioner 
type, graduation year, or country were observed. 
Table 4.16 Confidence level in detecting potentially malignant lesions (brackets contain row 
percentages) 
Practitioner Confidence  
characteristic Very confident Confident Not confident 
Practitioner type     
Dentist  30 (6.1) 325 (65.8) 139 (28.1) 
CDT 4 (12.1) 16 (48.5) 13 (39.4)
a
 
    
Graduation year    
Before 1976 2 (4.0) 34 (68.0) 14 (28.0) 
1976 to 1985 8 (6.5) 82 (66.7) 33 (26.8) 
1986 to 1995  11 (9.3) 77 (65.3) 30 (25.4) 
1996 to 2005 6 (5.9) 58 (57.4) 37 (36.6) 
2006 to 2015 7 (5.2) 90 (66.7) 38 (28.1)
a
 
    
Graduation country    
Asian 4 (9.8) 25 (61.0) 12 (29.3) 
New Zealand  24 (6.2)  244 (63.7)  115 (30.0)
a
 
Other 6 (5.8) 72 (70.0) 25 (24.3) 
    
Total  34 (6.5) 341 (64.7)  152 (28.8)
a 
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a
one response of “very unconfident” was received and was combined with the not confident responses for 
analytical purposes. 
 
4.1.9 Oral cancer screening examinations 
The responses to the question about the types of procedures that constitute an oral cancer 






Table 4.17 Procedures involved in screening for mouth cancer (brackets contain row percentages
a
) 












Practitioner type     
Dentist 476 (96.4) 395 (80.0)  324 (65.6) 290 (58.7) 187 (37.9) 167 (33.8) 
CDT 30 (90.9) 19 (57.6) 22 (66.7) 13 (39.4) 17 (51.5) 11 (33.3) 
       
Graduation year      
Before 1976 45 (90.0) 35 (70.0) 37 (74.0) 29 (58.0) 22 (44.0)
b
 22 (44.0) 
1976-1985 118 (95.9) 99 (80.5) 83 (67.5) 79 (64.2) 54 (43.9) 46 (37.4) 
1986-1995 113 (95.8) 89 (75.4) 76 (64.4) 75 (63.6) 58 (49.2) 43 (36.4) 
1996-2005 98 (97.0) 79 (78.2) 62 (61.4) 56 (55.4) 39 (38.6)
 
 36 (35.6) 
2006-2015 132 (97.8) 112 (83.0) 88 (65.2) 64 (47.4) 31 (23.0)
 
 31 (23.0) 
       
Graduation country       
New Zealand 372 (97.1) 292 (76.2)  243 (63.4) 226 (59.0) 145 (37.9) 126 (32.9) 
Asian 36 (87.8) 36 (87.8) 31 (75.6) 23 (56.1) 16 (39.0) 16 (39.0) 
Other 98 (95.1) 86 (83.5) 72 (69.9) 54 (52.4) 43 (41.7) 36 (35.0) 
       
Total 506 (96.0) 414 (78.6)  346 (65.7) 303 (57.5) 204 (38.7) 178 (33.8) 
       
a
Respondents were able to select more than one option, so that percentages do not sum to 100
 
b
 P < 0.05  
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Nearly all practitioners felt that a visual examination of all oral mucosal soft tissues was part 
of an OCS examination, and more than three-quarters identified that palpation of lymph nodes 
was also necessary. More than half of participants identified palpation of the floor of the 
mouth and radiographic examination of the alveolar bone as necessary for an OCS 
examination. Very few practitioners (3%) were unsure of what an OCS examination involved. 
No differences were recorded in responses by practitioner type, with over one-quarter of both 
dentists and CDTs identifying all the listed factors as necessary for an OCS examination. 
However, some significant differences by graduation year were observed. The youngest 
practitioners were less likely than older graduates to identify checking salivary flow as part of 
an OCS examination. Likewise, the youngest practitioners were the least likely to identify all 
the listed factors as part of an OCS examination. 
The participants were asked which types of health practitioner should screen individuals for 







Table 4.18 Practitioners who should screen for mouth cancer (brackets contain row percentages
a
) 

















Practitioner type         
Dentist 291 (58.9) 383 (77.5) 389 (78.7) 480 (97.2) 304 (61.5)  142 (28.7)  432 (87.4)  423 (85.6) 19 (3.8) 
CDT 21 (63.6) 21 (63.6) 29 (87.9) 27 (81.8) 22 (66.7)    8 (24.2) 29 (87.9) 25 (75.8) 4 (12.1) 
          
Graduation year          
Before 1976 28 (56.0) 36 (72.0) 38 (76.0) 48 (96.0)
 b
 28 (56.0) 15 (30.0) 39 (78.0) 36 (72.0)
b
 2 (4.0) 
1976-1985 78 (63.4) 92 (74.8) 97 (78.9) 116 (94.3)
 
 75 (61.0) 38 (30.9)  105 (85.4)  100 (81.3)
 
 7 (5.7) 
1986-1995 69 (58.5) 86 (72.9) 96 (81.4) 115 (97.5)
 
 77 (65.3) 32 (27.1)  108 (91.5)  105 (89.0)
 
 4 (3.4) 
1996-2005 52 (51.5) 72 (71.3) 73 (72.3) 93 (92.1)
 
 60 (59.4) 25 (24.8) 87 (86.1) 85 (84.2) 4 (4.0) 
2006-2015 85 (63.0) 118 (87.4) 114 (84.4) 135 (100.0)
 
 86 (63.7) 40 (29.6)  122 (90.4)  122 (90.4) 6 (4.4) 
          
Graduation country           
















 77 (74.8) 96 (93.2) 55 (53.4) 27 (26.2) 85 (82.5) 83 (80.6) 3 (2.9) 
          
Total 312 (59.2) 404 (76.7)
 b
 418 (79.3) 507 (96.2) 326 (61.9)  150 (28.4)  461 (87.4)  448 (85.0) 23 (4.3) 
          
a
Respondents were able to select more than one option, so that percentages do not sum to 100
 
b
P < 0.05 
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More than three-quarters of respondents identified general dentists, oral and maxillo-facial 
surgeons, oral medicine specialists, ENT surgeons and dental hygienists as practitioners who 
should screen for mouth cancer, while more than half also identified general medical 
practitioners and CDTs. Few suggested pharmacists for this role. No significant difference in 
response proportions was found by practitioner type. However, nearly all dentists thought 
general dentists should screen for mouth cancer, but fewer than two-thirds of CDTs thought 
CDTs should screen for mouth cancer. New Zealand graduates were significantly more likely 
than Asian or ‘Other’ country graduates to identify CDTs, dental hygienists and ENT 
surgeons as practitioners who should screen for mouth cancer. The oldest graduates were less 
likely than more recent graduates to identify oral medicine specialists as practitioners who 
should screen for mouth cancer 
4.1.9.1 Barriers to performing oral cancer screening examinations 
Practitioners were asked to identify factors that prevent them screening all patients for mouth 
cancer (Table 4.19). Nearly half felt that there were no barriers, but a lack of time and a lack 







Table 4.19 Perceived barriers to performing oral cancer screening examinations (brackets contain row percentages
a
) 
















Practitioner type      
Dentists 148 (30.0) 138 (27.9) 108 (21.9) 100 (20.2)  51 (10.3) 11 (2.2) 13 (2.6)   11 (2.2) 
CDTs 9 (27.3) 7 (21.2) 8 (24.2) 5 (15.2)  5 (15.2)     9 (27.3)  7 (21.2) 2 (6.1) 
         
Graduation year group      
Before 1976 21 (42.0)
 b
 14 (28.0) 16 (32.0)
 b
 13 (26.0)  6 (12.0) 3 (6.0)   6 (12.0)
 b
 4 (8.0) 
1976-1985 26 (21.1)
 
 27 (22.0) 21 (17.1)
 
 21 (17.1)  11 (8.9) 7 (5.7) 3 (2.4)
 
 3 (2.4) 
1986-1995 39 (33.1)
 
 37 (31.4) 22 (18.6)
 
 29 (24.6)  16 (13.6) 1 (0.8) 1 (0.8)
 
 1 (0.8) 
1996-2005 33 (32.7)
 
 28 (27.7) 24 (23.8)
 
 19 (18.8)  12 (11.9) 5 (5.0) 6 (5.9)
 
 1 (1.0) 
2006-2015 38 (28.1)
 
 39 (28.9) 33 (24.4)
 
 23 (17.0)  11 (8.1) 4 (3.0) 4 (3.0)
 
 4 (3.0) 
         
Graduation country group        
New Zealand   116 (30.3) 104 (27.2) 88 (23.0) 71 (18.5)  39 (10.2)  14 (3.7) 16 (4.2) 13 (3.4) 
Asian 15 (36.6) 16 (39.0) 11 (26.8) 13 (31.7)    8 (19.5) 3 (7.3)   1 (2.4)   0 (0.0) 
Other 26 (25.2) 25 (24.3) 17 (16.5) 21 (20.4)    9 (8.7) 3 (2.9)   3 (2.9)   0 (0.0) 
         
Total 157 (29.8) 145 (27.5) 116 (22.0) 105 (19.9)  56 (10.6) 20 (3.8) 20 (3.8) 13 (2.5) 
         
a
Respondents were able to select more than one option, so that percentages do not sum to 100
 
b
P < 0.05 
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More than one-fifth identified a lack of confidence and ten percent of practitioners felt patient 
resistance to OCS examinations was also a barrier. A few practitioners responded that OCS 
was outside their ‘scope of practice’, a ‘specialist only procedure’ or was ‘not necessary’. 
However, those from the earliest graduation group were significantly more likely than 
younger graduates to identify lack of training, lack of confidence and outside scope of 
practice, as barriers to performing OCS examinations routinely. 
4.1.10 Specialist referral for identified suspicious oral lesions 
Practitioners were asked to which practitioner or secondary service they would usually refer 
patients with suspicious lesions for review (Table 4.20). Over half referred patients to oral and 
maxillo-facial surgeons. Very few practitioners referred to ENT surgeons, general dentists or 







Table 4.20 Practitioner’s usual referral pathway (brackets contain row percentages
a
) 













Practitioner type       
Dentist 298 (60.3) 96 (19.4) 75 (15.2) 18 (3.6) 1 (0.2) 2 (0.4) 
CDT 16 (48.5) 1 (3.0) 1 (3.0) 2 (6.1) 8 (24.2) 4 (12.1) 
       
Graduation year       
Before 1976 28 (56.0) 14 (28.0) 6 (12.0) 2 (4.0) 0 (0.0) 0 (0.0) 
1976 to 1985 73 (59.3) 25 (20.3) 15 (12.2) 4 (3.3) 1 (0.8) 3 (2.4) 
1986 to 1995 78 (66.1) 17 (14.4) 15 (12.7) 3 (2.5) 3 (2.5) 0 (0.0) 
1996 to 2005 68 (67.3) 14 (13.9) 11 (10.9) 4 (4.0) 4 (4.0) 0 (0.0) 
2006 to 2015 67 (49.6) 27 (20.0) 29 (21.5) 7 (5.2) 1 (0.7) 3 (2.2) 
       
Graduation country       
New Zealand  234 (61.1) 66 (17.2) 53 (13.8) 16 (4.2) 7 (1.8) 4 (1.0) 
Asian  21 (51.2) 11 (26.8) 5 (12.2) 3 (7.3) 1 (2.4) 0 (0.0) 
Other  59 (57.3) 20 (19.4) 18 (17.5) 1 (1.0) 1 (1.0) 2 (1.9) 
       
Total  314 (59.6) 97 (18.4) 76 (14.4) 20 (3.8) 9 (1.7) 6 (1.1) 
       
a




The responses to questions about patients’ attendance at referral appointments are presented 
in Table 4.21. 














Practitioner type    
Dentist  410 (83.0) 305 (61.7)  123 (24.9)  41 (8.3) 
CDT 29 (87.9) 19 (57.6) 9 (27.2)  4 (12.1) 
     
Graduation year     
Before 1976 45 (90.0) 36 (72.0) 6 (12.0)  6 (12.0) 
1976 - 1985  107 (87.0) 80 (65.0) 32 (26.0)  6 (4.8) 
1986 - 1995  102 (86.4) 67 (56.8) 36 (30.5)  9 (7.6) 
1996 - 2005 79 (78.2) 51 (50.4) 29 (28.7)  15 (14.9) 
2006 - 2015  106 (78.5) 90 (66.7) 29 (21.5)  9 (6.7) 
     
Graduation country     
New Zealand  321 (83.8) 24 (58.5) 12 (29.3)  5 (12.2) 
Asian 34 (82.9) 232 (60.6) 97 (25.3)  35 (9.1) 
Other 84 (81.6) 68 (66.0) 23 (22.3)  5 (4.9) 
     
Total 439 (83.3) 324 (61.5) 132 (25.0)  45 (8.5) 
     
a
Rows contain responses to different questions, therefore row percentages do not sum to 100 
 
Most respondents felt that patients would usually attend a specialist appointment for review of 
a suspicious oral lesion. However, more than one in ten were unsure about whether patients 
would attend a specialist appointment. No significant difference was apparent by practitioner 
type, graduation year or country. When asked who should be responsible for checking 
whether patients present to their specialist review appointment, most practitioners felt that the 
referring practitioner was responsible, but one-quarter felt that the responsibility remained 
with the referred patient. Fewer than one in twelve felt that the onus of ensuring that a patient 
attended a specialist appointment should be on the service receiving the referral. 
4.2 Results from NZCR data on diagnosed OC and OPC cases 2012-2013 
There were 761 new cases of OC and OPC (ICD-10 codes C00-C14.8, excluding C11, 12 
&13) diagnosed in New Zealand residents from 1 January 2012 until 31 December 2013, and 
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these were 1.8% of all registered malignancies during this time. The crude cancer incidence 
rates (per 100,000) by anatomical site were; 1.0, 1.1, 2.8 and 4.1 for external lip, salivary 
gland, oropharynx and oral cavity, respectively. Three individuals each had two registered 
tumours.  
4.2.1 Anatomical and morphological characteristics of cases 
The cases of OC and OPC by anatomical site (according to the ICD-10 codes) are presented 
in Table 4.22. 
Table 4.22 Registered oral and oropharyngeal cancers in 2012─2013 by anatomical site 
(brackets contain column percentages). 
Site description ICD codes Number 
External lip C00—02 82 (10.8) 
   
Oral cavity carcinomas   
Internal lip C003—005 16 (2.1) 
Lip unspecified C006—009 3 (0.4) 
Tongue C020—23, C028, C029  152 (20.0) 
Floor of mouth C040—049 46 (6.0) 
Gum and cheek C030—039, C060-062 89 (11.7) 
Hard and soft palate C050—C059 35 (4.6) 
Other parts of mouth C068 5 (0.7) 
 Total Oral Cavity Cancers  346 (45.5) 
   
Oropharyngeal carcinomas   
Base of tongue, lingual tonsil C01, C024 79 (10.4) 
Tonsil C090—C099, C142  117 (15.4) 
Oropharynx C100—109 27 (3.5) 
Overlapping or unspecified lesion of 
oropharynx 
C140 and C148 13 (1.7) 
 Total OPCs  236 (31.0) 
   
Salivary glands carcinomas   
Minor salivary gland C069 18 (2.4) 
Major salivary gland C070—C089 79 (10.4) 
 
Total salivary gland 
cancers 
97 (12.8) 
Total C00—C148 761 (100.0) 
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The tongue was the most frequent cancer site (one-fifth of the tumours were in the oral 
tongue), followed by the tonsils (nearly one in six cases). Tumours of the salivary glands 
represented one in eight cases, with most of these in the major salivary glands.  
The morphology of the registered tumours is summarised in Table 4.23. 
Table 4.23 Morphology of registered oral and oropharyngeal carcinomas (brackets contain the 
column percentage). 
Morphology code Description Number of cases 
8000 & 8010 Unspecified morphology   22 (2.9) 
8051-8076, 8083-8094 Squamous cell carcinomas 628 (82.5) 
8013-8046, 8082, 8140-8982, Non-epithelial neoplasms 111 (14.6)  
     9041, 9270 and 9581   
Total  761 (100.0) 
 
Most of the OC and OPC were squamous cell carcinomas, with about one in seven derived 
from non-squamous cell tissue. The most frequently registered type of non-epithelial 
neoplasms were mucoepidermoid (30 cases), adenoid cystic (18 cases), acinar cell (16 cases) 
and adenocarcinomas (14 cases). A few cases had no specific morphology recorded.  
4.2.2 Demographic characteristics of cases 
Summary data on the sex of those diagnosed with OC and OPC is presented in Table 4.24 by 
the year, and age group at diagnosis and ethnic group.  
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Table 4.24 Sex of registered cases by year of diagnosis, age and ethnic group (brackets contain 
row percentages, except where indicated) 
 Sex  
 Male Female Total
 a
 
Year of diagnosis    
2012 232 (63.7) 132 (36.3) 364 (47.8) 
2013 241 (60.7) 156 (39.3) 397 (52.2) 
    
Age group at diagnosis (in years)   
Less than 30 9 (69.2)   4 (30.8) 13 (1.7) 
30-39 16 (59.3) 11 (40.7) 27 (3.5) 
40-49 50 (65.8) 26 (34.2) 76 (10.0) 
50-59 138 (68.7) 63 (31.3) 201 (26.4) 
60-69 128 (71.9) 50 (28.1) 178 (23.4) 
70-79  76 (52.4) 69 (47.6) 145 (19.1) 
80-84  33 (53.2) 29 (46.8) 62 (8.1) 
Over 85 23 (39.0) 36 (61.0) 59 (7.8) 
    
Ethnic group    
Non-Māori 440 (93.0) 263 (91.3) 703 (92.4) 
Māori 33 (7.0) 25 (8.7) 58 (7.6) 
    





Over one-third of the registered cases in each year were female (overall male:female ratio of 
1.6:1). However, the sex ratio of cases differed by age group, with half of the cases aged over 
70 years being female. The crude incidence rates per 100,000 were 12.1 and 7.0 for males and 
females, respectively. The age at diagnosis ranged from 2 to 100 years, with the age group 50 ̶ 
59 years having the highest number of diagnosed cases. The median age at diagnosis was 63 
years (interquartile range 54 ̶ 75 years), but the median age differed by sex with a median age 
of 61 years for males and 67 years for females.  
Most of the OC and OPC cases occurred in non-Māori (n=703, 92.4%), the majority of whom 
were New Zealand Europeans (n=628, 82.5%). Few cases were Pacific people (n=27, 3.5%), 
South East Asian (n=18, 2.4%) or Sub continental Indian (n=13, 1.7%). The crude incidence 
rates per 100,000 were 10.3 and 4.8 for non-Māori and Māori respectively. The crude 
incidence rate per 100,000 for non-Māori males was more than double that for Māori males 
(13.3 and 5.7 respectively), but less than double for females (7.5 and 4.0 for non-Māori and 
Māori respectively). 
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The age-specific rates for OC and OPC by sex are presented in Figure 4.1. 
 
Figure 4.1 Age-specific rates of oral and oropharyngeal cancer per 100,000 for 2012 ̶ 2013. 
 
The age-specific OC and OPC rates for both sexes were lowest in those younger than 30 years 
(0.4 per 100,000). The incidence rate showed a consistent age gradient which increased with 
age in women, but, for males, the highest age-specific rate (48.7 per 100,000) was in the 
80─84 year age group. 
The age-specific rates by sex and ethnicity are presented in Figure 4.2. 
 








































































Non-Māori males 80 or more years of age had the highest age-specific rates per 100,000 (48.9 
and 47.2 for 80─84 years and over 84 years, respectively). The age-specific rates by sex for 
Māori were lower than for non-Māori, except for Māori males aged 40─49 years and Māori 
females aged 50─59 years and 70─79 years. There were no Māori cases aged over 84 years. 
The extent of the OC and OPC by sex is presented in Table 4.25.  
Table 4.25 Extent of tumours by sex (brackets contain column percentages, except where 
indicated). 
 Sex  
Extent of tumour Male Female Total 
Localised to organ of origin 134 (28.3)  108 (37.5)
b
 242 (31.8) 
Invasion of adjacent tissue 29 (6.1) 16 (5.6) 45 (5.9) 
Regional lymph nodes 158 (33.4) 55 (19.1) 213 (28.0) 
Distant metastases 32 (6.8) 14 (4.9) 46 (6.0) 
Unknown 120 (25.4) 95 (33.0) 215 (28.3) 
    
Total
 a




 Test of difference in proportions (not adjusted for age or ethnicity) P<0.05  
 
The extent of the tumour was not recorded for over one-quarter of the cases. A greater 
proportion of females than males were registered with either localised tumours or tumours of 
unknown extent. One-third of males had regional lymph node involvement at diagnosis, 
whereas fewer than one-fifth of females did. 
The extent of the tumour at diagnosis is shown by anatomical site and type in Table 4.26. 
Table 4.26 Extent of tumour at diagnosis by the anatomical site and type (brackets contain 
column percentages, except where indicated). 
  Anatomical site and type   






Localised  67 (81.7)  134 (38.7)  14 (5.9) 27 (27.8)
c
 242 (31.8) 
Localised invasion  2 (2.4)  31 (9.0) 3 (1.3) 9 (9.3) 45 (5.9) 
Regional nodes
d
 1 (1.2)  69 (19.9)  127 (53.8) 16 (16.5) 213 (28.0) 
Distant metastases 0 (0.0)  18 (5.2)  17 (7.2) 11 (11.3) 46 (6.0) 
Unknown 12 (14.6)  94 (27.2)  75 (31.8) 34 (35.1)  215 (28.3) 





  346 (45.5)
b




 761 (100.0) 
a







Regional lymph node involvement 
 
Significant differences were observed in tumour extent by anatomical site. Most malignancies 
of the external lip were localised, whereas few oropharyngeal malignancies were localised. 
Also, fewer tumours of the external lip were of unknown extent. Over half of the OPCs had 
spread to the regional lymph nodes, whereas one-fifth of the OCCs had done so. A greater 
proportion of salivary gland tumours than other types had distant metastases at the time of 
diagnosis. 







Table 4.27 Extent of tumour by age group in years at diagnosis (brackets contain column percentage). 
    Age in years     
Extent of tumour <30 30—39 40—49 50—59 60—69 70—79 80—84 Over 84 Total 






Regional or distant spread 2 (15.4) 10 (37.0) 37 (48.6) 97 (48.3) 66 (37.1) 59 (40.6) 21 (33.9) 12 (20.4) 304 (39.9) 
Unknown 3 (23.1)   7 (25.9) 16 (21.1) 53 (26.4) 50 (28.1) 43 (29.7) 21 (33.9) 22 (37.3) 215 (28.3) 
          










Differences existed in the extent of the tumour by age at diagnosis. A greater proportion of 
those under 30 years than older age groups had localised disease and a greater proportion of 
those aged 80 or more years had tumours of unknown extent. Nearly half of those aged from 
40 to 59 years had tumours which had invaded either regionally (including to lymph nodes) or 
had metastatic spread at diagnosis.  
The extent of the tumour at diagnosis by ethnic group is presented in Table 4.28.  
Table 4.28 Extent of tumour at diagnosis by ethnic group (brackets contain column percentage 
unless indicated). 
 Ethnic Group  
Extent of Tumour Non-Māori  Māori Total
b
 
Localised to organ of origin 229 (32.6) 13 (22.4)
a
 242 (31.8) 
Invasion of adjacent tissue   42 (6.0)   3 (5.2)   45 (5.9) 
Regional lymph nodes 186 (26.5) 27 (46.6) 213 (28.0) 
Distant metastases   43 (6.1)   3 (5.2)   46 (6.0) 
Unknown 203 (28.9) 12 (20.7) 215 (28.3) 
    
Total
a




Test of difference in proportions (not adjusted for age or sex) P<0.05 
 
Māori had a lower proportion than non-Māori of tumours diagnosed at the localised stage, and 
a greater proportion of tumours with regional lymph node involvement. Non-Māori had a 
higher proportion (than Māori) of tumours with unrecorded extent.  
The anatomical site and type of oral and oropharyngeal tumour is shown by ethnic group in 
Table 4.29. 
Table 4.29 Anatomical site and type of cancer by ethnic group (brackets contain column 
percentage) 
 Ethnic Group  
Anatomical site & type Non-Māori Māori Total
c
 
External lip        79 (96.3)  3 (3.7)
 c
 82 (10.8) 
OCC 331 (95.7) 15 (4.3) 346 (45.5) 
OPC 209 (88.6) 27 (11.4) 236 (31.0) 
Salivary
a
 84 (86.6) 13 (13.4) 97 (12.7) 
    
Total
b
 703 (92.4) 58 (7.6) 761 (100.0) 
a




Test of difference in proportions (not adjusted for age or sex) P<0.05 
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Most of the diagnosed cancers of the external lip were found in non-Māori (96.3%). The 
proportion of Māori with either OPC or salivary gland tumours was greater than for the other 
types of cancer. 
4.2.3 Mortality 
The NZCR mortality records from 2012 and 2013 for individuals who had previously been 
registered OC and/or OPC were reviewed. In total, 109 individuals had died during this period 
(33 and 77 during 2012 and 2013, respectively), 88 (80.7%) of whom died from OC or OPC. 
For a further seven cases (6.4%), OC or OPC was recorded as a contributing cause of death. 
Other causes of death included other cancers (8 cases, 7.3%) and heart disease (6 cases, 
5.5%). The median age at death from OC and OPC is presented by sex and ethnic group in 
Table 4.30.  
Table 4.30 Age at death from oral and oropharyngeal cancer by ethnic group and sex (brackets 
contain age range in years except where indicated). 
 Number of deaths Median age (in years) at death 
Ethnic 
group 
Males Females Males Females Overall 
Non-Māori  46 (92.0)
a
  35 (92.1)
a
 69 (35 ̶ 96) 
  80 (51 ̶ 
100) 
 72 (35 ̶ 100) 
Māori   4 (8.0)    3 (7.9) 65 (48 ̶ 79) 59 (45 ̶ 64)  62 (45 ̶ 79) 
      





Overall, the median age at death was 70 years (range 35 ̶ 100 years). However, the median 
age at death was younger for males than females (69 and 78 years, respectively). Also, the 
median age at death was younger for Māori than non-Māori (62 and 72 years, respectively). 
Data on the mortality rate by sex and ethnicity are presented in Table 4.31. 
Table 4.31 Mortality rate per 100,000 by ethnicity and sex. 
 Sex  
Ethnicity Male Female Overall rate 
Non-Māori 1.4 1.0 1.2 
Māori 0.7 0.5 0.6 
    
Overall rate 1.3 0.9 1.1 
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The overall crude mortality rate per 100,000 was 1.1. Non-Māori males had the highest crude 
mortality rate (1.4) and the rates for non-Māori were double that of Māori for both males and 
females. Deaths from OC and OPC by anatomical site are presented in Table 4.32. 
Table 4.32 Deaths from oral and/or oropharyngeal cancer by anatomical site. 
 Death from oral and/or oropharyngeal cancers 
Anatomical site and type Number Percentage of deaths 
External lip   1    1.1 
OCC 42  47.7 
OPC 28  31.8 
Salivary gland 17  19.3 
   
Total 88  100.0 
 
Oral cavity cancer accounted for nearly half of deaths, with a further one-fifth from salivary 
gland tumours. Only one individual died from external lip cancer. The date of diagnosis is not 
contained within the mortality data. Therefore is it not possible to determine the mortality rate 
(neither overall nor site specific) within a defined period following diagnosis, from the 
mortality database. 
Of the 758 individuals who were diagnosed with OC and OPC within the study period, 223 
(29.4%) had died by 31 December 2015. The cause of death was available only for the 99 
individuals who died between 1 January 2012 and 31 December 2013, of whom 80 (10.6%) 
had died from OC or OPC. Accordingly, 10.6% (80 of 758) of the diagnosed cases had died 
from OC and/or OPC within two years of diagnosis. For the 20 who had died from other 
causes, the most common causes of death were other cancers (10 cases) and heart disease (5 
cases). Data on death from OC and/or OPC are presented in Table 4.33 by tumour extent, 
anatomical site and type.   
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Table 4.33 Cause of death by tumour extent for years 2012─2013 (brackets contain column 
percentages). 
Extent of tumour Death from OC /OPC  Total cases 
Localised to organ of origin 5 (6.2)
a
 242 (31.9) 
Invasion of adjacent tissue 2 (2.5)   44 (5.8) 
Regional lymph nodes  29 (36.3) 213 (28.1) 
Distant metastases  11 (13.8)   46 (6.1) 
Unknown  33 (41.2) 213 (28.1) 
   
Anatomical site and type   
External lip   1 (1.2)
a
   82 (10.8)  
Oral cavity cancer 39 (48.8) 344 (45.4) 
OPC 23 (28.8) 235 (31.0) 
Salivary gland 17 (21.3)   97 (12.8) 
   
Total  80 (10.6) 758 (100.0) 
a
P < 0.05 
 
For the three individuals diagnosed with two primary tumours, the site and type of tumour 
were the same, therefore only the first diagnosed tumour is represented in Table 4.33. Fewer 
than one in ten of those who died from OC or OPC had been diagnosed with either a localised 
tumour or with localised spread, whereas half of those with either regional lymph node 
involvement or distant metastases had died. The extent of tumour at diagnosis was not 
recorded for four out of ten individuals who died from OC or OPC. Oral cavity cancer was the 
primary cause of death for nearly half of those who died, and more than one-fifth of deaths 
were due to salivary gland tumours. Only one individual with cancer of the external lip had 
died. A greater proportion of Māori than non-Māori died from their OC or OPC within the 
study period (7 (12.1%) and 73 (10.4%) respectively). 
4.3 The observational study of hospital records of the CDHB cases 
There were 177 newly diagnosed cases of OC and OPC in 176 individuals diagnosed and/or 
treated in the CDHB from 1 January 2012 until 31 December 2013.  
4.3.1 Demographic characteristics of cases 
The number of cases of OC and OPC and crude incidence rate per 100,000 are presented by 
anatomical site, sex and ethnic group in Table 4.34. 
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Table 4.34 CDHB cases by anatomical site, sex, age and ethnic group (brackets contain column 
percentages) 
 Number of cases Crude incidence rate
a
 
Anatomical site   
External lip 33 (18.6) 2.3 
Oral cavity 72 (40.7) 5.1 
Oropharynx 52 (29.4) 3.7 
Salivary gland 19 (10.7) 1.3 
   
Sex   
Males 106 (59.9) 18.8 
Females 71 (40.1) 12.3 
   
Age group at diagnosis (in years)  
Less than 30 3 (1.7)   0.6 
30 ̶ 39 6 (3.4)   3.8 
40 ̶ 49 22 (12.4) 11.0 
50 ̶ 59 37 (20.9) 19.2 
60 ̶ 69 41 (23.2) 26.9 
70 ̶ 79 34 (19.2) 37.0 
80 ̶ 84 17 (9.6) 56.0 
Over 85 17 (9.6) 61.0 
   
Ethnic group   
Non-Māori 164 (92.7) 12.6 
Māori 13 (7.3) 11.3 
   
Total 177 (100.0) 12.4 
a
 Rate per 100,000 
 
At the time of diagnosis, most of the cases resided in the CDHB region (108 cases), with a 
further one-quarter residing in the NMDHB region (45 cases). The anatomical site with the 
highest incidence rate was the oral cavity. More than half of the cases were male and the 
incidence rate per 100,000 was higher in males than females. The cases ranged in age from 6 
years (for an acinar cell carcinoma of the parotid
6
) to 95 years, with a median age of 64 years. 
Few cases were younger than 40 years and the incidence rate was higher in older age groups, 
with the highest rate for those 85 or more years. Most of the cases were non-Māori and the 
crude incidence rate per 100,000 was higher for non-Māori than Māori. The incidence rate per 
100,000 for non-Māori males was more than double that for Māori males (16.0 and 6.9 
                                                 
6
 Acinar cell carcinomas are the second most common malignant epithelial tumours in paediatric patients and 
have been associated with familial predisposition and previous radiation therapy (Al-Zaher et al., 2009) 
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respectively). However, the incidence was higher for Māori females than non-Māori females 
(15.8 and 9.4, respectively). 
4.3.2 Anatomical site and HPV-16 status of cases 
A proportion of the tumours were tested for the presence of the oncogene HPV-16. The 
median age at diagnosis and anatomical site and type of tumours are presented by HPV-16 
status in Table 4.35. 
Table 4.35 HPV status of tumour by median age at diagnosis and tumour site (brackets contain 
row percentages unless indicated) 
 HPV-16 status of tumour  
Characteristic P16-positive P16-negative Not recorded Overall 
Median age (in years) 56 67 66 64 
     
Anatomical site    Total 
External lip  0 (0.0) 3 (9.1) 30 (90.9)      33 (18.8) 
Oral cavity  2 (2.8) 25 (34.7) 45 (62.5)      72 (40.9) 
Oro-pharyngeal 28 (53.8)  8 (15.4) 16 (30.8)      52 (29.5) 
Salivary gland 0 (0.0)  4 (21.1) 15 (78.9)      19 (10.8) 
     
Total number 30 (17.1) 40 (22.7) 106 (60.2) 176 (100.0) 
 
The medium age at diagnosis was similar for those with either HPV-negative tumours or 
tumours with unrecorded HPV-status, but was at least ten years younger for those with HPV-
positive tumours. Most of the HPV-positive tumours were OPCs, and over half of the OPCs 
were HPV-positive. Few of the OCCs and no external lip or salivary gland tumours were 
HPV-positive.  
4.3.3 Presenting signs and symptoms of OC and OPC 
The presenting signs or symptoms were not recorded in the hospital records for 21 (11.9%) 
cases. The most frequently observed signs included swelling or lump in the mouth, the neck 
or the submandibular area (66 cases, 22.0%), and a lesion in the mouth or lip (13 cases, 
7.4%). The most frequently reported symptoms were a non-healing ulcer (31 cases, 17.6%), 
pain (28 cases, 15.9%), persistent sore throat (12 cases, 6.8%) and difficulty swallowing (5 
cases, 2.8%). Incidental findings which prompted further investigation included mucosal 
change or lesion (5 cases, 2.8%) and an ulcer (2 cases, 1.1%). The full list of recorded signs 
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and symptoms is contained in Appendix I. Data on the recorded duration of signs noticed or 
symptoms experienced are presented in Table 4.36.  
Table 4.36 Duration of recorded signs and symptoms of OC and OPC (brackets contain column 
percentages). 
Sign/symptom duration Number of cases 
1 month or less  17 (9.7) 
2─3 months 59 (33.5) 
3─6 months 30 (17.0) 
7─11 months   8 (4.5) 
1─2 years 20 (11.4) 
2─5 years   4 (2.3) 
No information 38 (21.6) 
  
Total  176 (100.0) 
 
More than one-fifth of the cases lacked any recorded information on the duration of signs or 
symptoms prior to diagnosis. For the remaining 138 cases, the median duration of signs or 
symptoms was 4 months (range of 4 days up to 22 years). However, when considered by 
anatomical site of tumour, OCC and OPC had a shorter median duration (3 months). More 
than one in eight had been aware of a sign or symptom for more than twelve months prior to 
diagnosis. The tumour extent and anatomical site are presented by the recorded duration of 







Table 4.37 Extent and site of tumour by duration of signs and/or symptoms of OC (brackets contain column percentages unless indicated). 
 Duration of signs and symptoms  
Tumour features Incidental 
1 month or 
less 
2─6 months 7─11 months 
At least 12 
months 
Unknown Total 
Extent of Tumour        
Localised  6 (54.5) 5 (29.3) 26 (32.9) 9 (45.0) 8 (34.8) 19 (73.1) 73 (41.5) 
Regional or distant 
spread 
3 (27.3) 10 (58.8) 34 (43.0) 8 (40.0) 10 (43.5) 1 (3.8) 66 (37.5) 
Unknown 2 (18.2) 2 (11.8) 19 (24.1) 3 (15.0) 5 (21.7) 6 (23.1) 37 (21.0) 
        
Anatomical site of tumour        
External lip  1 (9.1) 1 (5.9) 10 (12.7) 1 (5.0) 2 (8.7) 18 (69.2) 33 (18.8) 
Oral cavity  6 (54.5) 8 (47.1) 26 (32.9) 15 (75.0) 9 (39.1) 8 (30.8) 72 (40.9) 
Oro-pharyngeal 3 (27.3) 7 (41.2) 32 (40.5) 2 (10.0) 8 (34.8) 0 (0.0) 52 (29.5) 
Salivary gland 1 (9.1) 1 (5.9) 11 (13.9) 2 (10.0) 4 (17.4) 0 (0.0) 19 (10.8) 
        
Total
a
 11 (6.3) 17 (9.7) 79 (44.9)  20 (11.3) 23 (13.1) 26 (14.8) 176 (100.0) 
a
 Row percentage 
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A higher proportion of the tumours found incidentally than those with a recorded duration of 
a sign or symptom were localised stage tumours. More than half of the incidental findings 
were for OCC, with a further one-quarter for OPC. No consistent gradient was seen for 
tumour extent by the duration of signs or symptoms. The latter information of the tumours 
was not known for more than one in seven cases and more than half of the external lip 
cancers. The proportion of tumours by extent at diagnosis is presented by the recorded 






Table 4.38 Extent of tumour by duration of signs and/or symptoms of oral cancer (brackets contain row percentages unless indicated). 
 Duration of signs and symptoms  
Extent of Tumour  Incidental 
1 month or 
less 
2─6 months 7─11 months 





        
Localised  6 (8.2) 5 (6.8) 28 (35.6) 9 (12.3) 8 (11.0) 19 (26.0) 73 (41.5) 
Regional or distant 
spread 
3 (4.5) 10 (15.2) 34 (51.5) 8 (12.1)  10 (15.2) 1 (1.5) 66 (37.5) 
Unknown 2 (5.4) 2 (5.4) 19 (51.4) 3 (8.1) 5 (13.5) 6 (16.2) 37 (21.0) 
        
Total 11 (6.3) 17 (9.7) 79 (44.9)  20 (11.3) 23 (13.1) 26 (14.8) 176 (100.0) 
a




A higher proportion of tumours with regional or distant spread, than localised tumours had 
either the shortest (one month or less), or longest sign or symptom duration (more than 12 
months) recorded. The duration of signs or symptoms of the tumours was not known for a 
higher proportion of tumours with either localised or unknown extent, than those with 
regional or distant spread. 
4.3.4 Referral information 
The referring practitioner and the service referred to was recorded for all but five cases. Most 
cases (n=139, 79.0%) were referred by GMPs, and fewer than one in twelve cases (n=15 
cases, 8.5%) referred by GDPs. Other referrers included other medical specialists (n=14 cases, 
7.9%) and Emergency Department doctors (n=3 cases, 1.7%). Of the cases referred by 
dentists, most were later diagnosed with OCC (n=14 cases, 7.9%), with the remaining case 
being an OPC. Nearly half of the cases detected incidentally had been referred by dentists 
(n=5 cases, 45.5%). The extent of OCC at diagnosis is presented by referring practitioner in 
Table 4.39. 
Table 4.39 Extent of tumour for oral cavity cases by original referring practitioner (brackets 
contain column percentages unless indicated) 





Localised    6 (42.8) 27 (46.5) 33 (45.9) 
Regional or distant spread 4 (28.6) 16 (27.6) 20 (27.7) 
Unknown 4 (28.6) 15 (25.9) 19 (26.4) 
    
Total
b
 14 (19.4) 58 (80.6) 72 (100.0) 
a
 Includes 3 cases where referrer was not known 
b
 Row percentage 
 
A higher proportion of the medically referred than dentally referred cases were localised 
tumours, whereas a higher proportion of dentally referred than medically referred cases were 
of either regional or distant spread, or were of unknown extent. The tumour extent was not 
known for more than one-quarter of the cases of OCC. 
The service to which cases were referred for treatment is presented by anatomical site and 
type of cancer in Table 4.40. 
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Table 4.40 Referred to service by anatomical cancer site and type (brackets contain column 
percentage unless indicated) 
Service referred  Lip 
Oral 
Cavity 
OPC Salivary Total 
ENT/ Head & Neck 4 (12.1)  39 (54.2) 47 (90.4) 17 (89.5) 107 (60.8) 
OMFS 1 (3.0)  19 (26.4) 2 (1.1) 1 (5.3) 23 (13.1) 
Plastics/Dermatolog
y 
20 (60.6) 3 (4.2) 0 (0.0) 0 (0.0) 23 (13.1) 
Hospital Dental 0 (0.0)  10 (13.9) 0 (0.0) 1 (5.3) 11 (6.3) 
General Surgery 8 (24.2) 1 (1.4) 3 (5.8) 0 (0.0) 12 (6.8) 
      
Total
a




More than half of cases were referred to ENT or Head and Neck specialists; however, the 
proportion of cancers referred to the specialist services differed by anatomical site. Most of 
the OPC and the salivary gland cancers (as well as over half the OCCs) were referred to ENT. 
Most of the external lip cancers were referred to Plastics or Dermatology, and nearly one-
quarter to General Surgery. More than one-quarter of the OCCs were referred to OMFS and 
nearly one in seven were referred to Hospital Dental departments.  
4.3.5 Existing co-morbidities 
The medical records were not available for 25 cases (14.2%). For the 151 cases with medical 
records, only four (2.6%) had no additional medical conditions recorded. More than half of 
the cases (n=94, 62.3%) had some form of heart disease (such as hypertension, ischaemic 
heart disease, valve replacement or atrial fibrillation), whereas one in eight (n=19, 12.5%) had 
co-existing respiratory illness (such as COPD). More than one-quarter (n=40, 26.5%) had 
previously been diagnosed with some form of cancer, of which lung cancer (8 cases), 
melanoma (6 cases) and other skin SCCs not occurring on the head or neck (6 cases), were the 
most frequently recorded. More than one-fifth of cases (n=32, 21.2%) had had a prior head or 
neck cancer; of those, 21 (13.9%) were SCCs. 
The tumour extent by smoking history is presented in Table 4.41. 
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Table 4.41 Tumour extent by smoking history (brackets contain row percentages unless 
indicated). 
 Smoking history   
 Non-smoker Ever-smoker Not recorded Total
ab
 
Extent     
Localised 31 (42.5) 28 (38.4) 14 (19.2) 73 (41.5) 
Regional or distant 
spread 
23 (34.9) 41 (62.1) 2 (3.0) 66 (37.5) 
Unknown 11 (29.7) 21 (56.8) 5 (13.5) 37 (21.0) 
     
Total 65 (36.9) 90 (51.1) 21 (11.9) 176 (100.0) 
a
 Column percentages 
b
 Test of difference in proportions P<0.05 
 
Over half of the cases were current or ex-smokers. Significant differences in tumour extent by 
smoking history were recorded. A higher proportion of smokers than non-smokers had 
tumours of regional or distant spread.  
4.3.6 Dental history of cases 
The number of patients who had a regular dentist by tumour extent, smoking history and 
employment status are presented in Table 4.42.  
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Table 4.42 CDHB cases by tumour extent, sex, ethnic group, smoking history and employment 
status (brackets contain row percentages unless indicated) 
 Has a regular dentist   
Characteristic Yes No Not recorded Total
a
 
Extent     
Localised 14 (30.4) 21 (45.6) 11 (23.9) 46 (32.2) 
Regional/distant 
spread 
26 (40.0) 34 (52.3) 5 (7.7) 65 (45.4) 
Unknown   6 (18.8) 20 (62.5) 6 (18.8) 32 (22.4) 
     
Sex     
Male 29 (35.4) 40 (48.8) 13 (15.8) 82 (57.3) 
Female 17 (27.9) 35 (57.4)  9 (14.7) 61 (42.7) 
     
Ethnic group     
Non-Māori 44 (33.8) 65 (50.0)  21 (16.2)  130 (90.9) 
Māori   2 (15.4) 10 (76.9)  1 (7.7) 13 (9.1) 
     
Smoking history      
Non-smoker 25 (50.0) 17 (34.0) 8 (16.0) 50 (35.0)
b
 
Ever-smoker 20 (24.7) 52 (64.2) 9 (11.1) 81 (56.6) 
Not recorded   1 (8.3)   6 (50.0) 5 (41.7) 12 (8.4) 
     
Employment status     
Working or no CSC  16 (47.1) 15 (44.1) 3 (8.8) 34 (23.8)
 b
 
Retired 24 (34.3) 36 (48.0) 10 (14.3) 70 (49.0) 
CSC holder  2 (12.5) 14 (87.5) 0 (0.0) 16 (11.1) 
Not recorded  4 (17.4) 10 (43.5) 9 (39.1) 23 (16.1) 
     
Total 46 (32.2) 75 (52.4) 22 (15.4)  143 (100.0) 
a
 Brackets contain column percentages 
b 
Test of difference in proportions P<0.05 
 
Nearly one-third had a regular dentist prior to their cancer diagnosis. No information about 
having a regular dentist had been recorded for more than one in seven cases. A lower 
proportion of those with localised tumours had a regular dentist than those without. However, 
the converse was observed for those with either tumours that had spread (regionally or 
distantly) or tumours of unknown extent. Half of non-Māori cases did not have a regular 
dentist, whereas three-quarters of the Māori cases did not. A higher proportion of males than 
females had a regular dentist, although the differences were not statistically significant. Also, 
a higher proportion of non-smokers than ever-smokers had a regular dentist. Alcohol 
consumption was recorded for nearly two-thirds of cases (91 cases, 63.6%). Fewer than one in 
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ten did not drink alcohol (14 cases, 9.8%), nearly one-quarter occasionally drank alcohol (35 
cases, 24.5%) and less than one-third (42 cases, 29.4%) were recorded as moderate or heavy 
drinkers. More than two-thirds were either ‘ever smokers’ or alcohol drinkers (101, 70.6%) 
and more than one-third of cases were both ‘ever smokers’ and alcohol drinkers (53 cases, 
37%). Only one in five who were both ‘ever smokers’ and alcohol drinkers had a regular 
dentist (11 of 53 cases, 20.8%). Few of those with a Community Services Card (CSC) had a 
regular dentist, while more than one-third of those retired had a regular dentist.  
Nearly one-third of cases (44 cases, 30.8%) had no date recorded since their last dental visit. 
The time since last dental visit ranged from 1 month up to more than 40 years. One in six (24 
cases) had been to the dentist within 3 to 12 months of diagnosis, but more than one-quarter 
(36 cases) had not been to the dentist for at least five years. One-third of patients that were 
dentally referred for their mouth cancer treatment were edentulous. 
The OPG radiographs revealed that most of the cases were dentate at the time of diagnosis; 
however, 8 (5.6%) had no available records. More than one-third of patients required dental 
extractions as part of their cancer therapy, with 24 (16.8%) having five or more teeth 
extracted. Twelve (8.4%) patients became edentulous as part of their cancer therapy. Data on 
being dentate at time of diagnosis and pre-cancer therapy extractions are presented by 
employment status in Table 4.43.  
Table 4.43 Dentate status and pre-cancer therapy extractions by employment status (brackets 
contain row percentages unless indicated) 








    
Working or no CSC  28 (82.4) 19 (55.9) 34 (23.8) 
Retired 36 (51.4) 17 (24.3) 70 (49.0) 
CSC holder 12 (75.0) 13 (81.3) 16 (11.1) 
Not recorded   1 (4.3)   4 (17.4) 23 (16.1) 
    
Total 89 (62.2) 53 (37.1) 143 (100) 
a
 Pre-cancer therapy dental extractions required 
b
 Column percentages 
 
Most of those either working or with a CSC were dentate at the time of cancer diagnosis, 
while just over half of those retired were so. Most CSC holders required extractions as part of 




Although many international studies have reported on the knowledge, beliefs and practices of 
primary dental care clinicians concerning OC, this is the first to explore the OC awareness of 
New Zealand dental clinicians. Quantitative data from the survey of general dentists and 
CDTs were compared with the descriptive data collected from the NZCR (cases diagnosed 
with OC and OPC from 1 January 2012 until 31 December 2013) to assess whether New 
Zealand general dentists and CDTs have adequate knowledge to enable early detection and 
referral of suspicious oral lesions. Moreover, the descriptive data from OC and OPC cases 
diagnosed within the CDHB during the study period were analysed for associations of tumour 
extent by regular dental attendance.  
The NZCR records show that the incidence of OC and OPC in New Zealand has increased 
over the last fifty years (Chelimo and Elwood, 2015; Cox et al., 1995). Examination of the 
OC and OPC cases from 2012–2013 suggests that the incidence remains highest for oral 
cavity cancer (crude incidence rates per 100,000 by anatomical site of 1.0, 1.1, 2.8 and 4.1 for 
external lip, salivary gland, oropharynx and oral cavity, respectively). Likewise, the distinct 
incidence patterns by gender, age, and ethnicity reported in earlier studies were also 
demonstrated in this study. Males were affected more commonly than females (with a ratio of 
males to females of 1.6:1). The median age at diagnosis was 63, and the age-specific rates 
were higher in older age groups (the highest AR of 48.7 per 100,000 recorded for males aged 
80─84 years). Most cases were New Zealand European (82.5% of cases), and the most 
common sites were the tongue (for OC) and the tonsils (for OPC). 
Most general dentists and CDTs identified OC and OPC as a male-dominated disease, with 
those over 40 years as more commonly affected and the tongue as a common site for OC. 
However, people aged over 60 years were less commonly identified (particularly those over 
70 years), and New Zealand Europeans were identified as at highest risk by comparatively 
few respondents (9.9%). Likewise, the tonsils as a common site for mouth cancer was 
identified by only 10% of New Zealand graduates, and few Asian and no graduates from other 
countries.  
The common signs and symptoms of mouth cancer (neck, submandibular or mouth lumps, 
non-healing ulcers and oral lesions) and the OPMLs (erythroleukoplakia, leukoplakia and 
erythroplakia) identified by most dentists and CDTs were consistent with those reported in the 
literature (Napier 2008; Scully and Bagan, 2009; van der Waal 2009; Warnakulasuriya 2009). 
 106 
However, fewer of the oldest graduates identified red lesions (erythro-leukoplakia and 
erythroplakia) as OPMLs.  
Most dentists and CDTs identified the proven risk factors for OC and OPC (areca nut, tobacco 
use, heavy alcohol consumption and HPV infection), but most also identified putative risk 
factors which are not fully supported by the literature (such as family history and marijuana 
use). Dentists and CDTs reported asking patients about their tobacco use, but less commonly 
asked about alcohol consumption.  
Fewer than one in ten (8.5%) of the OC and OPC cases diagnosed or treated at the CDHB 
during the study period had been referred by dentists. More than half of the cases were 
diagnosed within six months of becoming aware of a sign or symptom, while more than one 
in eight had a sign or symptom for at least 12 months before diagnosis. The pattern of dental 
attendance or duration of signs and symptoms was not consistently associated with tumour 
extent. However, factors that were associated with having a localised (rather than a more 
advanced) tumour included being a non-smoker and the tumour being an incidental finding. 
The CDHB cases were significantly less likely to have a regular dentist if they were either a 
smoker or had a CSC. Before cancer treatment, a higher proportion of those who were either 
working or with a CSC than those who were retired were dentate. Likewise, pre-cancer 
therapy extractions were more common for those who either had a CSC or were working than 
for those who were retired.  
During the study period, 88 people (50 males and 38 females) had died from OC or OPC. The 
annual number of deaths from OC and OPC is fewer than the 80 men and 35 women per 
annum reported by Cox et al. (1995) and suggests that the male-to-female ratio of OC and 
OPC deaths has reduced. Overall, the median age at death was 70 years, but sex and ethnic 
differences were observed (the median age was younger for males than females, and for 
Māori than non-Māori). In contrast to the findings of Robson et al. (2011), the mortality rate 
was twice as high for non-Māori than that of Māori (1.2 and 0.6 per 100,000 for non-Māori 
and Māori, respectively). Of those diagnosed with OC and OPC in the study period, 10.6% 
had died from their cancer within two years of diagnosis.  
The data gathered during this study will be discussed in the following section. First the 
strengths and limitations of the study will be discussed, and then the findings themselves will 
be considered.  
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5.1 Strengths and limitations of the study 
It is important to discuss the strengths and limitations of the study before discussing how its 
findings add to the understanding of the whether primary dental clinicians’ knowledge and 
patient factors impact on the stage of diagnosis of OC and OPC in New Zealand. The study’s 
strengths and weaknesses will be discussed in the following sections: study design, 
representativeness of the responding sample; NZCR data for OC and OPC cases 2012─2013; 
and retrospective data from the hospital records of OC and OPC cases treated at CDHB. 
5.1.1 Study design 
The response rate of a survey determines the strength of the quantitative data collected, with 
the strength of the data increasing along with the response rate. The study response rate 
(27.0%) seems low when viewed alongside some similar international studies surveying the 
knowledge of general dentists about OC (response rates of 49to 84.7% for postal surveys 
(Carter and Ogden, 2007; Mahalaha et al., 2009; Allen and Farah, 2015), although it is higher 
than the 18.1% response rate obtained in an online survey of Irish dentists (Decuseara et al., 
2011). Two recent online surveys conducted with New Zealand dentists on other matters had 
response rates of 18.8% (Pulp capping practices: Friedlander et al., 2015) and 39.6% 
(Community water fluoridation; Grant et al., 2013). One recent online survey of dental 
technicians exploring general issues of dental technology in New Zealand (not restricted 
solely to CDTs) achieved a response rate of 49.6% (Alameri et al., 2014). No comparable 
international studies of CDT’s knowledge of OC could be found, making it difficult to 
determine an expected response rate from this group. The survey upon which this study is 
based used two response methods (online and postal), and that may have affected the response 
rate (with 24.7% and 56.5% for online and postal responses, respectively). It is difficult to 
assess whether the use of two response methods increased the sample coverage and response 
rate. Using an online method only would have excluded those without an individual email 
address and it is possible this may have introduced a bias in the responses. Using postal 
questionnaires only would have increased increased the effort required to contact all reistered 
practitioners and process the response data. Therefore only a random sample of practitioners 
may have been able to participate in the study. This may have introduced some response bias 
into the study. Overall, however, the survey response rate is within the range which would be 
expected given those obtained in similar surveys.  
Several factors may have impacted on the response rate, including: the timing of the survey, 
the length of the survey, and the type of questions asked. Traditionally, the months of 
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November and December are busy months for dentists and CDTs (before the summer holiday 
season in December and January), so participating in a questionnaire at this time of year may 
have been a low priority for many clinicians. Moreover, potential respondents may have been 
dissuaded from participating due to the length of the questionnaire (feeling it would take too 
long to answer) or by its depth. The mouth cancer knowledge of New Zealand’s primary 
healthcare clinicians has not been explored previously, and so some clinicians may have been 
reluctant to respond due to a fear of not providing the ‘correct answers’. Although the length 
of the survey may have contributed to a lower-than-hoped for response rate, the range of 
questions asked enabled a variety of topics on knowledge and practices concerning mouth 
cancer to be explored, thereby aiding identification of areas which may be further investigated 
in the future.  
The design of the survey may have led to a degree of bias in responses. Respondents were 
asked to select response options rather than being asked open questions. The checklist 
supplied may have influenced respondents’ answers and not accurately tested their knowledge 
(as may have been the case if more open-ended questions had been asked). However, the 
checklist answer format enabled the results to be more easily quantified. Five questions 
(pertaining to OPMLs, signs and symptoms of mouth cancer, risk factors for mouth cancer 
and OCS examinations) had the option of an ‘All of the above’ answer, which may have 
prompted respondents to identify more of the variables than they would otherwise have done 
if given the option of identifying variables separately. Moreover, the postal respondents were 
able to select as many responses to the questions as desired, whereas the online respondents 
were restricted in many cases to one answer only (unless specifically indicated), and so some 
differences between the online and postal respondents may exist. This possibility was not 
explored. It is possible that the length of the questionnaire and the specific nature of some of 
the questions may have resulted in a higher response rate from those who were confident in 
answering questions about OC.  
The use of the term ‘mouth cancer’─rather than the more specific terms of oral cancer, oral 
cavity cancer and oropharyngeal cancer─may have been confusing for some respondents. The 
term ‘mouth cancer’ has been used in previous studies and is reported in the literature 
(Hassona et al., 2015; Parkin et al., 2005). It is also the term used in public health initiatives 
(such as ‘Smoking causes mouth cancer’ messages on tobacco products and ‘Mouth Cancer 
Awareness’ programmes), but its use have resulted in respondents failing to consider some 
anatomical sites of the oropharynx when considering variables such as common sites for 
mouth cancer. This may have reduced the proportion of participants who identified the tonsils 
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as a common site for mouth cancer and also those which identified HPV as associated with 
mouth cancer.  
5.1.2 Representativeness of the responding sample 
The demographic characteristics of the respondents were compared with those of the Dental 
Council Workforce Analysis 2010 (the latest workforce analysis available publicly). There 
were a higher proportion of female respondents than females registered with the DCNZ (44% 
and 34% of female respondents and registered dentists and CDTs, respectively). The higher 
proportion of females may have simply reflected the age distribution of respondents, with 
fewer of the oldest and more of the youngest graduates responding than registered, roughly 
correlating with the age-gender distribution among registered practitioners. However, no 
differences were apparent in the responses by sex of practitioner. Accordingly, a high 
response rate from female clinicians was unlikely to impact on the generalisability of the 
survey findings.  
Comparison was made between the respondents and the DCNZ-registered practitioners by 
geographic distribution. Although the measurement tool used to map the distribution was 
different (postcode for the survey, and DBH of work region for the DCNZ data), it was still 
possible to make broad comparisons. The geographic distribution was similar for both 
respondents and registered dentists, whereas some differences were noted in the geographic 
distribution of the CDTs. It is possible that there are some differences in the knowledge and 
practices about OC among clinicians from differing geographic locations. However, whether 
differences exist among these groups was not explored as views of non-responders were not 
gathered as part of this study.   
The age structure of respondents in the middle graduation cohorts (1976-1985, 1986-1995 and 
1996-2005) was similar to the age structure of DCNZ registered clinicians, whereas fewer 
older graduates and more recent graduates responded to the survey than are DCNZ registered 
(9.5% and 25.9% of respondents and 18.8% and 13.6% of registered dentists, for oldest and 
youngest cohorts respectively). The DCNZ data for CDTs were recorded by age (in years) 
rather than graduation cohorts, and so direct comparison of CDT age data was not made.  
The proportion of respondent dentists who graduated overseas (27.9% and 7.7% for overseas 
and specifically Asian graduates, respectively) is similar to the proportion of registered 
dentists (31.5% and 7.5% for overseas and Asian graduates, respectively). Therefore, it is 
likely the respondents are representative of the practising New Zealand dentists in this regard. 
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However, information was not available for graduation country of registered CDTs (the 
graduation country was available only for those CDTs who first gained New Zealand 
registration in 2010), so the representativeness of the CDT respondents by country of 
graduation was not explored. 
Non-responders have not been surveyed subsequently to determine whether their responses 
would differ significantly from responders. Thus, it is difficult to say with certainty that the 
findings are generalisable to general dentists and CDTs in New Zealand. However, since the 
responders have a similar demographic profile to registered dentists and CDTs in New 
Zealand, it is not unreasonable to assume that the survey findings may be generalisable to the 
broader population of New Zealand dental clinicians. 
5.1.3 NZCR data for OC and OPC cases 2012  ̶ 2013 
The use of NZCR data to describe the epidemiological patterns of the identified OC and OPC 
cases in New Zealand is consistent with previous studies (Cox et al., 1995; Gavidi et al., 
2014; Chelimo and Elwood, 2015), and it enabled capture of all the diagnosed cases in New 
Zealand residents within the study period. However, direct comparisons between this and 
previous studies are difficult because of differences in study inclusion criteria and duration. It 
should be noted that the study period was restricted to two years, rather than the longer 
timeframes in other studies (35, 11 and 30 years for the studies of Cox et al., 1995; Gavidi et 
al., 2014; and Chelimo and Elwood, 2015, respectively). In addition, the cause of mortality 
data were available only for those who had died within the study period. Therefore, using the 
study data, it was not possible to calculate mortality rates for OC and OPC beyond one or two 
years from diagnosis. However, since the NZCR data enabled capture of all the diagnosed 
New Zealand OC and OPC cases within the study period, the findings may be interpreted as a 
snapshot in time.  
The NZCR data contained complete records for most variables, including demographic 
characteristics such as age, sex, ethnicity and DHB of residence, and tumour characteristics 
such as anatomical site and morphology of tumour. However, the tumour extent at diagnosis 
had not been recorded for 215 cases (28.3%). Accordingly, the tumour extent findings must 
be viewed with this in mind. 
Incidence rates for OC and OPC by ethnicity (including crude, age-specific and mortality 
rates) could be achieved only for Māori and non-Māori groups, due to the use of the NZ 
Census data for baseline population statistics. This meant that more detailed exploration of 
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patterns of OC and OPC by ethnicity was not explored, and the matching of the incidence 
rates with all the ethnic groups identified by respondents as at high risk of OC and OPC was 
not achievable.  
5.1.4 Retrospective data from the CDHB records of cases 
Identification of the full set of diagnosed OC and OPC cases was achievable by utilising the 
NZCR data. However, much of the desired information was not recorded. Data were collected 
from hospital medical and dental records, but only general descriptions were available about 
dental attendance for many cases. No patients were interviewed to provide details about 
dental attendance, and no dental records from private dental practitioners were reviewed; 
accordingly adjunct information (such as being dentate at the time of diagnosis and whether 
dental extractions were required before cancer therapy) was used to inform assumptions about 
dental visiting patterns. This reliance on assumptions may have introduced a degree of bias 
and compromised the study findings about dental attendance prior to OC and OPC diagnosis. 
Few cases were dentally referred (8.5%), and so exploration of patterns of tumour extent by 
referring clinician type was limited. 
Data about having a regular dentist were available for most of the cases (84.6%), but a 
definition for ‘regular dentist’ was not applied. Whether having a regular dentist necessarily 
translated into visiting a dentist for routine care or episodic relief of pain was not clear. No 
timeframe was associated with the concept of ‘regular dentist’, and so it is open to 
interpretation how frequently an individual may visit the dentist but still consider him or 
herself to have a regular dentist. Consequently, the opportunities for general dentists to 
incidentally detect early OC or OPC lesions may be fewer than indicated by the proportion of 
diagnosed cases recorded as having a regular dentist. Likewise, data on the time elapsed since 
the last dental visit relied on estimates, because many records were missing. Many edentulous 
cases had notes about when their current dentures were made (such as ‘present dentures made 
20 years ago’). It was assumed that the individual had not consulted a dentist or CDT since 
the dentures were made. However, whether individuals had visited a clinician for denture 
adjustments was not recorded. Only general descriptions were recorded for the time since last 
dental visit. 
The accurate measurement of the duration of OC and OPC signs and/or symptoms prior to 
consulting a primary healthcare clinician is challenging due to patient recall bias and errors in 
measurement, and it may have resulted in the duration being underestimated (Allison et al., 
1998; Scott et al., 2008). A range of time (such as 2-3 months) was often noted in the medical 
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records, which limited the exploration of tumour extent by the duration of signs and 
symptoms.  
For those patients who required high-dose radiation therapy (60Gy or above) involving the 
maxilla or mandible as part of their cancer therapy, the accurate assessment of the health of 
the dentition is an important consideration in planning pre-radiation-therapy dental 
extractions. This meant that, for many of these patients, detailed records on previous dental 
care were obtainable. However, for those individuals who did not receive high dose radiation 
in the maxilla or mandible ─ or for those who were edentulous (or edentulous in the planned 
radiation field) ─ records on patterns of previous dental care were less available. Pre-radiation 
dental extractions were used in this study as an indicator of active dental disease (and 
therefore non-regular attendance); however, all dental extractions undertaken during the study 
period may not have strictly arisen from active dental disease. Early treatment protocols 
required all teeth within the planned field of high-dose radiation (frequently 60Gy or above) 
to be removed prior to radiation, to reduce the possibility of post-treatment osteo-necrosis of 
the jaw (ORN). While this regime is no longer recognised as best practice, it is possible that 
some of those in this study may have received such treatment and had otherwise healthy teeth 
extracted.  
Information on co-morbidities was available for most of the cases (bar one in seven). Only 
digital medical and dental records were reviewed. Further information may have been 
available if original hard copy files were reviewed. However, as DHBs transition into digital 
medical files, many of the hard copy files are difficult to obtain and attempts were not made 
to access them.  
The HPV-status of all tumours could not be reported. It is not usual to test external lip 
tumours for HPV status: however, nearly one-third of OPC did not have an HPV-status 
recorded even though tumours of the oropharynx are reported to be commonly associated with 
HPV infection (D’Souza et al., 2008; Gillison et al., 2012; International Agency for Research 
on Cancer, 100B, 2012). Accordingly, only limited exploration of the study data by HPV 
status could be achieved. 
Smoking history was available for most cases (91.6%), but it was unclear from some records 
whether those recorded as ‘non-smoker’ could be interpreted as ‘not currently smoking’ or 
‘never smoked’, and so the term ‘non-smoker’ was used in the assessment rather than the term 
‘never-smoker’. Data on alcohol consumption were listed for most of the cases (70.7%), but 
records on levels of consumption varied and included the descriptive terms of ‘heavy’, 
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‘moderate’, ‘not at abuse levels’ and ‘occasional’. It was difficult to know whether the use of 
these descriptive terms was applied consistently across clinicians, and so opportunities to 
explore the data for patterns by alcohol consumption were limited.  
Data on employment status were difficult to use and interpret. One in six did not have any 
information on employment status recorded and nearly half of the cases were retired. 
Employment status data may be entered in medical records for social history rather than as a 
measure of social-economic status. Eligibility for a CSC is commonly used in New Zealand 
as a measure of low income, and a CSC is available to both those who are working and those 
who are not working. Consequently, only those with a CSC recorded in this study were 
interpreted as low income. The CSC status of those who were working or retired may not 
have been recorded. It was not possible to measure the number of cases who may have been 
in this category from their medical records, and so patterns of dental attendance and tumour 
extent by socio-economic status could not be analysed in this study.  
5.2 Does the clinicians’ knowledge of mouth cancer match the true 
pattern? 
The responses of dentists and CDTs were reviewed alongside the NZCR data on diagnosed 
OC and OPC cases and the data collected for those diagnosed and/or treated at the CDHB. 
The responses will be discussed in the following sections: demographic characteristics of 
cases of OC and OPC; risk factors for mouth cancer; anatomical sites commonly affected by 
mouth cancer and OPMLs; detection of oral mucosal lesions; oral cancer screening 
examinations; and the referral practices of dental clinicians for mouth cancer cases.  
5.2.1 Knowledge of the demographic characteristics of cases  
Males accounted for 62.2% of those diagnosed with OC and OPC in the study. This finding is 
consistent with previous New Zealand studies (Cox et al., 1995; Gavidi et al., 2014; Chelimo 
and Elwood, 2015). However, fewer than two-thirds of respondents knew that mouth cancer is 
more common in men, and more than one-fifth of respondents did not know of any sex 
predilection for mouth cancer. 
The study findings of OC and OPC being more common in older age groups (overall median 
age 63 years and the highest age-specific rate (48.7 per 100,000) for men in the 80 ̶ 84 year 
age group) are consistent with findings from both international and New Zealand studies (Cox 
et al., 1995; Llewellyn et al., 2001; Bodner et al., 2013; Gavidi et al., 2014; Chelimo and 
Elwood, 2015). However, only one-third of respondents identified those aged 60-70 years and 
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fewer than one in six identified those over 70 years as more commonly affected by mouth 
cancer. This suggests that most New Zealand dentists and CDTs may not view the age group 
with the highest age-specific rates of OC and OPC as at high risk. A substantial proportion of 
respondents (one in five) were not aware of an age group more commonly affected by mouth 
cancer. However, this compares favourably with a study of Ohio rest home dentists, where 
33.3% were not aware of age group more commonly affected by OC (Mahalaha et al., 2009). 
Nearly one-quarter of respondents were not aware of any ethnic groups at higher risk of 
developing mouth cancer, and, the ethnic groups identified by the remaining respondents at 
highest risk of OC and OPC did not match those with the highest incidence. Fewer than one in 
ten respondents identified New Zealand Europeans as having high risk of mouth cancer, yet 
most of those diagnosed in the study period were New Zealand Europeans (82.5% of those 
diagnosed). This group was also identified by Gavidi et al. (2014) as the ethnic group most 
commonly affected in New Zealand. Māori were identified by less than one-fifth of 
respondents as at high risk of mouth cancer. In this study, Māori accounted for only 7.6% of 
the cases, and the overall age-specific rates for Māori were lower than for non-Māori. 
However, age-specific rates for Māori males aged 40 ̶ 49 years and Māori females aged 50 ̶ 59 
years and 70 ̶ 79 years, were higher than for non-Māori in these groups. Chelimo and Elwood 
(2015) also reported a higher ASR for OPC for Māori than European/Other ethnic groups and 
so, it is not unreasonable for some respondents to identify Māori at high risk of mouth cancer. 
That more than half the respondents identified sub-continental Indians as at high risk of 
mouth cancer, which is more likely to reflect the high rates of OC and OPC globally rather 
than specifically New Zealand cases. 
It is noteworthy that a substantial proportion of the youngest graduates (those with fewer than 
10 years since graduation) were not aware of the demographic characteristics of those at high 
risk of mouth cancer (19.3%, 14.8%, and 22.3% of the youngest graduates were unaware of a 
difference in mouth cancer risk by sex, age group and ethnicity respectively). Although a 
lower proportion of the newest graduates than older graduates did not know the sex or age 
group of those at highest risk of mouth cancer, the differences were not significant. This 
suggests that undergraduate training about mouth cancer risk may be quickly forgotten for a 
number of dentists and CDTs. The fact that the 1986 ̶ 1995 graduation cohort had the highest 
proportion of ‘Don’t know’ responses to the questions about the sex and age groups more 
commonly affected by mouth cancer adds weight to the finding that time since graduation is 
not a valid measure of the knowledge of the demographic characteristics of those at highest 
risk of mouth cancer. 
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5.2.2 Clinicians’ knowledge of the risk factors for mouth cancer  
That few respondents did not identify areca nut use, tobacco use (both smoked and chewed) 
and heavy alcohol use as risk factors for OC is consistent with the findings from international 
studies that most clinicians are aware of the common oral cancer risk factors (Carter and 
Ogden, 2007; Mahalaha et al., 2009; Saleh et al., 2016). However, most respondents also 
identified family history and smoking marijuana as risk factors, neither of which are fully 
supported by the literature (Moore et al., 2001; World Health Organization, 2005; Aldington 
et al., 2008). Other risk factors not supported by the literature (but identified by four out of ten 
respondents) were ill-fitting dentures and denture stomatitis.  
Whether this misinterpretation of risk factors affects dental clinicians’ ability to identify those 
most at risk of mouth cancer is unclear. While familial history has not been proven as a risk 
factor, it may be an indication of lifestyle factors within the family which increase mouth 
cancer risk (such as patterns of tobacco and alcohol use, and fruit and vegetable 
consumption), so it may be an indirect marker of mouth cancer risk. Likewise, both 
edentulism and mouth cancer are more common in older age groups, and so the wearing of 
dentures (rather than the presence of denture stomatitis or dentures being poorly fitting) is 
likely an indication of an individual being in an age group which has a higher rate of mouth 
cancer, (rather than the denture wearing itself conferring a high risk of mouth cancer). More 
than one-third of the diagnosed CDHB OC and OPC cases were edentulous at the time of 
diagnosis, whereas half the cases who had retired were also edentulous. 
More than two-thirds of the study cases treated at CDHB were either ‘ever smokers’ or 
alcohol drinkers, which is consistent with respondents’ identification of tobacco and alcohol 
as risk factors for OC and OPC. Likewise, that more than half of the OPC cases were HPV-
positive was consistent with most respondents identifying HPV as a risk factor for mouth 
cancer. However, despite most respondents being aware of heavy alcohol use as a risk factor, 
fewer than one-quarter routinely asked patients about their current alcohol use, whereas most 
asked about tobacco use. Also, fewer New Zealand graduates routinely asked about past 
tobacco use and alcohol (current or past) use than other graduates. Whether this reflects a 
difference in undergraduate training between countries or year groups (a lower proportion of 
non-New Zealand graduates were in the earliest graduate year groups) or other factors (such 
as cultural differences or previous exposure to public health campaigns raising awareness of 
mouth cancer) was not explored as part of this study. International studies also found that a 
higher proportion of dental clinicians routinely ask patients about tobacco, than alcohol use 
(Decuseara et al., 2011; Horowitz et al., 2000; Macpherson et al., 2003; Nicotera et al., 2004). 
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Furthermore, fewer records about alcohol consumption than tobacco use were available in the 
CDHB study data. This suggests that it may not only be dental practitioners who are 
uncomfortable about discussing alcohol use with patients, or it may reflect a requirement by 
the MoH for medical practitioners to collect tobacco use data but not alcohol use data for their 
patients.  
Half of the respondents routinely advise patients on risk factors for mouth cancer. However, 
information on the specific type of advice given to patients was not gathered in the survey. It 
is likely (given the low proportion of clinicians asking patients about alcohol use) that 
clinicians may advise patients only of the risks associated with tobacco use, but not heavy 
alcohol use. Respondents were not asked whether they felt their advice was likely to influence 
patients’ behaviour, so it is difficult to compare this study with studies of Australian and 
Spanish dentists which found that most dentists (56.7% and 84.4% respectively) believe they 
can influence patients to reduce/quit smoking or drinking alcohol (Allen and Farah, 2015; 
Seoane et al., 2006).  
Nearly two-thirds of respondents identified older age as a risk factor for mouth cancer, which 
is similar to findings of  studies of Irish and US dentists (53 and 57%, respectively identified 
age as a risk factor) (Decuseara et al., 2011; Mahalaha et al., 2009). However, while older age 
is not recognised as a true risk factor for mouth cancer in an epidemiological sense, by 
identifying it as such, respondents might be indicating that they are more likely to look for 
mouth cancer in older patients.  
5.2.3 Anatomical sites commonly affected by mouth cancer and OPMLs  
Consistent with previous New Zealand studies, this study found that OC was more common 
than OPC, with salivary gland tumours being much less common. Oral cancer cases were 1.5 
times more common than OPC cases, whereas Chelimo and Elwood (2015) reported OC to be 
nearly twice as common as OPC. Moreover, salivary gland tumours were more common in 
this study than previously reported (12.8% of total OC and OPC, but 2.9% of the tumours 
reported by Chelimo and Elwood, 2015). It is unclear from the current study whether the rate 
of salivary gland tumours is an aberrant finding or reflects a recent pattern of a higher 
prevalence of salivary gland tumours. 
The most common sites for diagnosed OC were the tongue, the gingiva or cheek mucosa and 
the floor of the mouth; this is in accordance with the findings from previous studies (Chelimo 
and Elwood, 2015; Gavidi et al., 2014). Respondents most commonly identified the floor of 
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the mouth and lateral border of the tongue as mouth sites affected by cancer, but fewer than 
one-third identified the buccal mucosa. In accordance with the findings of Chelimo and 
Elwood (2015), half of the OPCs cases were in the tonsil. However, it is concerning that only 
ten percent of New Zealand graduates (while few Asian and no ‘Other’ graduates) identified 
the tonsil as a common site for mouth cancer. It is possible that clinicians may not have 
considered the tonsils as part of the mouth. Lack of awareness of the prevalence of tonsil 
cancer suggests that dentists and CDTs may not consider this region part of their domain and 
may not assess tonsils when providing an oral examination (or even an OCS examination). 
With the recent increase in the incidence of OPC in New Zealand (Chelimo and Elwood, 
2015), dentists and CDTs should be encouraged to include these regions in their routine 
examinations in an attempt to detect OPCs (particularly tonsil cancers).  
Most practitioners identified erythro-leukoplakia, leukoplakia and erythroplakia as OPMLs. 
However, only one-third identified OSF as potentially malignant, despite the reported MTR 
being higher than for leukoplakia (up to the 7.6% reported by Murti et al., 1985). OSF is a 
condition closely associated with areca nut use, a practice not common among native-born 
New Zealanders. This means that many dental clinicians may not have seen OSF lesions 
previously, resulting in a lack of recognition of OSF as an OPML. However, since areca nut is 
now commonly available in many small stores in New Zealand and is a habit frequently 
continued by immigrants from parts of the world where its use is common (Yoganathan, 
2002), OSF may be encountered by dental clinicians. It is important that clinicians understand 
this condition’s potential for malignant transformation.  
The most frequently recorded signs and symptoms of OC and OPC for the CDHB cases were 
lumps (in the mouth, the neck or the submandibular area), pain, lesions in the mouth or lip, 
and non-healing ulcers. These matched the survey responses, with most dentists and CDTS 
identifying ulcers, erythro-leukoplakia, erythroplakia, leukoplakia, pain, and neck lumps as 
signs or symptoms of mouth cancer. It also compares favourably with a survey of British 
dentists that found similarly high proportions of respondents identifying ulcers, white patches 
and red patches, but low responses (less than 10%) for erythroplakia and lymphadenopathy 
(Carter and Ogden, 2007). The difference in knowledge of the clinicians among the two 
studies may be, (at least partially) explained by the British survey’s utilisation of open 
questions, rather than the closed items used in this study. The finding does suggest that most 
New Zealand dentists and CDTs do understand the clinical presentation of mouth cancer and 
OPMLs. 
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5.2.4 Detection of oral mucosal lesions  
That most practitioners reported routinely checking all patients for oral mucosal lesions is 
consistent with international findings (Allen and Farah, 2015; Horowitz et al., 2000; Seoane et 
al., 2006). Likewise, most practitioners reported being ‘confident’ or ‘very confident’ in 
detecting OPMLs. This was consistent with Farrand et al. (2003) who found that most UK 
dentists had high levels of confidence in their clinical ability to detect oral cancer, but it is in 
contrast with Macpherson et al. (2003) who reported that only 37.8% of Scottish dentists were 
either ‘confident’ or ‘very confident’ about detecting oral cancer. Suspicious oral lesions had 
previously been detected by most respondents (88.2%), although it was noteworthy that 10% 
of those who had been practising for at least 40 years had never detected a suspicious lesion. 
This proportion is higher than had been expected and differs from the 93.1% of dentists who 
reported expecting to see a patient with OC in their practising lifetime (Allen and Farah, 
2015). It raises the question of whether some of the oldest clinicians routinely undertake OCS 
examinations, and whether their knowledge of the presentation of OPMLs and early OC 
enables detection of suspicious oral mucosal lesions. Respondents were asked about whether 
they felt patients could self-detect oral mucosal lesions as an indication of how reliant they  
were on symptoms when providing OCS examinations. One-third of respondents felt that 
patients were able to self-detect oral lesions, although more of the youngest graduates believe 
so. This is in contrast with just 3.1% of Australian dentists who agreed patients can self-detect 
oral mucosal pathology (Allen and Farah, 2015), and suggests that New Zealand clinicians 
may rely more heavily than their Australian counterparts on patient-identified symptoms in 
the detection of oral lesions.  
5.2.5 Oral cancer screening examinations 
That most practitioners felt that a visual examination of the oral tissues was integral to an 
OCS examination is supported by the review of OCS techniques conducted by Walsh et al. 
(2013). Most respondents also identified that palpation of lymph nodes and the floor of the 
mouth should be included in an OCS examination. This compares favourably to United States 
studies, which found that palpation of lymph nodes was performed by only half of dentists 
during OCS examination (Horowitz et al., 2000; Mahalaha et al., 2009). 
Most clinicians reported providing OCS examinations for all patients, however less than half 
reported there were no barriers to providing OCS examinations. It is unclear whether 
clinicians felt there were barriers but these were easily overcome, or whether the barriers 
prevented them from providing OCS examinations for all patients. Also the percentage of 
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dentists who reported providing OCS examinations to all patients and those who provide them 
only to high-risk patients sums to more than 100% (526, 106.5%). It is therefore possible that 
the proportion of dentists who routinely provide OCS examinations for all patients is 
overestimated in this study. 
The types of barriers to performing OCS examinations identified by respondents (such as lack 
of training, time, confidence, and ability to charge for this service) are similar to those 
identified in international studies (Macpherson et al., 2003; Laronde et al., 2008; Brocklehurst 
et al., 2010; Allen and Farah, 2015). The most frequently identified barrier (lack of training) 
was identified by fewer than one-third of respondents (although by more of the oldest 
graduates). This compares favourably with international studies in which barriers to routine 
OCS examinations were identified by at least 40.2% of the dentists surveyed (Macpherson et 
al., 2003; Allen and Farah, 2015). This suggests that New Zealand clinicians may be more 
inclined to routinely undertake OCS examinations than other dentists.  
Most respondents supported OCS examinations being performed by general dentists, OMFSs, 
oral medicine specialists, ENT surgeons, dental hygienists, GMPs and CDTs. However, the 
fact that only two-thirds of respondents suggested GMPs should provide OCS examinations is 
noteworthy because most of the study cases of OC and OPC were detected by GMPs. Most 
Australian dentists (90.9%) also reported that oral mucosal screening is appropriately 
performed by dentists, but fewer than half (48.2%) felt that doctors could fulfil this role 
(Allen and Farah, 2015). GMPs are less likely to examine the oral mucosa of patients and are 
less confident in doing so than their dental colleagues (Carter and Ogden, 2007). Perhaps 
dentists and CDTs recognise this lack of confidence in their medical colleagues, and so fewer 
dental clinicians support OCS being performed by GMPs. One-third of CDTs did not support 
CDTs performing OCS examinations, but whether they routinely suggest patients have this 
service performed by another practitioner was not explored. It is concerning that a substantial 
proportion of CDTs do not recognise that OCS examinations are an important part of their 
role, particularly since they are more likely to treat older patients and edentulous patients who 
may be unlikely to visit the dentist. Few respondents identified pharmacists for this role, but 
some studies have found that a substantial number of patients subsequently diagnosed with 
OC have self-treated with pharmacy-bought medication before diagnosis (Grant et al., 2010; 
Varea-Centelles et al., 2012). Accordingly, pharmacists may be an important group to target 
when developing OC awareness programmes.  
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5.2.6 Dental clinicians’ referral practices for mouth cancer 
It is not surprising that most practitioners would usually refer patients with suspicious oral 
lesions to dental specialists (either directly to OMFSs, oral medicine specialists or to hospital 
dental departments). The selection of the particular service to refer to is probably dependent 
on the locally available service mix, and whether the patient is a private or public referral. 
Few regions in New Zealand have oral medicine specialists, and, where they exist, they are 
usually part of hospital dental departments. Notably, few practitioners would refer directly to 
ENT/Head and Neck surgeons, even though the MDTs that manage public OC and OPC 
services throughout New Zealand are headed by ENT/Head and Neck surgeons. Whether the 
lack of direct referral of patients by dentists to ENT/Head and Neck specialists could cause 
treatment delays for OC and OPC patients has not been explored as part of this study.  
The service to which the diagnosed OC and OPC cases were referred was associated with the 
site of the tumour and the referring practitioner (dental or medical), with dentists more 
commonly referring to dental specialists. Most OCC, OPC and salivary gland tumours were 
referred to ENT/Head and Neck specialists, while one-third of OCCs were referred to OMFs 
or hospital dental departments.  
Most respondents (83.3%) believed that patients would attend a specialist appointment when 
referred: this is higher than reported by Australian dentists (61.5% of whom believed patients 
would attend an appointment; (Allen and Farah, 2015)). Likewise, while most respondents 
(61.5%) believed that it was the referrer’s responsibility to check whether this occurred, it was 
fewer than among Australian dentists (89.0%). It was surprising that some practitioners (41 
dentists and 4 CDTs) believed the onus of ensuring patients attended a specialist appointment 
rested with the service referred to, since there would be occasions when services (for 
whatever reason) may not receive the referral, making it impossible to ensure that it is acted 
upon. It is possible that over-confidence in patients’ attendance at specialist appointments and 
clinicians not following up on patient referrals may lead to delays in diagnosis for some 
patients.  
5.3 Patterns of dental attendance for the CBHD cases  
Data collected from the hospital dental and medical records from the OC and OPC cases 
(identified from the NZCR) diagnosed and/or treated within the CDHB were analysed to 
assess whether tumour extent at diagnosis was associated with regular dental attendance, as 
has been reported in international studies. The study findings will be discussed in the 
 121 
following sections: tumour stage at diagnosis, regular dental attendance, dental status of 
diagnosed cancer patients and patterns of co-morbidities. 
In accordance with Holmes et al. (2003), the study found that a higher proportion of the 
tumours found incidentally than those detected due to an identified sign or symptom were 
localised stage tumours. However, no consistent gradient was apparent for tumour extent by 
the duration of signs or symptoms, and a higher proportion of tumours with regional or distant 
spread had either the shortest (one month or less) or the longest sign or symptom duration 
recorded. This is in contrast with the findings of Brouha et al. (2005), but in accordance with 
other studies that have reported the duration of diagnostic delay to not be consistently 
associated with stage of disease at diagnosis (Goy et al., 2009; Kaing et al., 2016; Scott et al., 
2004). This finding is difficult to fully explain as it may reflect variability in tumour 
aggressiveness (with some oral cancers known to arise without an OPML) or it may reflect 
errors in the measurement of the pre-diagnosis sign/symptom duration (such as recall bias), 
which have resulted in an underestimation of the duration of the signs and symptoms. 
However, the finding that duration of diagnostic delay is not consistently related to stage at 
diagnosis may also suggest that lesions may be present for a period of time without patients 
being aware of them, which supports the view of many respondents that patients are unable to 
reliably self-detect oral mucosal pathology. A prospective study of newly diagnosed OC and 
OPC cases that interviews patients and reviews primary care health records, may help to 
clarify the relationship between duration of sign/symptom duration and stage at diagnosis in 
New Zealand. 
More males than females were recorded as having a regular dentist, although the differences 
were not statistically significant. This is in contrast with the most recent NZ Oral Health 
Survey (Ministry of Health, 2010) and may reflect the lack of dental history data found in the 
study. Also, edentulism rates by sex, were not explored in this study and, it is possible that 
more female cases were edentulous (due to the higher median age of females at diagnosis than 
males), which could result in fewer of them having a regular dentist. Other factors associated 
with having a regular dentist included: being non-Māori (although not statistically 
significant), a non-smoker, or not a CSC holder. Poorer access to dental care for Māori and 
those of high deprivation is consistent with the findings of the NZ Oral Health Survey 
(Ministry of Health, 2010). However, the study did not find any association between tumour 
extent and dental attendance and so it is not possible to conclude that poorer access to dental 
care for these groups resulted in more advanced tumours (leading to a poorer prognosis). The 
proportion of males and retired people who had a regular dentist suggests that there are 
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opportunities for dentists to detect OPMLs and early cancerous lesions in these high-risk 
groups.  
Only half of those retired were dentate before their cancer therapy, whereas most of the 
working and CSC holders were dentate. Most of the CSC holders and over half of the 
working group required dental extractions as part of their cancer therapy, whereas fewer than 
one-quarter of those retired did so, probably reflecting a higher prevalence of edentulism in 
older people.  
The high prevalence of medical co-morbidities among the diagnosed OC and OPC CHDB 
cases is not surprising, since the risk factors and risk markers for OC and OPC are similar to 
the proven risk factors for other diseases (such as tobacco use, heavy alcohol use, and older 
age). In accordance with the findings of das Neves et al. (2015), the current study found 
smokers to be more likely to have a tumour of regional or distant spread than non-smokers. 
This adds weight to the argument for the opportunistic screening of smokers for mouth cancer 
when they present for primary healthcare, as well as for engaging in health promotion with 
tobacco smokers to ensure they do not delay in seeking care if they experience symptoms of 
oral mucosal pathology. The prevalence of co-morbidities may also prompt more patients to 
seek treatment for their OCs or OPCs in a medical setting, since they may be already 
attending their GMPs for treatment of other conditions. It is noteworthy that more than one-
fifth of cases had previously been diagnosed with head or neck cancer (most of which were 
SCCs). This is in agreement with the findings from international studies (Atienza and Dasanu, 
2012; Jégu et al., 2015), and reinforces the need for long-term follow-up care for those 
diagnosed with these tumours to check for both the recurrence of tumours and the 
development of new primary tumours. 
5.4 Study implications 
Exploring the mouth cancer knowledge, beliefs and practices of current primary healthcare 
practitioners is essential to identifying knowledge gaps and thereby developing educational 
strategies that will improve both clinicians’ knowledge and patient outcomes (Decuseara et 
al., 2011). The present study suggests that, while many clinicians are knowledgeable about 
many aspects of OC and OPC, differences exist among dental clinicians; this suggests that 
some are more able to detect OPMLs and early OCs than others. There was some evidence 
that a longer time from graduation, the type of clinician and the graduation country influences 
some beliefs and practices about OC and OPC. The causes of the recorded variations in OC 
and OPC beliefs and practices between different clinician groups have not been explored as 
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part of this study. The role of factors such as variations in undergraduate curriculum (between 
year groups and between countries), variations in the patterns of OC and OPC across 
countries, participation in previous OC professional development activities and exposure to 
previous public health  mouth cancer awareness campaigns, were not explored as part of this 
study. Therefore, further studies─focusing on recognition of OPMLs and early malignant 
lesions, OCS practices, participation in continuing education activities, and the manner in 
which clinicians engage with patients in mouth cancer prevention─would further inform the 
development of educational strategies to improve OC and OPC early detection rates and, 
ultimately, OC and OPC outcomes for patients. 
General medical practitioners continue to detect most of the OC and OPC in New Zealand, 
but their knowledge, beliefs and practices in respect of mouth cancer have yet to be explored. 
The high prevalence of medical co-morbidities among the diagnosed OC and OPC CHDB 
cases suggests that opportunities exist for opportunistic screening within a primary care 
setting (particularly for tobacco users) which may enable detection of early stage tumours. 
Identification of the factors that may contribute to delays in OC and OPC diagnosis by GMPs 
is needed to gain a better understanding of the opportunities to improve the detection rate for 
early malignant lesions, and to reduce disparities in OC and OPC survival. Without an 
understanding of the role of GMPs in the diagnosis of OC and OPC, it will be difficult to 
fulfil the MoH vision for ‘better, faster cancer care’ as outlined in the New Zealand Cancer 
Plan 2015 ̶ 2018.  
A lack of data on the dental history of diagnosed OC and OPC cases constrains the possibility 
of the current study finding associations between attendance at a dentist for regular routine 
care and the extent of tumours diagnosed. A prospective study of diagnosed OC and OPC 
cases which collects specific data on dental visiting patterns may enable exploration of 
whether differential access to dental care (and pre-diagnosis signs and symptoms duration) 
impacts on stage of diagnosis for OC and OPC in New Zealand. Exploring factors which may 
impact on the stage of diagnosis of tumours was also restricted by incomplete NZCR data 
records. Efforts to improve the completeness of the NZCR data may enable better exploration 
of associations between tumour stage at diagnosis and other factors. 
Furthermore, exploration of the general public’s knowledge about mouth cancer (including 
risk factors for and clinical presentation of mouth cancer) is an important area that has yet to 
be explored in New Zealand. As part of the New Zealand Oral Health Survey, individuals 
aged 18 years or over had an oral examination which included an oral mucosal screening 
examination (Ministry of Health, 2010). However, participants were not interviewed about 
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their knowledge of mouth cancer. There is an opportunity for future New Zealand Oral Health 
surveys to interview participants about their knowledge of mouth cancer. Findings could then 
be used to inform future public health campaigns aimed at reducing the rates of OC and OPC, 
as well as in reducing patient-associated delays in diagnosis.  
6 Conclusion 
NZCR records from 2012–2013 suggest that the incidence of OC and OPC in New Zealand 
continues to increase and the distinct incidence patterns by gender, age, ethnicity and 
anatomical site reported in previous New Zealand studies remain. The current study found 
that males continue to be more commonly affected by OC and OPC, and higher age-specific 
rates persist in older age groups. Most cases were NZ Europeans and the most common 
anatomical sites for tumours were the tongue (for OC) and the tonsils (for OPC). 
Dental clinicians were knowledgeable about many aspects of OC and OPC including: the 
demographic characteristics of those most commonly affected; the risk factors for mouth 
cancer, and the signs, symptoms and clinical presentation of mouth cancer. However, 
differences in knowledge exist among dental clinicians, with some dentists and CDTs more 
able than others to detect OPMLs and early oral cancers. There was some evidence that a 
longer time from graduation, the clinician type and the graduation country may influence 
knowledge, beliefs and practices about OC and OPC. However, further studies are required to 
gain a better understanding of the deficiencies in dentists’ and CDTs’ knowledge of OC and 
OPC. These could inform the development of educational strategies to improve early 
detection rates (and ultimately OC and OPC outcomes) for patients in New Zealand. 
Most clinicians reported undertaking OCS examinations for all patients, however one-third 
identified barriers to doing so. It was noteworthy that a substantial proportion of CDTs do not 
recognise undertaking OCS examinations as an important part of their role, and most 
clinicians did not recognise the tonsils as a common site for mouth cancer. Therefore, it is 
likely that a proportion of dentists and CDTs do not provide routine OCS examinations, or 
may not thoroughly examine at all risk-sites to enable early detection of OC and OPC. It is 
suggested that a nationwide OCS educational programme be developed and implemented 
throughout New Zealand to improve the knowledge of primary oral healthcare clinicians to 
enable further opportunities for early-stage OC and OPC diagnosis. 
General medical practitioners continue to detect most of the OC and OPC in New Zealand, 
but little is known about their knowledge, beliefs and practices concerning OC and OPC. 
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Identification of the factors that may contribute to delays in OC and OPC diagnosis by GMPs 
is needed to gain a better understanding of the opportunities to improve the detection rate of 
early malignant lesions, and to reduce disparities in OC and OPC survival. 
Non-smokers and those of higher SES were more likely to be routine users of dental care than 
others, and so detection rates of early oral cancers by dental clinicians may be limited by the 
fact that the groups most at risk of OC may not receive regular dental care. However, there is 
a lack of data on the dental history of diagnosed OC and OPC cases, and so whether 
differential access to dental care impacts on the stage of diagnosis for OC and OPC in New 
Zealand could not be explored in this study. A prospective study of newly diagnosed OC and 
OPC cases in New Zealand may clarify the association between regular dental attendance and 
stage of diagnosis.  
Furthermore, opportunities to explore the general public’s knowledge about mouth cancer 
(including risk factors for and clinical presentation of mouth cancer) should be sought. 
Findings could then be used to inform future public health campaigns aimed at reducing the 
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Tuesday, 19 May 2015. 
Professor William Thomson, 





Tēnā Koe Professor William Thomson, 
The role of primary healthcare clinicians in the detection and diagnosis of mouth cancer 
in New Zealand 
The Ngāi Tahu Research Consultation Committee (the committee) met on Tuesday, 19 May 
2015 to discuss your research proposition. 
By way of introduction, this response from The Committee is provided as part of the 
Memorandum of Understanding between Te Rūnanga o Ngāi Tahu and the University. In the 
statement of principles of the memorandum it states ″Ngāi Tahu acknowledges that the 
consultation process outline in this policy provides no power of veto by Ngāi Tahu to research 
undertaken at the University of Otago″. As such, this response is not ″approval″ or ″mandate″ 
for the research, rather it is a mandated response from a Ngāi Tahu appointed committee. This 
process is part of a number of requirements for researchers to undertake and does not cover 
other issues relating to ethics, including methodology they are separate requirements with 
other committees, for example the Human Ethics Committee, etc. 
Within the context of the Policy for Research Consultation with Māori, the Committee base 
consultation on that defined by Justice McGechan: 
″Consultation does not mean negotiation or agreement. It means: setting out a proposal not 
fully decided upon; adequately informing a party about relevant information upon which the 
proposal is based; listening to what the others have to say with an open mind (in that there is 
room to be persuaded against the proposal); undertaking that task in a genuine and not 
cosmetic manner. Reaching a decision that may or may not alter the original proposal.″ 
The Committee notes this is Southern District Health Board research.  
 
The Committee considers the research to be of importance to Māori health. 
 
As this study involves human participants, the Committee strongly encourage that ethnicity 
data be collected as part of the research project. That is the questions on self-identified 
ethnicity and descent, these questions are contained in the latest census. 
 
The Committee suggests dissemination of the findings to relevant Māori health organisations, 
for example the National Māori Organisation for Dental Health, Oranga Niho and to 
Professor John Broughton and Mr Malcolm Dacker, who are involved in Māori Dental 







We wish you every success in your research and the committee also requests a copy of the 
research findings. 
This letter of suggestion, recommendation and advice is current for an 18 month period from 
Tuesday, 19 May 2015 to 19 November 2016. 
 
 
Nāhaku noa, nā 
 
Mark Brunton 
Kaiwhakahaere Rangahau Māori 
Research Manager Māori 
Research Division 
Te Whare Wānanga o Otāgo 

























For the purposes of this questionnaire, mouth cancer is considered to be oral cancer and oro-
pharyngeal cancer.
 
Thank you for participating in our survey. Your feedback is important.
Welcome  to my survey on the role of clinical dental  technicians in diagnosing mouth cancer in
NZ.





For the purposes of this questionnaire, mouth cancer is considered to be oral cancer and oro-
pharyngeal cancer.
Exploring the role of  clinical dental technicians in detecting mouth cancer.




2. In which year did you graduate?*










United States of America
Other (please specify)






5. What is the postcode of your main work location?
6. In New Zealand, is  mouth cancer more commonly found in men or women?*
More commonly found in women
More commonly found in men
Found as commonly in women and men
Don't know





































9. Which site or sites, do you think are the most common sites of mouth cancer in New Zealand? (Tick as









Lateral border of tongue
Major salivary glands




10. Which of the following oral conditions do you consider to have significant malignant potential? (Tick as









Oral submucous fibrosis 
Recurrent cold sores
All of the above 
None of the above 






11. Which of the following sigs are  associated with mouth cancer? (Tick as many as you think apply).*
Bad breath




Loose tooth or teeth 





All of the above
None of the above





12. Which of the following symptoms may be associated with mouth cancer? (Tick as many as you think
apply).
*







All of the above
None of the above
Don't know















Previous infection with Epstein Barr virus (EBV)





Wearing ill fitting dentures
All of the above
None of the above 
Unsure of the risk factors for mouth cancer
Other (please specify)















17. What do you consider to be involved in screening for mouth cancer? (Tick as many as apply).*
Checking salivary flow
Palpation of cervical and submandibular lymph nodes
Palpation of the floor of the mouth
Radiographic examination of alveolar bone
Use of special tests
Visual examination of oral mucosal soft tissues
All of the above
None of the above
Unsure what is involved in screening for mouth cancer
Other (please specify, include any special tests used)
18. Who should screen patients for mouth cancer? (Tick as many as you feel apply)*
Clinical dental technicians
Dental hygienists

















20. What patient-identified symptoms would alert you to a suspicious oral mucosal lesion? Please list.




Very confident Confident Not confident Very unconfident
22. How confident do you feel about identifying a potentially malignant mouth lesion by clinical
presentation?
*
23. Do you routinely ask patients about their current tobacco use?*
Yes
No
24. Do you routinely ask patients about their past tobacco use?*
Yes
No
25. Do you routinely ask patients about their current alcohol use?*
Yes
No







27. What do you perceive to be the barriers to doing an oral cancer screening (OCS) exam for patients?
(Tick as many as you feel apply).
*
Difficult to charge patients for this procedure
Lack of confidence in doing an OCS exam
Lack of time during regular appointments
Lack of training for clinicians in doing OCS exam
Oral cancer is so rare, that an OCS exam is not necessary
OCS exam is outside my scope of practice
Resistance from patients
Screening should be done only by a specialist
No barriers to doing an OCS exam
Other (please specify)
28. Who would you usually refer a patient to, if you found a suspicious oral lesion?*




Oral and maxillo-facial surgeon
Oral medicine specialist
Other (please specify)
29. Do you agree or disagree with this statement? Patients referred to specialists for review of oral








30. Should you follow up referrals to ensure that patients have presented to the specialist for review?*
Yes, it is my responsibility to check the referral has been acted on
No, it is the responsibility of the patient
No, it is the responsibility of the service the patient is referred to
Don't know
31. Please include any additional comments you would like to make about mouth cancer in New Zealand.
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Appendix G – Letters to dentists/clinical dental technicians 
Covering letter for survey 
 
15 November 2015 
Dear Clinical Dental Technician/Dentist 
Typically, there are 340-400 new cases of oral cancer and oro-pharyngeal cancer (together 
referred to as mouth cancer) diagnosed in New Zealand per year. The incidence of mouth 
cancer in New Zealand is increasing. Mouth cancer causes significant morbidity and 
mortality, and its early diagnosis is crucial to improving sufferers’ quality of life and survival.  
As part of my Masters of Community Dentistry thesis, I am exploring the role of primary 
healthcare clinicians in the diagnosis of mouth cancer in New Zealand. As part of this study, I 
wish to collect information on the opinions and practices of New Zealand dentists and clinical 
dental technicians with regards to mouth cancer. Approval for this research has been granted 
by the Health and Disability Ethics Committee (Reference number: 15/CEN/90). 
It would be greatly appreciated if you could take 5 or 10 minutes to complete the enclosed 
survey and return it in the enclosed self-addressed envelope. This survey is also being 
conducted via Survey Monkey where a unique email address has been available through the 
NZ Dental Council. The survey data will be collected anonymously and the findings will be 
published in due course.  
Those of you who complete the survey will be eligible to be included in two prize draws for 
Prezzy Card Gift Vouchers worth $200 each. For the prize draws, the code on the cover page 
of the survey will be removed prior to the responses being recorded. This will ensure survey 
data will remain anonymous. The prize draws will take place on December 10, 2015. To be 
eligible please return your survey to me before this date. 
If you wish to find out further information about this study, please contact me 
(Donna.Kennedy@nmdhb.govt.nz) or the Lead Supervisor for this study (Professor Murray 
Thomson; murray.thomson@otago.ac.nz) at the Department of Oral Sciences in the 
University of Otago.  
Your participation in this study is very much appreciated. 
Yours sincerely 
 
Dr Donna Kennedy, BDS 





Reminder letter for survey 
 
 
05 December 2015 
 
Dear Dentist 
Thank you to all the dentists and dental technicians who have completed this survey. We have 
received a lot of great feedback on the importance of researching this field and we are very 
grateful to all of you who took the time to complete it. 
We appreciate it is a very busy time of year and some of the questions may be a bit 
challenging, but by participating in this survey you will enable us to develop an understanding 
of the diagnosis of mouth cancer in New Zealand. It is hoped this understanding will 
ultimately lead to developing some strategies to improve the early diagnosis of mouth cancer. 
It is expected the survey will take only 5-10 minutes to complete and all responses are 
anonymous. All those who complete the survey by December 14, 2015 will be entered into 
the pre-Christmas prize draws to win a Prezzy Card worth $200.00. It is hoped by extending 
the draw by another four days we will receive some more responses. 
If you have any other questions about the survey please email me 
(Donna.Kennedy@nmdhb.govt.nz) or Professor Murray Thomson, the lead supervisor for this 
study (murray.thomson@otago.ac.nz). Thank you for taking the time to complete this survey.  
Yours sincerely  
 
 
Dr Donna Kennedy, BDS 




Appendix H – Letter to Ministry of Health requesting NZCR data 
 
31 December 2015 
Dear Sir/Madam,  
I am writing to request information from the NZ Cancer Registry as part of my thesis towards 
a MComDent through the Faculty of Dentistry at the University of Otago. The study title is 
‘Exploring the role of primary healthcare clinicians in the detection and diagnosis of mouth 
cancer in New Zealand by: 1.Assessing whether differential access to dental care impacts on 
the stage of diagnosis of mouth cancer in the South Island, New Zealand; 2. Assessing the 
opinions and practices of New Zealand dentists and clinical dental technicians with regards to 
mouth cancer and whether this impacts on stage of diagnosis; 3. Developing an understanding 
of the awareness of mouth cancer by general medical practitioners in Canterbury and Nelson 
and whether this impacts on the stage of diagnosis.  
Ethical approval has been granted for this study by the HDEC (ethics ref: 15/CEN/90). I have 
attached a copy of the approval letter. To gain adequate information to answer the study 
questions I request the following information:  
1. Cancer registrations  
For all oral cancer and oro-pharyngeal cancer registrations (ICD-10 codes C00-C10 and C14) 
for 2000 to 2014, and for the first six months of 2015. I request the following information for 
records where the NHI has a NZ resident status = N.  
For each record I seek the information of the following fields:  
Master NHI number  
Date of birth   
Age at diagnosis  
Sex  
Prioritised ethnic group  
Ethnicity 1  
Ethnicity 2  
Ethnicity 3  
Date of diagnosis  
Registration year  
Registration month  
Basis of diagnosis code  
Cancer notes  
Extent of disease  
Multiple tumours flag  
Site code (4 characters)  
Site code description  
Morphology code  
Morphology description  
DHB of domicile  
 185 
DHB at diagnosis  
Date of death (from the NHI)  
NZ resident status (from the NHI)  
2. Mortality  
I ask for a file of all registered deaths from 2000 to 2014 of patients listed in section 1 above 
and provide, where available, the following fields:  
 
Unique patient identifier (this will be a one-off encryption that still uniquely identifies the 
individual)  
Registration year  
Death date  
Country of birth  
Date of birth  
Death type  
Sex  
Age at death  
Prioritised ethnic group  
Ethnicity 1  
Ethnicity 2  
Ethnicity 3  
Domicile code  
Death information source code  
Occupation free text  
Years in New Zealand  
Clinical coding system ID  
Underlying cause of death (Diagnosis Type “D”)  
Other relevant diseases present (B1) (Diagnosis Type “F”)  
Other contributing causes (B2) (eg, medical misadventure) (Diagnosis Type “G”)  
Cancer as a non-contributing cause of death (Diagnosis Type “C”)  
Certifier of death  
Post mortem indicator  
3. Hospital discharge data  
I request a file of all publicly funded hospitalisations from 1988 to the first six months of 
2015 for the people registered and listed in section 1 above..   
 
For each record I seek the information of the following fields:  
 
Unique patient identifier (this will be a one-off encryption that still uniquely identifies the 
individual)  
NZ resident status  
Specialty code  
Event start date  
Event end date  
MDC code  
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MDC grouper type  
Agency code  
Agency type  
Facility code  
Facility type  
Domicile code  
DHB of domicile  
Admission source  
Admission type  
Age at admission  
Sex  
Prioritised ethnic group  
Ethnicity 1  
Ethnicity 2  
Ethnicity 3  
Event type  
Event end type  
Event local identifier  
Event leave days  
Diagnosis codes (first 15 reported, ICD-9-CMA-II)  
Accident/ecodes (first 10 reported, ICD-9-CMA-II)  
Accident date (first 10 reported)  
Accident date flag (first 10 reported)  
Operation codes (first 15 reported, ICD-9-CMA-II)  
Operation dates (first 15 reported)  
AN-DRG v3.1 code  
CCL  
AR-DRG current  
DRG grouper type  
Purchase unit  
Costweight code  
Costweight  
Your assistance with gathering this data is very much appreciated. If you require further 
information please contact either myself, or one of my study supervisors Prof Murray 
Thomson (murray.thomson@otago.ac.nz) or Assoc. Prof. Brian Cox (brian.cox@otago.ac.nz).  
Thank you again.  
Yours sincerely  
Dr Donna Kennedy Langley, BDS 
Dental Surgeon 




Appendix I – List of CDHB patient-identified signs and symptoms 




Painful mouth/tongue  
Bleeding lesion 
Persistent cough 
Lump/swelling in mouth 
Neck swelling 
Submandibular lump 
Hoarse voice,  
Jaw bruising 
Weight loss 
Painless swelling side of tongue 




Tonsil swelling/asymmetrical tonsil 
Difficulty swallowing 
Trismus 






Limited tongue movement 
Loose teeth 
Expanded upper arch 
Multiple skin lesions on face/lip/ear 
Boil on cheek 
Swelling behind jaw 
Blood stained sputum 
Paraesthesia or numbness 
Non-healing extraction site 
Unusual sensation 
Painful dry mouth 
Delirium 
Confusion 
Mucosal colour/texture change 
Oral lichen planus 
Fever 
 
